WO2021160049A1 - 抑菌组合物及其制备方法和用途 - Google Patents

抑菌组合物及其制备方法和用途 Download PDF

Info

Publication number
WO2021160049A1
WO2021160049A1 PCT/CN2021/075655 CN2021075655W WO2021160049A1 WO 2021160049 A1 WO2021160049 A1 WO 2021160049A1 CN 2021075655 W CN2021075655 W CN 2021075655W WO 2021160049 A1 WO2021160049 A1 WO 2021160049A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
group
vaginal
bacteriostatic composition
range
Prior art date
Application number
PCT/CN2021/075655
Other languages
English (en)
French (fr)
Inventor
曾忠铭
Original Assignee
深圳优丽康生物技术有限公司
新加坡善泽国际私人有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳优丽康生物技术有限公司, 新加坡善泽国际私人有限公司 filed Critical 深圳优丽康生物技术有限公司
Priority to CN202180014214.2A priority Critical patent/CN115515556A/zh
Priority to EP21753951.9A priority patent/EP4101437A4/en
Priority to CA3167761A priority patent/CA3167761A1/en
Publication of WO2021160049A1 publication Critical patent/WO2021160049A1/zh
Priority to US17/886,476 priority patent/US20220395481A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/362Polycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/02Suppositories; Bougies; Bases therefor; Ovules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02Local antiseptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52Stabilizers
    • A61K2800/524Preservatives
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a bacteriostatic composition, a method for inhibiting harmful microorganisms, and a method for regulating vaginal flora. It also relates to a bacteriostatic composition for the preparation of fatty acids and/or their salts for regulating vaginal flora.
  • the application in the invention and the preparation method of a bacteriostatic composition are particularly advantageous for preventing a bacteriostatic composition.
  • the skin and mucous membranes of the human body are connected to the outside world and are prone to be contaminated with various germs, and can further develop into the colonization, infection, or carry and spread of germs on the skin and/or mucous membranes.
  • Using antibacterial products to clean the skin and/or mucous membranes can effectively reduce the pathogen load on the skin and/or mucous membranes, and even kill the bacteria, thereby helping to prevent the infection and spread of the bacteria.
  • the bacteria in the female vagina are mainly Lactobacillus, which metabolize the glycogen in the vaginal mucosal epithelial cells to produce acid, keep the vaginal pH in the range of 3.5-4.5, and produce hydrogen peroxide, bacteriocins and other substances , It has inhibitory effect on pathogenic bacteria and conditional pathogenic bacteria, so it is a beneficial bacteria in the vagina, or called "normal vaginal flora".
  • Gardnerella vaginalis Prevotella, kinesococcus, Escherichia coli, Staphylococcus, Candida, etc. are also inhabited in the vagina. When the number is small, it is not pathogenic, and when the number is large, it can produce harmful Metabolites, toxins and other substances cause pathological changes and diseases in the human body, so they are called "conditional pathogens".
  • Staphylococcus aureus is highly pathogenic and representative; among Candida bacteria, Candida albicans is the most, accounting for more than 70% of the total number of vaginal and/or vulvar Candida infections. Representative.
  • vaginal flora When the vaginal flora is abnormal and the number of lactobacilli is low, not only the number of pathogenic bacteria such as Gardnerella vaginalis increases, but the resistance to pathogenic bacteria with strong virulence and pathogenicity is also reduced, resulting in infectious diseases of the reproductive tract.
  • the risk of infection is increased, such as the risk of infectious diseases caused by gonococcus, trichomoniasis, chlamydia, mycoplasma, HIV, HPV, etc.
  • vaginal microbial diseases are still mainly antibacterial.
  • antibacterial treatment can inhibit or kill pathogenic bacteria, it often has an inhibitory or even killing effect on beneficial lactobacilli, resulting in a decrease in vaginal anti-infective power, causing repeated vaginal infections or prolonged infections.
  • How to protect the beneficial bacteria in the vagina during antibacterial treatment so as to improve the effectiveness of the prevention and treatment of vaginal infections is still a hot issue in medical research.
  • a safe and effective antibacterial product is not only suitable for the cleansing and antibacterial of human skin and mucous membranes, but also for the antiseptic of personal toiletries such as bath products, skin care products and cosmetics, as well as products suitable for medical purposes.
  • Antiseptic, medicine, etc. can also be used to inhibit abnormal vaginal flora, restore and/or maintain vaginal lactobacilli, restore and/or maintain normal vaginal flora, restore and/or maintain normal vaginal microecology, so it has a strong The practicality and great market demand.
  • An object of the present invention is to provide a bacteriostatic composition.
  • Another object of the present invention is to provide a method for inhibiting harmful microorganisms.
  • Another object of the present invention is to provide a method for regulating vaginal flora, including inhibiting abnormal vaginal flora, restoring and/or maintaining vaginal lactobacilli.
  • Another object of the present invention is to provide the use of fatty acid and/or its salt in preparing a bacteriostatic composition for regulating vaginal flora.
  • Another object of the present invention is to provide a method for preparing a bacteriostatic composition.
  • the present invention provides a bacteriostatic composition, which comprises the following components:
  • fatty acids and/or their salts selected from acetic acid, glycolic acid, lactic acid, propionic acid, levulinic acid, butyric acid, isobutyric acid, hydroxybutyric acid, valeric acid, caproic acid , Heptanoic acid, caprylic acid, nonanoic acid, capric acid, undecanoic acid, undecylenic acid, and lauric acid, preferably consisting of propionic acid, butyric acid, caproic acid, caprylic acid, capric acid, and undecanoic acid Group, the total content of component (1) in terms of fatty acids is in the range of 0.001-3.00% (w/w);
  • the dibasic acid is selected from the group consisting of glutaric acid, adipic acid, and pimelic acid, preferably, the dibasic acid is adipic acid Diacid, the total content of component (2) calculated as dibasic acid is in the range of 0.05-5.00% (w/w);
  • aromatic alcohols are selected from the group consisting of benzyl alcohol, 2,4-dichlorobenzyl alcohol, phenethyl alcohol, phenoxyethanol, and cinnamyl alcohol, preferably phenethyl alcohol, cinnamyl alcohol
  • the total content of component (3) is in the range of 0.03-1.00% (w/w);
  • aromatic acids and/or their salts the aromatic acids selected from benzoic acid, p-hydroxybenzoic acid, p-methoxybenzoic acid, salicylic acid, cinnamic acid, gentisic acid, and coffee
  • the group consisting of acids preferably the group consisting of benzoic acid, cinnamic acid, and p-hydroxybenzoic acid, the total content of component (4) calculated as aromatic acid is in the range of 0.03-1.00% (w/w);
  • the bacteriostatic composition adopts one of the following dosage forms: aqueous solutions, water-soluble gels, foams, sprays, ointments, powders, films, capsules, suppositories, and tablets, preferably aqueous solutions , Water-soluble gels, foams, sprays, and ointments.
  • the total content of one or more fatty acids and/or their salts is preferably in the range of 0.001-2.00% (w/w), more preferably in the range of 0.001-1.50% (w/w), based on fatty acids Within the range, most preferably in the range of 0.002%-1.25% (w/w); and/or the total content of one or more dibasic acids and/or salts thereof is preferably in the range of 0.10-3.50% (w/w) based on the dibasic acid /w), more preferably in the range of 0.50-2.50% (w/w), most preferably in the range of 0.50-1.50% (w/w); and/or the total content of one or more aromatic alcohols is preferably In the range of 0.03-0.70% (w/w), more preferably in the range of 0.05-0.60% (w/w), most preferably in the range of 0.08-0.50% (w/w); and/or one or more The total content of the aromatic acids and/or their salts is preferably in the range of
  • the bacteriostatic composition further contains one or more selected from the group consisting of malic acid, citric acid, succinic acid, tartaric acid, and maleic acid with a total content in the range of 0.10-2.50% (w/w) , Isocitric acid, suberic acid, azelaic acid, and dibasic acid and/or polybasic acid of the group consisting of sebacic acid, and/or its salt, preferably, contains one or more selected from malic acid, Citric acid, dibasic acid and/or polybasic acid of succinic acid, and/or salt thereof.
  • the acid and/or its salt has a buffering effect, which can enhance the pH stability of the bacteriostatic composition of the present disclosure, and further enhance the pH adjustment effect of the bacteriostatic composition of the present disclosure on human skin and/or mucosa. .
  • the bacteriostatic composition optionally contains one or more monosaccharides and/or oligosaccharides and/ Or polysaccharides: glucose, fructose, mannose, galactose, maltose, isomaltose, sucrose, isomaltulose, lactose, lactulose, trehalose, cellobiose, melibiose, gentiobiose, sucrose , Saccharose, saccharose, saccharose, isomaltotriose, isomalt tetraose, isomalt pentaose, gentio-oligosaccharide, raffinose, panose, malto-oligosaccharide, isomaltulose, Fructooligosaccharide, glucomannan, galacto-oligosaccharide, dextrin, starch, and glycogen; preferably isomaltulose, lactose,
  • the sugar-containing bacteriostatic composition of the present disclosure can both inhibit Candida, Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Gardnerella vaginalis, Prevotella, kinesococcus spp.
  • Aspergillus, abnormal flora of the skin and/or mucosa, etc. can promote and/or maintain the lactic acid bacteria in the skin and/or mucosa, promote and/or maintain the acidity of the skin and/or mucosa, which can be used for prevention and/or Or to treat the reduction of lactic acid bacteria in the skin and/or mucous membranes, and the imbalance of the flora of the skin and/or mucous membranes, such as the prevention and/or treatment of bacterial vaginosis, or aerobic vaginitis, or atrophic vaginitis, Or used for auxiliary treatment of vaginitis, or recovery after vaginitis treatment, or for the treatment of genital tract infections.
  • the bacteriostatic composition optionally contains one or more amino acids and/or salts thereof selected from the following group with a total content in the range of 0.10-6.00% (w/w): L- Glutamic acid, glutamine, L-aspartic acid, asparagine, leucine, isoleucine, phenylalanine, valine, proline, and threonine, preferably total content Glutamic acid and/or its salt, and/or aspartic acid and/or its salt, or a mixture thereof in the range of 0.50-3.00% (w/w).
  • amino acids and/or salts thereof selected from the following group with a total content in the range of 0.10-6.00% (w/w): L- Glutamic acid, glutamine, L-aspartic acid, asparagine, leucine, isoleucine, phenylalanine, valine, proline, and threonine, preferably total content Glutamic acid and/or its salt, and/or aspartic acid and
  • the bacteriostatic composition containing amino acids and/or their salts of the present disclosure can reduce acid production by lactic acid bacteria, thereby reducing the acidity of skin and/or mucosal parts, and is suitable for regulating the microenvironment of skin and/or mucosal parts, such as for treatment or Adjuvant treatment of cytolytic vaginosis, vaginal vulvar candida disease, etc.
  • the bacteriostatic composition optionally contains one or more monoterpenoids or sesquiterpenoids in a total content in the range of 0.001-0.50% (w/w), including but not limited to: Citronellol, linalool, geraniol, nerol, eucalyptol, terpineol, carvol, menthol, and lavender alcohol. Containing monoterpenoids or sesquiterpenoids can not only enhance the bacteriostatic effect of the bacteriostatic composition, but also provide aromatic odor to the composition.
  • the bacteriostatic composition optionally contains one or more plant aromatic oils in a total content within the range of 0.0001-0.05% (w/w), including but not limited to: rose essential oil, clove Oil, thyme oil, lavender oil, peppermint oil, mugwort oil, eucalyptus oil, sassafras oil, Litsea cubeba oil, cinnamon oil, bay leaf oil, and thyme oil.
  • the plant aroma oil can not only enhance the antibacterial effect of the composition, but also provide the composition with aromatic odor.
  • the bacteriostatic composition optionally contains a total content in the range of 0.001-0.50% (w/w) of one or more vitamin substances selected from the following group: vitamin A, vitamin C, Vitamin D and vitamin E.
  • the vitamin substances can be either high-purity vitamin substances or plant extracts containing the vitamin substances, which have antioxidant properties or promote skin Cell growth, or regulation of immune function, or maintenance of mucosal epithelial cell integrity, etc., can enhance the stability of the antibacterial composition, or have a protective effect on human skin and/or mucosa.
  • the bacteriostatic composition optionally contains one or more components selected from the group consisting of dehydroacetic acid, sodium dehydroacetate, sorbic acid, potassium sorbate, sodium sorbate, sodium Tamycin, bergenin, tropolone, cinnamic aldehyde, kenya acetic acid, chlorogenic acid, 1,2-pentanediol, 1,2-hexanediol, 1,6-hexanediol, 1,2-octanediol, 1,2-decanediol, p-hydroxyacetophenone, 2,4-dihydroxyacetophenone, methyl p-hydroxybenzoate, ethyl p-hydroxybenzoate, p-hydroxybenzoic acid Propyl ester, lysozyme, glyceryl monocaprylate, glyceryl monocaprate, and glyceryl monolaurate.
  • dehydroacetic acid sodium dehydroacetate
  • the components are used to further enhance the bacteriostatic composition of the present disclosure against Candida, Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Gardnerella vaginalis, Prevotella, and Mosquito Bacillus, Aspergillus niger, abnormal flora of skin and/or mucosa, etc., and other harmful microorganisms including but not limited to the antibacterial or antibacterial effect of viruses such as HIV and HPV.
  • the antibacterial composition further contains one or more antibacterial drugs, including but not limited to: nitroimidazole drugs such as metronidazole, tinidazole, ornidazole, aminoglycoside drugs Such as gentamicin, tobramycin, amikacin, sisomicin, netilmicin, quinolone drugs such as ciprofloxacin, ofloxacin, levofloxacin, furan drugs such as nifuratel , Nifuroxime, nitrofuran, furazolidone, nitrofurantoin, sulfa drugs such as silver sulfadiazine, sodium sulfacetamide, pyrrole drugs such as clotrimazole, fluconazole, miconazole, ketoconazole, allylamine drugs such as Naftifine, terbinafine, polyene antibiotics such as amphotericin B, nystatin, zymostat, natamycin.
  • the antibacterial composition containing antibacterial drugs of the present disclosure is suitable for skin and/or mucous membranes, such as the prevention and/or treatment of bacterial and/or fungal infections of the skin, the prevention and/or treatment of bacterial or fungal infections of the oral mucosa, and the prevention and / Or treatment of bacterial vaginosis of the vaginal mucosa, or aerobic vaginitis, or vaginal vulvar candida, etc.
  • the bacteriostatic composition adopts one of the following dosage forms: an aqueous solution, a water-soluble gel, a foam, a spray, and an ointment; the aqueous solution, or a water-soluble gel
  • the pH value of the preparation, foam, spray, or ointment is in the range of 3.1-4.8, preferably the pH value is in the range of 3.6-4.6, and more preferably the pH value is in the range of 3.8-4.4.
  • the bacteriostatic composition is a water-soluble gel
  • the water-soluble gel also contains one or more non-flowing, viscous, water-soluble colloidal matrix, including but not limited to xanthogen Gum, carbomer, polycarbophil, dextran, glucomannan, tragacanth, tragacanth, methyl cellulose (MC), carboxymethyl cellulose (CMC), hydroxyethyl cellulose (HEC) ), hydroxyethyl methyl cellulose (HEMC), hydroxypropyl methyl cellulose (HPMC), preferably xanthan gum and carbomer.
  • xanthogen Gum carbomer
  • polycarbophil dextran
  • glucomannan glucomannan
  • tragacanth tragacanth
  • methyl cellulose methyl cellulose
  • CMC carboxymethyl cellulose
  • HEC hydroxyethyl cellulose
  • HEMC hydroxyethyl methyl cellulose
  • HPMC hydroxypropyl
  • the bacteriostatic composition of the present disclosure has an inhibitory effect on harmful microorganisms, wherein the harmful microorganisms include but are not limited to Candida, Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Gardnerella vaginalis, Prevotella, kinesobacterium, Aspergillus niger, abnormal flora of skin and/or mucous membrane, other various pathogenic or conditionally pathogenic aerobes, facultative aerobes, anaerobes, molds , And viruses such as HPV and HIV.
  • Candida Candida
  • Staphylococcus aureus Escherichia coli
  • Pseudomonas aeruginosa Gardnerella vaginalis
  • Prevotella kinesobacterium
  • Aspergillus niger abnormal flora of skin and/or mucous membrane
  • other various pathogenic or conditionally pathogenic aerobes facultative aerobes,
  • the bacteriostatic composition of the present disclosure can be used for cleaning and/or bacteriostasis and/or disinfection of human skin and/or mucosa, such as cleaning and/or bacteriostasis and/or disinfection of vaginal mucosa, and can also be used for Anti-corrosion of various bath products, shampoo products, skin care products, cosmetics and other personal toiletries, or anti-corrosion of products and medicines used for medical purposes.
  • the bacteriostatic composition of the present disclosure can be used as a therapeutic product, or an effective component thereof, or a preservative thereof.
  • the therapeutic product includes, but is not limited to, medicines, disinfectants, mucosal surface microbicides, Antibacterial agents, bacteriostatic agents, micro-ecological regulators, flora regulators, micro-environment regulators, microbial regulators, disposable medical supplies, etc., or medical devices, pharmaceutical devices, disinfection devices, and vaginal devices
  • the components of the form exist.
  • the bacteriostatic composition of the present disclosure is a non-therapeutic product, or an effective component thereof, or a preservative thereof, wherein the non-therapeutic product exists in one of the following groups: health care products, Hygiene products, personal toiletries, cosmetics, disposable sanitary products, cleaning products, daily necessities, micro-ecological care products, deodorants, lubricants, humectants, lotions, detergents, curing agents, antipruritic agents, refreshing Or as a component of sanitary napkins, sanitary pads, and tampons.
  • the bacteriostatic composition of the present invention is a bacteriostatic composition for vagina
  • the bacteriostatic composition for vagina includes the following components:
  • the total content of propionic acid, butyric acid, caproic acid, caprylic acid, capric acid, undecanoic acid, or their mixtures in the inner surface is more preferably in the range of 0.002-1.25% (w/w);
  • dibasic acids and/or their salts selected from the following group with a total content of 0.50-2.50% (w/w) in terms of dibasic acid: glutaric acid, adipic acid , Pimelic acid, preferably adipic acid with a total content of 0.50-1.50% (w/w);
  • One or more aromatic acids and/or their salts selected from the group consisting of benzoic acid, p-hydroxybenzoic acid, para Methoxybenzoic acid, salicylic acid, cinnamic acid, gentisic acid, and caffeic acid, preferably benzoic acid, cinnamic acid, p-hydroxybenzoic acid, or their total content in the range of 0.08-0.20% (w/w) mixture.
  • the bacteriostatic composition for vagina adopts one of the following dosage forms: aqueous solution, water-soluble gel, foam, spray, ointment, powder, film, capsule, suppository, and tablet, preferably Aqueous solutions, water-soluble gels, foams, sprays, and ointments.
  • the bacteriostatic composition for vagina of the present disclosure further contains one or more estrogenic substances selected from the group consisting of diethylstilbestrol, diethylstilbestrol, Hexestrol, estradiol, estrone, estriol, nylestriol, ethinyl estradiol, ethinyl estradiol cyclopentyl ether, ethinyl estradiol, and proestrene, preferably estriol, proestrene .
  • one or more estrogenic substances selected from the group consisting of diethylstilbestrol, diethylstilbestrol, Hexestrol, estradiol, estrone, estriol, nylestriol, ethinyl estradiol, ethinyl estradiol cyclopentyl ether, ethinyl estradiol, and proestrene, preferably estriol, proestrene .
  • vaginal bacteriostatic composition containing estrogen substances of the present disclosure can promote the synthesis of glycogen in vaginal mucosal epithelial cells and promote the growth of beneficial lactobacilli, and is especially suitable for menopause or postmenopause or postpartum.
  • the bacteriostatic composition for vagina of the present disclosure further contains one or more phytoestrogens selected from the group consisting of soybeans with a total content in the range of 0.001-1.00% (w/w) Glycosides, daidzein, glycitein, puerarin, estradiol, genistein, equol, apigenin, genistein, genistein, chickpein, couestrol, awn Pseudoflavin, resveratrol, flax lignans, and lignans.
  • phytoestrogens selected from the group consisting of soybeans with a total content in the range of 0.001-1.00% (w/w) Glycosides, daidzein, glycitein, puerarin, estradiol, genistein, equol, apigenin, genistein, genistein, chickpein, couestrol, awn Pse
  • the phytoestrogens-containing vaginal bacteriostatic composition of the present disclosure can promote the synthesis of glycogen in vaginal mucosal epithelial cells and promote the growth of beneficial lactobacilli, and is especially suitable for menopause or postmenopausal or postpartum.
  • the bacteriostatic composition for vagina of the present disclosure can selectively contain water, xanthan gum, or carbomer and other different dosage bases according to different applicable requirements, or optionally further contain one or more of the aforementioned groups.
  • Dibasic acids such as malic acid, citric acid, succinic acid and/or their salts, polybasic acids and/or their salts, and/or dehydroacetic acid with a total content within the range of 0.10-2.50% (w/w)
  • Amino acid substances such as glutamic acid and/or its salt, aspartic acid and/or its salt within the range, and/or citronellol with a total content of 0.001-0.50% (w/w),
  • the bacteriostatic composition for vagina of the present disclosure has an inhibitory effect on the abnormal flora in the vagina, but has a recovery and/or maintenance and/or promotion effect on the lactobacilli in the vagina, and can be used to restore and/or maintain the normal bacteria in the vagina Group, restore and/or maintain the normal microecology of the vagina, restore and/or maintain the normal acidity of the vagina.
  • the bacteriostatic composition for vagina of the present disclosure can be used to clean and care the vagina and/or vulva, and/or reduce and/or eliminate vaginal vulva itching, and/or pain, and/or dryness, and/or irritation, and/or Or sexual intercourse discomfort, and/or alleviate and/or eliminate abnormal vaginal discharge, and/or leucorrhea peculiar smell, etc., and for the prevention and/or treatment and/or adjuvant treatment of vaginal flora imbalance, and/or bacterial vaginosis, and/or Or aerobic vaginitis, and/or cytolytic vaginosis, and/or vaginal vulvovaginal candida, and/or atrophic vaginitis, etc.
  • the present invention also provides a method for inhibiting harmful microorganisms, including the step of using a bacteriostatic composition, wherein the bacteriostatic composition contains:
  • fatty acids and/or their salts selected from acetic acid, glycolic acid, lactic acid, propionic acid, levulinic acid, butyric acid, isobutyric acid, hydroxybutyric acid, valeric acid, caproic acid , Heptanoic acid, caprylic acid, nonanoic acid, capric acid, undecanoic acid, undecylenic acid, and lauric acid, preferably free of propionic acid, butyric acid, caproic acid, caprylic acid, capric acid, and undecanoic acid Group; the total content of component (1) in terms of fatty acids is in the range of 0.001-3.00% (w/w), preferably in the range of 0.001-2.00% (w/w), more preferably in the range of 0.001-1.50% (w/ w) in the range, most preferably in the range of 0.002%-1.25% (w/w);
  • dibasic acids and/or salts thereof is selected from the group consisting of glutaric acid, adipic acid, and pimelic acid, preferably adipic acid;
  • the total content of component (2) is in the range of 0.05-5.00% (w/w), preferably in the range of 0.10-3.50% (w/w), more preferably in the range of 0.50-2.50% (w/w) , Most preferably in the range of 0.50-1.50% (w/w);
  • aromatic alcohol is selected from the group consisting of benzyl alcohol, 2,4-dichlorobenzyl alcohol, phenethyl alcohol, phenoxyethanol, and cinnamyl alcohol, preferably phenethyl alcohol, cinnamyl alcohol , Or their mixture; the total content of component (3) is in the range of 0.03-1.00% (w/w), preferably in the range of 0.03-0.70% (w/w), more preferably in the range of 0.05-0.60% (w /w), most preferably in the range of 0.08-0.50% (w/w);
  • aromatic acids and/or their salts the aromatic acids selected from benzoic acid, p-hydroxybenzoic acid, p-methoxybenzoic acid, salicylic acid, cinnamic acid, gentisic acid, and coffee
  • the group consisting of acid is preferably a group consisting of benzoic acid, cinnamic acid, and p-hydroxybenzoic acid; the total content of component (4) calculated as aromatic acid is in the range of 0.03-1.00% (w/w), preferably In the range of 0.03-0.50% (w/w), more preferably in the range of 0.05-0.25% (w/w), most preferably in the range of 0.08-0.20% (w/w).
  • the bacteriostatic composition adopts one of the following dosage forms: aqueous solution, water-soluble gel, foam, spray, ointment, powder, film, capsule, suppository, and tablet, preferably an aqueous solution Agents, water-soluble gels, foams, sprays, and ointments.
  • the harmful microorganisms described in the method for inhibiting harmful microorganisms of the present disclosure include but are not limited to at least one of the following groups of microorganisms: Candida, Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa Spores, Gardnerella vaginalis, Prevotella, Animus, Aspergillus niger, abnormal flora of skin and/or mucous membranes, other various pathogenic or conditionally pathogenic aerobic bacteria, facultative Aerobic bacteria, anaerobes, molds, and viruses HPV, HIV, etc.
  • Candida Staphylococcus aureus
  • Escherichia coli Escherichia coli
  • Pseudomonas aeruginosa Spores Gardnerella vaginalis
  • Prevotella Animus
  • Aspergillus niger abnormal flora of skin and/or mucous membranes
  • the bacteriostatic composition described in the method for inhibiting harmful microorganisms of the present disclosure can be used for cleaning and/or bacteriostasis and/or disinfection of human skin and/or mucous membranes, such as cleaning and/or inhibiting vaginal mucosa.
  • Bacteria and/or disinfection can also be used for the antiseptic of various bath products, or shampoo products, or skin care products, or cosmetics and other personal toiletries, or used for the antiseptic of products and medicines for medical purposes.
  • the bacteriostatic composition described in the method for inhibiting harmful microorganisms of the present disclosure is a therapeutic product, or an effective component thereof, or a preservative thereof.
  • the therapeutic product includes, but is not limited to, medicine, disinfection Agents, antibacterial agents, bacteriostatic agents, mucosal surface microbicides, flora regulators, microecological regulators, microenvironment regulators, microbial regulators, disposable medical supplies, etc., or medical devices, or pharmaceutical devices, Or disinfection equipment, and a component of vaginal equipment.
  • the bacteriostatic composition described in the method for inhibiting harmful microorganisms of the present disclosure is a non-therapeutic product, or an effective component thereof, or a preservative thereof, and the non-therapeutic product includes but is not limited to health care Supplies, personal toiletries, cosmetics, hygiene products, disposable hygiene products, cleaning products, daily necessities, micro-ecological care products, deodorants, lubricants, humectants, lotions, detergents, curing agents, antipruritic agents , Fresheners, etc., or can be used as a component of sanitary products or cleaning care products, such as sanitary napkins, or sanitary pads, or tampons.
  • the bacteriostatic composition described in the method for inhibiting harmful microorganisms of the present disclosure is used for preservation, it is necessary to make bath products, or shampoo products, or skin care products, or cosmetics, or medicines, and other products for medical purposes, etc.
  • the content of each component of the bacteriostatic composition described in the present disclosure contained in the product that is, the total content of one or more fatty acids and/or their salts based on fatty acids, and one based on dibasic acid
  • the present invention also provides a method for regulating vaginal flora, wherein regulating vaginal flora includes at least one of the following: inhibiting abnormal vaginal flora, restoring and/or maintaining vaginal lactobacilli, and the method includes using vaginal
  • the step of the bacteriostatic composition wherein the vaginal bacteriostatic composition contains one or more fatty acids and/or salts thereof with a total content of 0.001-2.00% (w/w) calculated as fatty acids, and
  • the fatty acid is selected from the group consisting of butyric acid, valeric acid, caproic acid, heptanoic acid, caprylic acid, nonanoic acid, capric acid, undecanoic acid, undecylenic acid, and lauric acid, and preferably the total content is 0.001-1.50% (w/ w) within the range, more preferably within the range of 0.002-1.25% (w/w) selected from the group consisting of butyric acid, ca
  • the bacteriostatic composition for vagina adopts one of the following dosage forms: aqueous solution, water-soluble gel, foam, spray, ointment, powder, film, capsule, suppository, and tablet; Preferred are aqueous solutions, water-soluble gels, foams, sprays, and ointments.
  • the bacteriostatic composition for vagina described in the method for regulating vaginal flora of the present invention further contains a dibasic acid with a total content in the range of 0.50-2.50% (w/w) Or multiple dibasic acids and/or salts thereof, the dibasic acid is selected from the group consisting of glutaric acid, adipic acid, and pimelic acid, preferably the total content is in the range of 0.50-1.50% (w/w) Adipic acid, and/or its salt.
  • the combination of the dibasic acid such as adipic acid and/or its salt and the fatty acid such as butyric acid and/or its salt of the present disclosure can enhance the antibacterial effect of the fatty acid and/or its salt against Candida albicans.
  • the bacteriostatic composition for vagina described in the method for regulating vaginal flora of the present invention further contains one or more selected from the group consisting of a total content in the range of 0.05-0.60% (w/w) Group of aromatic alcohols: benzyl alcohol, 2,4-dichlorobenzyl alcohol, phenoxyethanol, phenoxyethanol, cinnamyl alcohol, preferably phenethyl alcohol, cinnamyl alcohol, or cinnamyl alcohol with a total content in the range of 0.08-0.50% (w/w) Their mixture.
  • the combination of the aromatic alcohols such as phenethyl alcohol and the fatty acids such as butyric acid and/or their salts of the present disclosure can enhance the resistance of the fatty acids and/or their salts to Candida albicans, Staphylococcus aureus, Escherichia coli, and Antibacterial effect of abnormal vaginal flora.
  • the bacteriostatic composition for vagina described in the method for regulating vaginal flora of the present invention further contains one or one whose total content in terms of aromatic acid is within the range of 0.05-0.25% (w/w)
  • aromatic acid is selected from the group consisting of benzoic acid, p-hydroxybenzoic acid, p-methoxybenzoic acid, salicylic acid, cinnamic acid, gentisic acid, and caffeic acid, preferably Benzoic acid, cinnamic acid, p-hydroxybenzoic acid, or their mixtures with a total content in the range of 0.08-0.20% (w/w).
  • the combination of the aromatic acid such as benzoic acid and/or its salt and the fatty acid such as butyric acid and/or its salt of the present disclosure can enhance the effect of the fatty acid and/or its salt on Candida albicans, Staphylococcus aureus, and large intestine. Antibacterial effect of Escherichia and abnormal vaginal flora.
  • the vaginal bacteriostatic composition described in the method for regulating vaginal flora of the present invention contains: (1) a total content of fatty acids in the range of 0.001-2.00% (w/w) One or more fatty acids and/or their salts, the fatty acids selected from the group consisting of butyric acid, valeric acid, caproic acid, heptanoic acid, caprylic acid, nonanoic acid, capric acid, undecanoic acid, undecylenic acid, and lauric acid Group, preferably the total content is within the range of 0.001-1.50% (w/w), more preferably within the range of 0.002-1.25% (w/w) selected from butyric acid, caproic acid, caprylic acid, capric acid, undecanoic acid , Or their mixture of fatty acids, and/or their salts; (2) One or more dibasic acids with a total content of 0.50-2.50% (w/w) in terms of dibasic acids and / Or
  • dibasic acid such as adipic acid and/or its salt
  • aromatic alcohol such as phenethyl alcohol
  • fatty acid such as butyric acid and/or its salt of the present disclosure
  • the vaginal bacteriostatic composition described in the method for regulating vaginal flora of the present disclosure contains: (1) a total content of fatty acids in the range of 0.001-2.00% (w/w) One or more fatty acids and/or their salts, the fatty acids selected from the group consisting of butyric acid, valeric acid, caproic acid, heptanoic acid, caprylic acid, nonanoic acid, capric acid, undecanoic acid, undecylenic acid, and lauric acid Group, preferably the total content is within the range of 0.001-1.50% (w/w), more preferably within the range of 0.002-1.25% (w/w) selected from butyric acid, caproic acid, caprylic acid, capric acid, undecanoic acid, Or their mixtures of fatty acids and/or their salts; (2) one or more dibasic acids and/or their total content in the range of 0.50-2.50% (w/w) calculated as dibasic acids Salt,
  • dibasic acid such as adipic acid and/or its salt
  • aromatic acid such as benzoic acid and/or its salt
  • fatty acid such as butyric acid and/or its salt of the present disclosure
  • the vaginal bacteriostatic composition described in the method for regulating vaginal flora of the present disclosure contains: (1) a total content of fatty acids in the range of 0.001-2.00% (w/w) One or more fatty acids and/or their salts, the fatty acids selected from the group consisting of butyric acid, valeric acid, caproic acid, heptanoic acid, caprylic acid, nonanoic acid, capric acid, undecanoic acid, undecylenic acid, and lauric acid Group, preferably the total content is within the range of 0.001-1.50% (w/w), more preferably within the range of 0.002-1.25% (w/w) selected from butyric acid, caproic acid, caprylic acid, capric acid, undecanoic acid, Or their mixture of fatty acids and/or their salts; (2) One or more aromatic alcohols selected from the following group with a total content in the range of 0.05-0.60% (w/w): benzyl alcohol
  • aromatic alcohols such as phenethyl alcohol, aromatic acids such as benzoic acid and/or their salts, and fatty acids such as butyric acid and/or their salts of the present disclosure has synergy with Candida albicans, Staphylococcus aureus, Escherichia coli, etc. Antibacterial effect, and has an inhibitory effect on abnormal vaginal flora.
  • the vaginal bacteriostatic composition in the method for regulating vaginal flora of the present disclosure contains: (1) one with a total content of fatty acids in the range of 0.001-2.00% (w/w) Or more fatty acids and/or their salts, the fatty acids selected from the group consisting of butyric acid, valeric acid, caproic acid, heptanoic acid, caprylic acid, nonanoic acid, capric acid, undecanoic acid, undecylenic acid, and lauric acid , Preferably the total content is within the range of 0.001-1.50% (w/w), more preferably within the range of 0.002-1.25% (w/w) selected from butyric acid, caproic acid, caprylic acid, capric acid, undecanoic acid, or Fatty acids and/or their salts in the group consisting of their mixtures; (2) One or more dibasic acids and/or dibasic acids with a total content of 0.50-2.50% (w/w/w)
  • the combination of dibasic acid such as adipic acid and/or its salt, aromatic alcohol such as phenethyl alcohol, aromatic acid such as benzoic acid and/or its salt, and fatty acid such as butyric acid and/or its salt of the present disclosure is effective against Candida albicans , Staphylococcus aureus, Escherichia coli, etc. have a synergistic antibacterial effect, as well as an inhibitory effect on abnormal vaginal flora. After the bacteriostatic composition is applied to the vagina, the abnormal flora in the vagina is significantly reduced, and the lactobacilli are significantly increased.
  • the composition has the advantages of inhibiting the abnormal vaginal flora, restoring and/or maintaining and/or promoting the lactobacilli in the vagina And the role of restoring and/or maintaining the normal acidity of the vagina.
  • the bacteriostatic composition for vagina described in the method for regulating vaginal flora of the present disclosure further contains a total content of one or more selected from within the range of 0.001-1.00% (w/w)
  • the following group of estrogen substances diethylstilbestrol, hexestrol, estradiol, estrone, estriol, nylestriol, ethinyl estradiol, ethinyl estradiol cyclopentyl ether, ethinyl estradiol, proestrone Of these, estriol and proestrene are preferred.
  • Estrogenic substances can promote the synthesis of glycogen in vaginal mucosal epithelial cells and promote the growth of beneficial lactobacilli.
  • the antibacterial composition containing estrogen substances of the present disclosure is especially suitable for menopause or postmenopausal or postpartum.
  • the bacteriostatic composition for vagina described in the method for regulating vaginal flora of the present disclosure further contains one or more selected from the group consisting of a total content in the range of 0.001-1.00% (w/w) Phytoestrogens in the following group: daidzein, daidzein, glycitein, puerarin, pseudoestrone, genistein, equol, apigenin, genistein, genistein, chicken Glycinin, couestrol, formononetin, resveratrol, flax lignans, and lignans.
  • Phytoestrogens can promote the synthesis of glycogen in vaginal mucosal epithelial cells and promote the growth of beneficial lactobacilli.
  • the antibacterial composition containing phytoestrogens of the present disclosure is especially suitable for menopause or postmenopausal or postpartum.
  • the method for regulating vaginal flora of the present invention includes applying a vaginal bacteriostatic composition to restore and/or maintain the normal vaginal flora and/or restore and/or maintain the normal vaginal microecology , And/or restore and/or maintain the normal acidity of the vagina, and/or clean and care for the vagina and/or vulva, and/or reduce and/or eliminate vaginal vulvar itching, and/or pain, and/or dryness, and/or Stimulate, and/or discomfort during sexual intercourse, and/or reduce and/or eliminate abnormal leucorrhea and/or leucorrhea peculiar smell.
  • the method for regulating vaginal flora of the present invention includes using a vaginal bacteriostatic composition for the prevention and/or treatment of vaginal flora disorders, and/or bacterial vaginosis, and/or aerobic bacteria Vaginitis, and/or cytolytic vaginosis, and/or vaginal vulvovaginal candida, and/or atrophic vaginitis.
  • the present invention also provides the use of fatty acids and/or their salts in preparing bacteriostatic compositions for regulating vaginal flora.
  • the fatty acids are selected from the group consisting of butyric acid, valeric acid, caproic acid, heptanoic acid, caprylic acid, pelargonic acid, and decanoic acid.
  • the total content of the fatty acid and/or its salt in the composition is 0.001-2.00% (w/ w) within the range; preferably the total content is within the range of 0.001-1.50% (w/w), more preferably within the range of 0.002-1.25% (w/w) selected from butyric acid, caproic acid, caprylic acid, capric acid, ten The fatty acid and/or its salt of a monoacid or a mixed group of these.
  • the fatty acids and/or their salts used in the TM have the same concentration or properties.
  • vaginal flora the use of the fatty acid and/or its salt according to the present invention in the preparation of a bacteriostatic composition for regulating vaginal flora, wherein the regulation of vaginal flora is the same as in the method for regulating vaginal flora of the present disclosure.
  • the type of vaginal flora is the same, that is, it includes at least one of the following: inhibiting abnormal vaginal flora, restoring and/or maintaining vaginal lactobacilli.
  • the use of the fatty acid and/or its salt according to the present invention in the preparation of a bacteriostatic composition for regulating vaginal flora includes applying a vaginal bacteriostatic composition to Restore and/or maintain the normal vaginal flora, and/or restore and/or maintain the normal vaginal microecology, and/or restore and/or maintain the normal acidity of the vagina, and/or clean and care for the vagina and/or vulva, and/or Or reduce and/or eliminate vaginal genital pruritus, and/or pain, and/or dryness, and/or irritation, and/or discomfort during sexual intercourse, and/or reduce and/or eliminate abnormal vaginal discharge and/or leucorrhea peculiar smell.
  • the use of the fatty acid and/or its salt according to the present invention in the preparation of a bacteriostatic composition for regulating vaginal flora includes applying a vaginal bacteriostatic composition to Prevention and/or treatment of vaginal flora imbalance, and/or bacterial vaginosis, and/or aerobic vaginosis, and/or cytolytic vaginosis, and/or vaginal vulvovaginal candida, and/or Or atrophic vaginitis.
  • the present invention also provides a method for preparing a bacteriostatic composition.
  • the preparation method includes the following steps: adding the following components to an excipient base, wherein the excipient base is an aqueous solution or a water-soluble colloid or foam Excipient base for dosage forms or suppositories or tablets:
  • One or more fatty acids and/or their salts with a total content of 0.001-3.00% (w/w) in terms of fatty acids the fatty acids being selected from acetic acid, glycolic acid, lactic acid, propionic acid, acetyl
  • One or more dibasic acids and/or their salts selected from the group consisting of glutaric acid and adipic acid with a total content in the range of 0.05-5.00% (w/w) based on dibasic acid , Pimelic acid, preferably adipic acid;
  • aromatic alcohols selected from the following group with a total content within the range of 0.03-1.00% (w/w): benzyl alcohol, 2,4-dichlorobenzyl alcohol, phenethyl alcohol, phenoxyethanol, And cinnamyl alcohol, preferably phenethyl alcohol, cinnamyl alcohol, or a mixture thereof.
  • aromatic acids and/or their salts selected from the group consisting of benzoic acid, p-hydroxybenzoic acid, p-hydroxybenzoic acid and Methoxybenzoic acid, salicylic acid, cinnamic acid, gentisic acid, and caffeic acid, preferably benzoic acid, cinnamic acid, p-hydroxybenzoic acid, or a mixture thereof;
  • composition adopts one of the following dosage forms: aqueous solution, water-soluble gel, foam, spray, ointment, powder, film, capsule, suppository, and tablet, preferably aqueous solution, or Water-soluble gel, or foam, or spray, or ointment.
  • the total content of the one or more fatty acids and/or salts thereof added in the preparation method is preferably in the range of 0.001-2.00% (w/w), more preferably Within the range of 0.001-1.50% (w/w), most preferably within the range of 0.002%-1.25% (w/w); and/or the added one or more dibasic acids in terms of dibasic acid And/or the total content of its salt is preferably in the range of 0.10-3.50% (w/w), more preferably in the range of 0.50-2.50% (w/w), most preferably in the range of 0.50-1.50% (w/w) And/or the total content of the added one or more aromatic alcohols is preferably in the range of 0.03-0.70% (w/w), more preferably in the range of 0.05-0.60% (w/w), most preferably In the range of 0.08-0.50% (w/w); and/or the total content of one or more aromatic acids and/or their salts added in terms of aromatic acids is preferably in the range of 0.00
  • a non-flowing, viscous, water-soluble colloidal matrix should be selected, which enables the composition to uniformly contact the vaginal mucosa and stays for a long time to exert its effect.
  • the matrix is xanthan gum, and/or carbomer, and/or polycarbophil, and/or dextran, and/or glucomannan, and/or tragacanth, and / Or tragacanth gum, and/or methyl cellulose (MC), and/or carboxymethyl cellulose (CMC), and/or hydroxyethyl cellulose (HEC), and/or hydroxyethyl methyl cellulose (HEMC) and/or hydroxypropyl methylcellulose (HPMC), preferably xanthan gum and carbomer.
  • the composition can be prepared according to the following process: (1) one or more fatty acids and/or their salts, such as propionic acid and/or their sodium salts, and (2) one or more fatty acids and/or their sodium salts.
  • Various dibasic acids and/or their salts such as adipic acid and/or their salts
  • one or more aromatic alcohols such as phenethyl alcohol
  • one or more aromatic acids and/or their salts such as Benzoic acid and/or its sodium salt
  • One or more colloidal bases such as xanthan gum, and other components, etc., mix well, add distilled water quantitatively, stir and mix, dissolve each component and swell the colloidal matrix It is a homogeneous colloid;
  • the pH of the composition is adjusted to the range of 3.1-4.8, preferably 3.6-4.6, more preferably 3.8-4.4 with acid and/or alkali.
  • further sterilization treatment can be performed, and the sterilization can choose the following processes: radiation sterilization, high temperature sterilization (such as 115.6°C, 15-20 minutes; or 100°C, 30 minutes sterilization), or intermittent Sterilize (such as first 80°C for 30 minutes, then 36°C for 5-10 hours, then 80°C for 30 minutes, then 36°C for 5-10 hours, and finally 80°C for 30 minutes).
  • radiation sterilization high temperature sterilization (such as 115.6°C, 15-20 minutes; or 100°C, 30 minutes sterilization), or intermittent Sterilize (such as first 80°C for 30 minutes, then 36°C for 5-10 hours, then 80°C for 30 minutes, then 36°C for 5-10 hours, and finally 80°C for 30 minutes).
  • components such as benzoic acid and/or its sodium salt are separately formulated into a solution, filtered and sterilized, and then added to the sterilized water-soluble colloidal matrix.
  • the above-mentioned components other than xanthan gum can be mixed, water is added, the components are dissolved, sterilized, and divided; or the components are dissolved, filtered, and divided. .
  • the selection of the base and the specific preparation process can refer to methods known to those skilled in the art, for example, in the "Pharmaceutical Science” edited by Fang Liang (see Reference 1 for details) The method of introduction.
  • the prepared tablets when preparing tablets, methods known to those skilled in the art can be referred to, such as the method introduced in "Pharmaceuticals” edited by Fang Liang (for details, see Reference 2), the quantitative fatty acids and / Or its salt, dibasic acid and/or its salt, aromatic alcohol, aromatic acid and/or its salt, and other components, etc., mix uniformly with filling auxiliary materials, and press directly to obtain tablets; auxiliary materials may also be added Ingredients, such as lubricants such as magnesium stearate or disintegrating agents such as sodium carboxymethyl starch, are mixed uniformly and compressed.
  • the prepared tablets can also be dispensed into a drug delivery device, or a sterilization device, or a medical device, or a drug device.
  • the fatty acids and/or their salts, dibasic acids and/ Or its salts, aromatic alcohols, aromatic acids and/or its salts and other components such as sodium benzoate, sodium propionate, caproic acid, phenethyl alcohol, adipic acid, and other components, plus the corresponding auxiliary components to make Powders, films, tablets, or capsules, and then built into sanitary napkins, sanitary pads, or tampons, etc.
  • the fatty acids of the present disclosure And/or its salt, dibasic acid and/or its salt, aromatic alcohol, aromatic acid and/or its salt and other components, such as sodium propionate, caproic acid, phenethyl alcohol, sodium benzoate, adipic acid, and other components It is graded and attached to the inner layer materials of sanitary napkins or sanitary pads or tampons with appropriate auxiliary material components.
  • each unit dosage form when preparing dosage forms such as capsules, suppositories, or tablets, contains a specific content range of each component of the composition of the present disclosure.
  • each unit dosage form contains one or more fatty acids and/or their salts in a total amount of 0.00005-0.15 g in terms of fatty acids, and a total amount of 0.0025-0.25 g in terms of dibasic acid and/or polybasic acid.
  • each unit dosage form contains 0.00005-0.100 grams of one or more fatty acids and/or their salts in a total amount of 0.00005-0.100 grams, and the total amount is 0.005 in terms of dibasic acid and/or polybasic acid -0.175 grams of one or more dibasic acids and/or salts thereof, the total amount of one or more aromatic alcohols is 0.0015 to 0.035 grams, and the total amount of aromatic acids is 0.0015 to 0.025 grams of one or Various aromatic acids and/or their salts.
  • organic acids or their salts used in the preparation method of the present disclosure such as fatty acids and/or their salts, or dibasic acids and/or their salts, or aromatic acids and/or their salts, are soluble in water and are unionized
  • the ratio of molecules to ionized ions, unionized molecules to ionized ions depends on the pH value of the solution and the pKa value of the ionization constant of the organic acid. It can be seen that the organic acid and its salt are both organic acid molecules or organic acid radical ions after being dissolved in water. From this point of view, there is no substantial difference between the two.
  • Commonly used preservatives for skin care products, cosmetics, and bath products, as well as common preservatives for medical products and pharmaceuticals, such as chlorobutanol, benzalkonium chloride, etc. usually have an inhibitory effect on Lactobacillus and other lactic acid bacteria.
  • the prior art (such as PCT/CN2017/105296, ZL201080036139, US8765819) discloses some low-concentration bacteriostatic agents, such as low-concentration phenethyl alcohol, propionic acid and/or its salt, and/or benzoic acid and/or its salt. These low-concentration bacteriostatic agent-containing compositions can inhibit Escherichia coli and Staphylococcus aureus.
  • the inhibition rate of Escherichia coli and Staphylococcus aureus can reach more than 50%, the inhibition rate of Candida albicans is low, and the inhibition rate is less than 50%.
  • bacteriostatic agent can enhance the bacteriostatic effect on Candida albicans.
  • concentration of bacteriostatic agent can not only enhance the antibacterial effect of the antibacterial combination, but also Effectively inhibit Escherichia coli, Staphylococcus aureus, etc., and the inhibition rate of Candida albicans is greater than 50%.
  • concentration of the bacteriostatic agent the stronger the inhibitory effect on Lactobacillus and other lactic acid bacteria.
  • bacteriostatic composition that effectively inhibits harmful microorganisms but does not inhibit beneficial bacteria such as Lactobacillus, and can be used for skin and/or mucous membrane cleaning or bacteriostasis or disinfection, and can be used as an antiseptic for skin care products, cosmetics, bath products, etc.
  • beneficial bacteria such as Lactobacillus
  • the inventor continues to conduct in-depth research on antibacterial compositions as preservatives for medical products and medicines. It was found that suitable fatty acids and/or their salts selectively combined with dibasic acids, aromatic alcohols, aromatic acids, etc., not only have a synergistic antibacterial effect on Staphylococcus aureus and Escherichia coli, but also on Candida albicans, etc.
  • the bacteriostatic composition prepared accordingly is used in the vagina, which can significantly reduce the abnormal flora of the vagina and increase the lactobacillus, and has the effect of regulating the vaginal flora and the acidity of the vagina. Therefore, the bacteriostatic composition of the present disclosure can be used for cleaning or bacteriostasis or disinfection of the skin and/or mucous membranes; and for the preservation of bath products, skin care products, and cosmetics, as well as for the preservation of medical products, medicines, and the like.
  • Lactobacillus refers to the bacteria of the genus Lactobacillus, English Lactobacillus, is a gram-positive, rod-shaped, non-spore, capable of fermenting metabolizable sugars to produce large amounts of lactic acid bacteria, including hundreds of species and subspecies.
  • Lactobacillus is a general term for bacteria that can metabolize fermentable carbohydrates to produce large amounts of lactic acid, including 18 genera and more than 200 species of bacteria. Among them, Lactobacillus is also a kind of lactic acid bacteria.
  • Normal vaginal flora refers to the Nugent score of vaginal flora with a score of 1-3.
  • the bacteria in the vagina are mainly Lactobacillus and the number is large, and the number of other types of bacteria is small.
  • the "other types of bacteria” include gram-positive cocci such as staphylococcus, streptococcus, etc., gram-negative bacilli such as Gardnerella vaginalis, Escherichia coli, etc., and gram-negative cocci such as Veillonella, etc. Sexual anaerobic Prevotella, kinetic Campylobacter, etc.
  • Vaginal abnormal flora refers to the Nugent score of 5-10 points for the vaginal flora.
  • the number of lactobacilli in the vagina is small, and the number of other types of bacteria is large.
  • the "other types of bacteria” include gram-positive cocci such as staphylococcus, streptococcus, etc., gram-negative bacilli such as Gardnerella vaginalis, Escherichia coli, etc., and gram-negative cocci such as Veillonella, etc.
  • Hard microorganisms generally refer to various pathogenic microorganisms with strong pathogenicity, or pathogenic microorganisms of various conditions that cause disease when the body's immunity is reduced, or those that cause food, medicine, cosmetics, and sanitary products to spoil.
  • Microorganisms including but not limited to the following groups of microorganisms: Candida, Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Gardnerella vaginalis, Prevotella, Animus Campylobacter, Aspergillus niger , Skin and/or mucous membrane abnormal flora, and viruses HPV, HIV, etc.
  • Components refer to various ingredients in the composition, including bacteriostatic agents and other ingredients that have no bacteriostatic effect.
  • Bacteriostatic agent refers to various ingredients or combinations thereof that have bacteriostatic effects, and is not limited to conventional bacteriostatic agents or combinations thereof recognized by those skilled in the art.
  • Bacteriostatic rate refers to the test method and judgment standard in Appendix C of GB 15979-2002 "Sanitary Standards for Disposable Sanitary Products”. Antibacterial rate of bacteria.
  • Bacteriostatic effect refers to the inhibitory effect of bacteriostatic agents on bacteria, fungi, etc.
  • the antibacterial effect is judged by the level of antibacterial rate, and the specifics are as follows: antibacterial rate>50%, it is “has antibacterial effect”; antibacterial rate>90%, it is “strong antibacterial effect”.
  • Low-concentration bacteriostatic agent refers to a bacteriostatic agent with a low concentration of ⁇ 50% against Candida albicans.
  • High-concentration bacteriostatic agent refers to a bacteriostatic agent with a high concentration of antibacterial rate>50% against Candida albicans.
  • “Synergy antibacterial effect” refers to the antibacterial rate of the combination of two or more antibacterial agents against Escherichia coli or Staphylococcus aureus or Candida albicans, which is higher than the antibacterial rate of each antibacterial agent alone. The sum is more than 15% higher.
  • compositions of the antibacterial composition are a variety of exemplary compositions of the antibacterial composition.
  • exemplary components in the composition refer to the following substances:
  • the raw materials were weighed according to the following ratio, and 100 g of the composition was prepared basically according to the method of Example 1.
  • Glutamic acid 0.76g, glutamine 0.34g, aspartic acid 0.60g, asparagine 0.98g, isoleucine 0.31g, methionine 0.35g, phenylalanine 0.20g, valine 0.46g, bright 0.78 g of acid and 0.89 g of proline;
  • the raw materials were weighed according to the following ratio, and 100 g of the composition was prepared basically according to the method of Example 1.
  • a tablet containing 60 mg of adipic acid, 5 mg of sodium benzoate, 30 mg of propionic acid, and 60 mg of sucrose per tablet was prepared.
  • vaginal suppository containing 60 mg of adipic acid, 5 mg of sodium benzoate, 30 mg of propionic acid, and 60 mg of maltose per capsule was prepared.
  • This example is used to verify the effect of the composition.
  • the antibacterial rate of Candida albicans is significantly higher than any three of them.
  • the bacteriostatic rate of the solution of the combination of components is also significantly higher than the sum of the bacteriostatic rates of the four components acting separately, suggesting that these four components have a synergistic antibacterial effect on Candida albicans.
  • cinnamic acid 0.05-0.10% salicylic acid can inhibit the white false color of the solution containing the three-component combination of "1.50% adipic acid, 0.45% phenethyl alcohol, and 1.50% propionic acid".
  • the effect of silk yeast has an effect or a significant effect, and the antibacterial effect increases as the concentration of cinnamic acid or salicylic acid increases.
  • the basic antibacterial liquid has antibacterial effect on Candida albicans, and the antibacterial rate is 53.77%;
  • the basic antibacterial solution was added with 1.00% citric acid, 0.70% malic acid, and 0.61% succinic acid.
  • the antibacterial rates against Candida albicans were 49.25%, 54.77%, and 53.27%, respectively.
  • cinnamyl alcohol has a significant effect on the inhibition of Candida albicans by a solution of "1.50% pimelic acid, 0.20% sodium benzoate, and 2.00% propionic acid", and the antibacterial effect is enhanced.
  • the pH value of the solution is 3.86
  • the 0.04% and 0.06% puerarin contained in the components respectively have no effect on the inhibitory effect of Candida albicans, and the antibacterial effect is not weakened. .
  • estrogenic substances such as diethylstilbestrol, hexestrol, estradiol, estrone, estriol, nylestriol, ethinyl estradiol, ethinyl estradiol, ethinyl estradiol, Proestene, and other phytoestrogens, such as daidzein, daidzein, glycitein, puerarin, estradiol, genistein, equol, apigenin, genistein, dyes Lignin, chickpexanthin, couestrol, formononetin, resveratrol, flax lignan, lignan are similar to puerarin in nature and principle of action, therefore, the foregoing can also be inferred
  • the estrogen-like substances and phytoestrogens of the composition will not significantly weaken the inhibitory effect of the composition on Candida albicans.
  • amino acid substances such as glutamine, L-aspartic acid, asparagine, leucine, isoleucine, phenylalanine, valine, proline, Threonine is similar to glutamic acid in nature and principle of action. Therefore, it can also be inferred that the aforementioned amino acid substances will not affect the inhibitory effect of the composition on Candida albicans.
  • the composition contains: 1.50% (w/w) adipic acid, 0.14% (w/w) sodium benzoate, 0.32% (w/w) phenethyl alcohol, 0.54% (w/w) propionic acid, 0.20% ( w/w) caproic acid, 0.20% (w/w) palatinose, 0.60% (w/w) maltose, 0.0005% (w/w) rose essential oil, 2.15% (w/w) xanthan gum
  • Group B gel contains 2.50% (w/w) maltose, 0.20% (w/w) isomaltulose, 0.16% (w/w) sodium benzoate, 0.60% (w/w) sodium propionate, 0.35 %(W/w) phenethyl alcohol, 1.00%(w/w) citric acid, 1.168%(w/w) adipic acid, 2.15%(w/w) xanthan gum, adjust the pH to 3.6
  • Group C gel contains 2.50% (w/w) maltose, 0.20% (w/w) isomaltulose, 0.16% (w/w) sodium benzoate, 0.60% (w/w) sodium propionate, 0.35 %(W/w) phenethyl alcohol, 0.61%(w/w) succinic acid, 1.168%(w/w) adipic acid, 2.15%(w/w) xanthan gum, adjust the pH to 3.6
  • the second group gel contains 1.15% (w/w) sodium propionate, 0.45% (w/w) phenethyl alcohol, 0.20% (w/w) sodium benzoate, 1.50% (w/w) maltose, 1.00% (w/w) citric acid, 2.15% (w/w) xanthan gum, adjust the pH to 3.6
  • Nugent score is vaginal secretion smear and Gram staining followed by microscopic examination. The score is based on the staining, morphology, and number of bacteria, as follows:
  • the vaginal bacteria are mainly gram-negative bacilli, and/or negative cocci and positive cocci, with no or very few gross positive bacilli;
  • vaginal bacteria are mainly gram-negative bacilli, and/or negative cocci, and/or positive cocci, and there are few large gram-positive bacilli;
  • vaginal flora is normal, and the bacteria are mainly gram-positive bacilli.
  • the three groups of gels with a pH value of 3.6 in this experiment have the effects of inhibiting abnormal vaginal flora, restoring vaginal acidity, and restoring vaginal lactobacilli, containing adipic acid and 2 containing citric acid and succinic acid respectively.
  • group gels (B and C groups) the effect of group B is better than that of group C and the second group of gel without adipic acid.
  • the second group of gel without adipic acid inhibits abnormal vaginal flora and restores vaginal acidity
  • the effect of restoring vaginal lactobacillus is the weakest among the three groups of gels.
  • Group A gel contains 2.00% (w/w) isomaltulose, 0.12% (w/w) sodium benzoate, 0.60% (w/w) butyric acid, 1.31% (w/w) adipic acid, 0.30% (w/w) phenethyl alcohol, 0.35% (w/w) malic acid, 2.15% (w/w) xanthan gum, adjust the pH to 4.1
  • Group B gel contains 2.00% (w/w) isomaltulose, 0.12% (w/w) sodium benzoate, 0.60% (w/w) butyric acid, 0.0010% (w/w) capric acid, 1.31 %(W/w) adipic acid, 0.30%(w/w) phenethyl alcohol, 0.35%(w/w) malic acid, 2.15%(w/w) xanthan gum, adjust the pH to 4.1
  • Group C gel contains 2.00% (w/w) isomaltulose, 0.12% (w/w) sodium benzoate, 0.60% (w/w) butyric acid, 0.0015% (w/w) capric acid, 1.31 %(W/w) adipic acid, 0.30%(w/w) phenethyl alcohol, 0.35%(w/w) malic acid, 2.15%(w/w) xanthan gum, adjust the pH to 4.1
  • the three groups of gels containing 0.60% (w/w) butyric acid, 0.00125% (w/w) decanoic acid, and 0.0015% (w/w) decanoic acid in the components of this experiment have Inhibit abnormal vaginal flora, regulate vaginal flora, restore vaginal lactobacillus, and restore normal vaginal acidity.
  • the first group gel contains 0.14% (w/w) sodium benzoate, 0.54% (w/w) propionic acid, 1.46% (w/w) adipic acid, 0.30% (w/w) phenethyl alcohol, 0.35 %(W/w) malic acid, 2.15%(w/w) xanthan gum, adjust the pH to 3.8
  • the second group gel contains 2.00% (w/w) maltose, 0.14% (w/w) sodium benzoate, 0.54% (w/w) propionic acid, 1.46% (w/w) adipic acid, 0.30% (w/w) Phenyl alcohol, 0.35% (w/w) malic acid, 2.15% (w/w) xanthan gum, adjust the pH to 3.8
  • the third group of gel contains 2.0% (w/w) isomaltulose, 0.14% (w/w) sodium benzoate, 0.54% (w/w) propionic acid, 1.46% (w/w) adipic acid , 0.30% (w/w) phenethyl alcohol, 0.35% (w/w) malic acid, 2.15% (w/w) xanthan gum, adjust the pH to 3.8
  • the fourth group of gel contains 2.00% (w/w) isomaltulose, 0.12% (w/w) sodium benzoate, 0.38% (w/w) propionic acid, 1.31% (w/w) adipic acid , 0.0015% (w/w) capric acid, 0.30% (w/w) phenethyl alcohol, 0.35% (w/w) malic acid, 2.15% (w/w) xanthan gum, adjust the pH to 3.9
  • the fifth group of gel contains 2.00% (w/w) isomaltulose, 0.12% (w/w) sodium benzoate, 0.38% (w/w) propionic acid, 1.31% (w/w) adipic acid , 0.01% (w/w) caprylic acid, 0.30% (w/w) phenethyl alcohol, 0.35% (w/w) malic acid, 2.15% (w/w) xanthan gum, adjust the pH to 3.9
  • the pH of vaginal secretions dropped to 4.1 or below in all three groups; the Nugent score of vaginal flora, two of the four cynomolgus monkeys in group 1 without sugar dropped to 4-6 points, and two dropped to 4-6 points.
  • the Nugent score of vaginal flora two of the four cynomolgus monkeys in group 1 without sugar dropped to 4-6 points, and two dropped to 4-6 points.
  • the pH value of this experiment is 3.8, containing 1.46% (w/w) adipic acid, 0.35% (w/w) malic acid, 0.54% (w/w) propionic acid, 0.30% (w/w) phenylethyl alcohol , 0.14% (w/w) sodium benzoate" combination, but no sugar gel, has the effect of inhibiting abnormal vaginal flora, restoring vaginal acidity, and restoring vaginal lactobacillus, as shown in the first group of experimental results.
  • the gels of the second and third groups containing maltose or isomaltulose have a faster and stronger effect of restoring the vaginal lactobacillus than the gel of the first group without sugar, as shown in the second
  • the results of the group experiment and the third group experiment are shown.
  • the pH value of this experiment is 3.9, containing "1.31% (w/w) adipic acid, 0.35% (w/w) malic acid, 0.38% (w/w) propionic acid, 0.30% (w/w) phenylethanol” , 0.12% (w/w) sodium benzoate, 2.0% (w/w) isomaltulose, and gels containing 0.0015% (w/w) capric acid and 0.01% (w/w) caprylic acid respectively, with The effect of inhibiting abnormal vaginal flora, restoring the acidity of the vagina, and restoring the effect of vaginal lactobacillus, as shown in the results of the fourth group of experiments and the fifth group of experiments.
  • the first group of gel contains 2.00% (w/w) isomaltulose, 0.12% (w/w) sodium benzoate, 0.38% (w/w) propionic acid, 1.31% (w/w) adipic acid , 0.04% (w/w) heptanoic acid, 0.30% (w/w) phenethyl alcohol, 0.35% (w/w) malic acid, 2.15% (w/w) xanthan gum, adjust the pH to 3.9
  • the second group of gel contains 2.00% (w/w) isomaltulose, 0.12% (w/w) sodium benzoate, 0.38% (w/w) propionic acid, 1.31% (w/w) hexamethylene Acid, 0.10% (w/w) hexanoic acid, 0.30% (w/w) phenethyl alcohol, 0.35% (w/w) malic acid, 2.15% (w/w) xanthan gum, adjust the pH to 3.9
  • the third group of gel contains 2.00% (w/w) isomaltulose, 0.12% (w/w) sodium benzoate, 0.38% (w/w) propionic acid, 1.31% (w/w) hexamethylene Acid, 0.20% (w/w) valeric acid, 0.30% (w/w) phenethyl alcohol, 0.35% (w/w) malic acid, 2.15% (w/w) xanthan gum, adjust the pH to 3.9
  • the pH value of this experiment is 3.9, containing "2.00% (w/w) isomaltulose, 0.12% (w/w) sodium benzoate, 0.38% (w/w) propionic acid, 1.31% (w/w) /w) adipic acid, 0.30% (w/w) phenethyl alcohol, 0.35% (w/w) malic acid” and 0.04% (w/w) heptanoic acid, 0.10% (w/w) caproic acid,
  • the three groups of gels of 0.20% (w/w) valeric acid and 2.15% (w/w) xanthan gum have the effects of inhibiting abnormal vaginal flora and restoring vaginal lactobacilli.
  • the two groups of gels containing 0.04% (w/w) heptanoic acid and 0.10% (w/w) caproic acid respectively have the effect of restoring the acidity of the vagina.
  • the first group of gel contains 0.10% (w/w) caproic acid, 1.50% (w/w) adipic acid, 2.00% (w/w) maltose, 2.15% (w/w) xanthan gum, adjust pH to 3.1
  • the second group gel contains 2.00% (w/w) propionic acid, 0.30% (w/w) cinnamyl alcohol, 0.60% (w/w) succinic acid, 2.00% (w/w) maltose, 2.15% ( w/w) Xanthan gum, adjust pH to 3.8
  • the third group of gel contains 0.02% (w/w) caprylic acid, 0.25% (w/w) benzoic acid, 1.00% (w/w) citric acid, 2.00% (w/w) maltose, 2.15% (w /w) Xanthan gum, adjust the pH to 3.8
  • the fourth group of gel contains 0.20% (w/w) benzoic acid, 0.25% (w/w) benzyl alcohol, 0.001% (w/w) undecanoic acid, 1.00% (w/w) malic acid, 2.00 %(W/w) maltose, 2.15%(w/w) xanthan gum, adjust the pH to 3.80
  • the fifth group gel contains 0.20% (w/w) benzoic acid, 0.50% (w/w) propionic acid, 1.50% (w/w) adipic acid, 2.00% (w/w) maltose, 2.15% (w/w) Xanthan gum, adjust pH to 3.8
  • the sixth group of gel contains 1.00% (w/w) pimelic acid, 0.60% (w/w) phenethyl alcohol, 1.25% (w/w) butyric acid, 2.00% (w/w) maltose, 2.15% (w/w) Xanthan gum, adjust pH to 3.8
  • pH value 3.8 containing "0.20% (w/w) benzoic acid, 0.25% (w/w) benzyl alcohol, 0.001% (w/w) undecanoic acid, 1.00 %(W/w) malic acid, 2.00%(w/w) maltose, 2.15%(w/w) xanthan gum” was administered 5 times, and the pH value of vaginal secretions in 2 cynomolgus monkeys dropped to 4.6. 1 was reduced to 3.8; 1 was reduced to 4-6 points, and 1 was reduced to 0-3 points;
  • pH value 3.8 containing "0.20% (w/w) benzoic acid, 0.50% (w/w) propionic acid, 1.50% (w/w) adipic acid, 2.00 %(W/w) maltose, 2.15%(w/w) xanthan gum”, after 5 times of medication, the pH value of vaginal secretions in 2 cynomolgus monkeys dropped to 4.6 and 1 dropped to 3.8; vaginal flora Nugent score 1 fell to 4-6 points, 1 fell to 0-3 points;
  • pH value 3.8 containing "1.00% (w/w) pimelic acid, 0.60% (w/w) phenethyl alcohol, 1.25% (w/w) butyric acid, 2.00 %(W/w) maltose, 2.15%(w/w) xanthan gum”, after 5 times of medication, the pH value of vaginal secretions in 2 cynomolgus monkeys dropped to 3.8 and 1 dropped to 4.1; vaginal flora Nugent score 1 dropped to 0-3 points, and 1 dropped to 4-6 points.
  • composition gels have the effects of inhibiting abnormal vaginal flora, restoring vaginal acidity, and restoring vaginal lactobacilli.
  • the first group of gel contains 1.50% (w/w) fumaric acid, 1.00% (w/w) propionic acid, 0.08% (w/w) cinnamic acid, 0.25% (w/w) phenethyl alcohol, 1.40% ( w/w) maltose, 2.15% (w/w) xanthan gum, adjust the pH to 3.8
  • the second group of gel contains 1.50% (w/w) adipic acid, 1.00% (w/w) propionic acid, 0.08% (w/w) cinnamic acid, 0.25% (w/w) phenethyl alcohol, 1.40 %(W/w) maltose, 2.15%(w/w) xanthan gum, adjust the pH to 3.8
  • the gel containing 1.50% (w/w) adipic acid in this experiment has the effects of inhibiting abnormal vaginal flora, restoring vaginal lactobacilli, and restoring vaginal acidity.
  • Gel A contains 1.46% (w/w) adipic acid, 0.70% (w/w) sodium propionate, 0.14% (w/w) sodium benzoate, 0.32% (w/w) phenethyl alcohol, 1.00 %(W/w) citric acid, 1.60%(w/w) maltose, 0.20%(w/w) palatinose, 0.0005%(w/w) rose essential oil, 2.15%(w/w) xanthan gum , Adjust the pH to 3.70
  • the pH value is measured using a pH standard range colorimetric card.
  • the colorimetric card is divided into two ranges, 3.8-4.1 indicates normal, and 4.6-5.4 indicates abnormal
  • the drug was discontinued for 3 days for observation after 5 times of medication, and it had no effect on the pH value and flora of the vaginal secretions of healthy volunteers.
  • the pH value of this experiment is 3.70, containing "1.46% (w/w) adipic acid, 0.70% (w/w) sodium propionate, 0.14% (w/w) sodium benzoate, 0.32% (w/w) /w) Phenyl alcohol, 1.00% (w/w) citric acid, 1.60% (w/w) maltose, 0.20% (w/w) palatinose, 0.0005% (w/w) rose essential oil, 2.15% ( w/w) “Xanthan gum” gel can significantly reduce the abnormal flora in the vagina of BV patients, significantly increase the lactobacillus, and decrease the pH value.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

一种抑菌组合物及其制备方法和用途。抑菌组合物包含一种或多种脂肪酸和/或其盐,一种或多种二元酸和/或其盐,一种或多种芳香醇,和一种或多种芳香酸和/或其盐。抑菌组合物可以制成水溶液剂、水溶性凝胶剂、泡沫剂、喷雾剂、软膏剂、散剂、膜剂、胶囊剂、栓剂或片剂,可用于抑制有害微生物,特别是阴道内的异常菌群。

Description

抑菌组合物及其制备方法和用途 技术领域
本发明涉及一种抑菌组合物,涉及一种抑制有害微生物的方法,还涉及一种调节阴道菌群的方法,还涉及脂肪酸和/或其盐在制备用于调节阴道菌群的抑菌组合物中的用途,以及涉及一种抑菌组合物的制备方法。
背景技术
人体皮肤和黏膜部位与外界相通,易于沾染各种病菌,并可进一步发展为皮肤和/或黏膜部位的病菌定植、感染,或携带并传播病菌。使用抑菌产品清洁皮肤和/或黏膜部位,可有效降低皮肤和/或黏膜部位的病菌载荷,甚至杀灭病菌,从而有助于防止病菌感染和传播。
各种个人洗护用品,如护肤品、或化妆品、或沐浴用品、或洗发用品等,以及医疗用途的各种产品、药品等,为了防止在储存和使用的过程中因微生物污染而导致变质,需要抑制微生物的生长、甚至杀灭污染的微生物,如抑制或杀灭霉菌、酵母菌、大肠埃希菌、绿脓杆菌、金黄色葡萄球菌等。
特别在人体阴道黏膜表面,栖居着大量细菌、真菌等微生物。健康状态下,女性阴道中的细菌以乳杆菌为主,其代谢阴道黏膜上皮细胞中的糖原产酸,使阴道pH值保持在3.5-4.5的范围,并产过氧化氢、细菌素等物质,对致病菌、条件致病菌具有抑制作用,因而是阴道中的有益菌,或称为“阴道正常菌群”。
阴道中还栖居着阴道加德纳菌、普雷沃菌、动弯杆菌、大肠埃希菌、葡萄球菌、假丝酵母菌等,在数量少时无致病性,数量多时则可产生有害的代谢产物、毒素等物质,导致人体发生病理改变和疾病,因而被称为“条件致病菌”。葡萄球菌中,金黄色葡萄球菌的致病性较强,具有代表性;假丝酵母菌中,以白假丝酵母菌最多,占阴道和/或外阴假丝酵母菌感染总数的70% 以上,具有代表性。
当阴道菌群异常、乳杆菌数量少时,不但阴道加德纳菌等条件致病菌的数量增加,而且对毒力强、致病力强的病原菌的抵抗力也降低,因而患生殖道传染性疾病的风险升高,如患淋球菌、滴虫、衣原体、支原体、HIV、HPV等引起的传染病的风险升高。
阴道微生物疾病的治疗当前仍以抗菌为主。抗菌治疗虽然能抑制或杀灭致病菌,但对有益的乳杆菌常常也具有抑制、甚至杀灭作用,导致阴道抗感染力降低,使得阴道感染反复发生、或感染迁延不愈。如何在抗菌治疗时保护阴道中的有益菌,从而提高阴道感染的预防治疗效果,仍然是医学研究的热点问题。
因而,一种安全有效的抑菌产品,既适用于人体皮肤、黏膜部位的清洁卫生抑菌,又适用于沐浴用品、护肤品、化妆品等个人洗护用品的防腐,以及适用于医疗用途的产品、药品等的防腐,还可用于抑制阴道异常菌群、恢复和/或维护阴道的乳杆菌、恢复和/或维护阴道正常菌群、恢复和/或维护阴道的正常微生态,因而具有很强的实用性和很大的市场需求。
背景技术中的信息仅仅在于说明本发明的总体背景,不应视为承认或以任何形式暗示这些信息构成本领域一般技术人员所公知的现有技术。
发明内容
本发明的一个目的是提供一种抑菌组合物。
本发明的另一个目的是提供一种抑制有害微生物的方法。
本发明的又一个目的是提供调节阴道菌群的方法,包括抑制阴道异常菌群、恢复和/或维护阴道的乳杆菌。
本发明的又一个目的是提供脂肪酸和/或其盐在制备调节阴道菌群的抑菌组合物中的用途。
本发明的再一个目的是提供一种抑菌组合物的制备方法。
本发明提供一种抑菌组合物,所述抑菌组合物包括以下组分:
(1)一种或多种脂肪酸和/或其盐,所述脂肪酸选自由乙酸、羟基乙酸、乳酸、丙酸、乙酰丙酸、丁酸、异丁酸、羟基丁酸、戊酸、己酸、庚酸、辛酸、壬酸、癸酸、十一酸、十一烯酸、以及月桂酸组成的组,优选由丙酸、丁酸、己酸、辛酸、癸酸、以及十一酸组成的组,以脂肪酸计的组分(1)的总含量在0.001-3.00%(w/w)范围内;
(2)一种或多种二元酸和/或其盐,所述二元酸选自由戊二酸、己二酸、以及庚二酸组成的组,优选地,所述二元酸为己二酸,以二元酸计的组分(2)的总含量在0.05-5.00%(w/w)范围内;
(3)一种或多种芳香醇,所述芳香醇和选自由苯甲醇、2,4-二氯苯甲醇、苯乙醇、苯氧乙醇、以及肉桂醇组成的组,优选由苯乙醇、肉桂醇组成的组,组分(3)的总含量在0.03-1.00%(w/w)范围内;
(4)一种或多种芳香酸和/或其盐,所述芳香酸选自由苯甲酸、对羟基苯甲酸、对甲氧基苯甲酸、水杨酸、肉桂酸、龙胆酸、以及咖啡酸组成的组,优选由苯甲酸、肉桂酸、以及对羟基苯甲酸组成的组,以芳香酸计的组分(4)的总含量在0.03-1.00%(w/w)范围内;
所述抑菌组合物采用下组的其中一种剂型:水溶液剂、水溶性凝胶剂、泡沫剂、喷雾剂、软膏剂、散剂、膜剂、胶囊剂、栓剂、以及片剂,优选水溶液剂、水溶性凝胶剂、泡沫剂、喷雾剂、以及软膏剂。
在一些实施方案中,一种或多种脂肪酸和/或其盐的总含量以脂肪酸计优选在0.001-2.00%(w/w)范围内,更优选在0.001-1.50%(w/w)范围内,最优选在0.002%-1.25%(w/w)范围内;且/或一种或多种二元酸和/或其盐的总含量以二元酸计优选在0.10-3.50%(w/w)范围内,更优选在0.50-2.50%(w/w)范围内,最优选在0.50-1.50%(w/w)范围内;且/或一种或多种芳香醇的总含量优选在0.03-0.70%(w/w)范围内,更优选在0.05-0.60%(w/w)范围内,最优选在0.08-0.50%(w/w)范围内;且/或一种或多种芳香酸和/或其盐的总含量以芳香 酸计优选在0.03-0.50%(w/w)范围内,更优选在0.05-0.25%(w/w)范围内,最优选在0.08-0.20%(w/w)范围内。
在一些实施方案中,所述抑菌组合物进一步含有总含量在0.10-2.50%(w/w)范围内的一种或多种选自苹果酸、柠檬酸、琥珀酸、酒石酸、马来酸、异柠檬酸、辛二酸、壬二酸、以及癸二酸组成的组的二元酸和/或多元酸,和/或其盐,优选地,含有一种或多种选自由苹果酸、柠檬酸、以及琥珀酸的二元酸和/或多元酸,和/或其盐。所述酸和/或其盐具有缓冲作用,可增强本公开的抑菌组合物的pH稳定性,以及进一步增强本公开的抑菌组合物对人体皮肤和/或黏膜部位的pH值的调节作用。
在一些实施方案中,所述抑菌组合物可选地含有总含量在0.01-20.00%(w/w)范围内的一种或多种选自下组的单糖和/或寡糖和/或多糖:葡萄糖、果糖、甘露糖、半乳糖、麦芽糖、异麦芽糖、蔗糖、异麦芽酮糖、乳糖、乳果糖、海藻糖、纤维二糖、蜜二糖、龙胆二糖、蔗果三糖、蔗果四糖、蔗果五糖、异麦芽三糖、异麦芽四糖、异麦芽五糖、低聚龙胆糖、棉子糖、潘糖、麦芽寡糖、低聚异麦芽酮糖、低聚果糖、葡甘聚糖、低聚半乳糖、糊精、淀粉、以及糖原;优选总含量在0.10-2.00%(w/w)范围内的异麦芽酮糖、乳糖、乳果糖、麦芽糖、异麦芽糖、海藻糖、糖原、或它们的混合物。本公开的含糖的抑菌组合物既可抑制假丝酵母菌、金黄色葡萄球菌、大肠埃希菌、铜绿假单胞菌、阴道加德纳菌、普雷沃菌、动弯杆菌、黑曲霉菌、皮肤和/或黏膜部位的异常菌群等,又可促进和/或维护皮肤和/或黏膜部位的乳酸菌、促进和/或维护皮肤和/或黏膜部位的酸度,可用于预防和/或治疗皮肤和/或黏膜部位的乳酸菌减少、皮肤和/或黏膜部位的菌群失调,如用于预防和/或治疗细菌性阴道病、或需氧菌性阴道炎、或萎缩性阴道炎,或用于阴道炎辅助治疗、或阴道炎治疗后恢复,或用于生殖道感染的治疗等。
在一些实施方案中,所述抑菌组合物可选地含有总含量在0.10-6.00%(w/w)范围内的一种或多种选自下组的氨基酸和/或其盐:L-谷氨酸、 谷氨酰胺、L-天冬氨酸、天冬氨酰胺、亮氨酸、异亮氨酸、苯丙氨酸、缬氨酸、脯氨酸、以及苏氨酸,优选总含量在0.50-3.00%(w/w)范围内的谷氨酸和/或其盐、和/或天冬氨酸和/或其盐、或它们的混合物。本公开的含氨基酸和/或其盐的抑菌组合物可减少乳酸菌产酸,从而减弱皮肤和/或黏膜部位的酸度,适用于调节皮肤和/或黏膜部位的微环境,如用于治疗或辅助治疗细胞溶解性阴道病、阴道外阴假丝酵母菌病等。
在一些实施方案中,所述抑菌组合物可选地含有总含量在0.001-0.50%(w/w)范围内的一种或多种单萜或倍半萜类化合物,包括但不限于:香茅醇、芳樟醇、香叶醇、橙花醇、桉叶醇、松油醇、香芹醇、薄荷醇、以及薰衣草醇。含单萜或倍半萜类化合物既可增强抑菌组合物的抑菌作用,又可为组合物提供芳香气味。
在一些实施方案中,所述抑菌组合物可选地含有总含量在0.0001-0.05%(w/w)范围内一种或多种植物芳香油类物质,包括但不限于:玫瑰精油、丁香油、麝香草油、薰衣草油、薄荷油、艾叶油、桉叶油、黄樟油、山苍子精油、肉桂精油、月桂叶油、以及百里香油。植物芳香油既可增强组合物的抑菌作用,又可为组合物提供芳香气味。
在一些实施方案中,所述抑菌组合物可选地含有总含量在0.001-0.50%(w/w)范围内一种或多种选自下组的维生素类物质:维生素A、维生素C、维生素D、以及维生素E,所述维生素类物质既可为高纯度的所述维生素类物质,也可为含有所述维生素类物质的植物提取物,所述维生素类物质具有抗氧化、或促进皮肤细胞生长、或调节免疫功能、或维持黏膜上皮细胞完整性等作用,可增强抑菌组合物的稳定性,或对人体皮肤和/或黏膜起保护作用。
在一些实施方案中,所述抑菌组合物可选地含有一种或多种选自下组的组分:脱氢乙酸、脱氢乙酸钠、山梨酸、山梨酸钾、山梨酸钠、纳他霉素、岩白菜素、环庚三烯酚酮、肉桂醛、土槿乙酸、绿原酸、1,2-戊二醇、1,2- 己二醇、1,6-己二醇、1,2-辛二醇、1,2-癸二醇、对羟基苯乙酮、2,4-二羟基苯乙酮、对羟基苯甲酸甲酯、对羟基苯甲酸乙酯、对羟基苯甲酸丙酯、溶菌酶、单辛酸甘油酯、单癸酸甘油酯、以及单月桂酸甘油酯。所述组分用于进一步增强本公开的抑菌组合物对假丝酵母菌、金黄色葡萄球菌、大肠埃希菌、铜绿假单胞菌、阴道加德纳菌、普雷沃菌、动弯杆菌、黑曲霉菌、皮肤和/或黏膜部位的异常菌群等,以及其它有害微生物包括但不限于HIV、HPV等病毒的抑菌或抗菌作用。
在一些实施方案中,所述抑菌组合物进一步含有一种或多种抗菌药物,包括但不限于:硝基咪唑类药物如甲硝唑、替硝唑、奥硝唑,氨基糖甙类药物如庆大霉素、妥布霉素、阿米卡星、西索米星、奈替米星,喹诺酮类药物如环丙沙星、氧氟沙星、左氧氟沙星,呋喃类药物如硝呋太尔、硝呋醛肟、呋喃西林、呋喃唑酮、呋喃妥因,磺胺类药物如磺胺嘧啶银、磺胺醋酰钠,吡咯类药物如克霉唑、氟康唑、咪康唑、酮康唑,丙烯胺类药物如萘替芬、特比萘芬,多烯类抗生素如两性霉素B、制霉菌素、制酵母菌素、纳他霉素。优选甲硝唑、硝呋太尔、克霉唑、或它们的混合物。本公开的含抗菌药物的抑菌组合物适用于皮肤和/或黏膜,如预防和/或治疗皮肤的细菌和/或真菌感染、预防和/或治疗口腔黏膜的细菌或真菌感染,以及预防和/或治疗阴道黏膜的细菌性阴道病、或需氧菌阴道炎、或阴道外阴假丝酵母菌病等。
在一些实施方案中,所述抑菌组合物采用下组的其中一种剂型:水溶液剂、水溶性凝胶剂、泡沫剂、喷雾剂、以及软膏剂;所述水溶液剂、或水溶性凝胶剂、或泡沫剂、或喷雾剂、或软膏剂的pH值的范围为3.1-4.8,优选pH值的范围为3.6-4.6,更优选pH值的范围为3.8-4.4。
在一些实施方案中,所述抑菌组合物为水溶性凝胶剂,所述水溶性凝胶剂还含有一种或多种非流动性、粘性、水溶性胶体基质,包括但不限于黄原胶、卡波姆、聚卡波非、葡聚糖、葡甘聚糖、黄芪胶、西黄芪胶、甲基纤维素(MC)、羧甲基纤维(CMC)、羟乙基纤维素(HEC)、羟乙基甲基纤维素 (HEMC)、羟丙基甲基纤维素(HPMC),优选黄原胶、卡波姆。
本公开的抑菌组合物对有害微生物具有抑制作用,其中所述有害微生物包括但不限于假丝酵母菌、金黄色葡萄球菌、大肠埃希菌、铜绿假单胞菌、阴道加德纳菌、普雷沃菌、动弯杆菌、黑曲霉菌,皮肤和/或黏膜的异常菌群,其它各种致病性或条件致病性的需氧菌、兼性需氧菌、厌氧菌、霉菌,以及HPV、HIV等病毒。
因而,本公开的抑菌组合物既可用于人体皮肤和/或黏膜的清洁和/或抑菌和/或消毒,如用于阴道黏膜的清洁和/或抑菌和/或消毒,也可用于各种沐浴用品、洗发用品、护肤品、化妆品等个人洗护用品的防腐,或用于医疗用途的产品、药品等的防腐。
在一些实施方案中,本公开的抑菌组合物可作为治疗性产品、或其有效组分、或其防腐剂,所述治疗性产品包括但不限于药品、消毒剂、黏膜表面杀微生物剂、抗菌剂、抑菌剂、微生态调节剂、菌群调节剂、微环境调节剂、微生物调节剂、一次性使用医疗用品,等等,或者以医疗器械、药物器械、消毒器械、以及阴道用器械的组成部分的形式存在。
在一些实施方案中,本公开的抑菌组合物为非治疗性产品、或其有效组分、或其防腐剂,其中所述非治疗性产品以下组中的其中一种形式存在:保健用品、卫生用品、个人洗护用品、化妆品、一次性使用卫生用品、清洁用品、日用品、微生态护理品、除异味剂、润滑剂、湿润剂、洗剂、清洁剂、养护剂、止痒剂、清新剂,或者以卫生巾、卫生护垫、以及卫生棉条的组成部分的形式存在。
在一些实施方案中,本发明的抑菌组合物为阴道用抑菌组合物,所述阴道用抑菌组合物包括以下组分:
(1)以脂肪酸计的总含量在0.001-2.00%(w/w)范围内的一种或多种选自下组的脂肪酸和/或其盐:乙酸、羟基乙酸、乳酸、丙酸、乙酰丙酸、丁酸、戊酸、己酸、庚酸、辛酸、壬酸、癸酸、十一酸、十一烯酸、以及月桂酸, 优选总量在0.001-1.50%(w/w)范围内的丙酸、丁酸、己酸、辛酸、癸酸、十一酸、或它们的混合物,更优选的总含量在0.002-1.25%(w/w)范围内;
(2)以二元酸计的总含量在0.50-2.50%(w/w)范围内的一种或多种选自下组的二元酸和/或其盐:戊二酸、己二酸、庚二酸,优选总含量在0.50-1.50%(w/w)范围内的己二酸;
(3)总含量在0.05-0.60%(w/w)范围内的一种或多种选自下组的芳香醇:苯甲醇、2,4-二氯苯甲醇、苯乙醇、苯氧乙醇、肉桂醇,优选总含量在0.08-0.50%(w/w)范围内的苯乙醇、肉桂醇、或它们的混合物;
(4)以芳香酸计的总含量在0.05-0.25%(w/w)范围内的一种或多种选自下组的芳香酸和/或其盐:苯甲酸、对羟基苯甲酸、对甲氧基苯甲酸、水杨酸、肉桂酸、龙胆酸、以及咖啡酸,优选总含量在0.08-0.20%(w/w)范围内的苯甲酸、肉桂酸、对羟基苯甲酸、或它们的混合物。
所述阴道用抑菌组合物采用下组的其中一种剂型:水溶液剂、水溶性凝胶剂、泡沫剂、喷雾剂、软膏剂、散剂、膜剂、胶囊剂、栓剂、以及片剂,优选水溶液剂、水溶性凝胶剂、泡沫剂、喷雾剂、以及软膏剂。
在一些实施方案中,本公开的阴道用抑菌组合物还进一步含有总含量在0.001-1.00%(w/w)范围内的一种或多种选自下组的雌激素类物质:己烯雌酚、己烷雌酚、雌二醇、雌酮、雌三醇、尼尔雌醇、炔雌醇、炔雌醇环戊醚、炔雌甲醚、以及普罗雌烯,优选雌三醇、普罗雌烯。本公开的含有雌激素类物质的阴道用抑菌组合物可促进阴道黏膜上皮细胞合成糖原,促进有益的乳杆菌生长,尤其适用于绝经期或绝经后或产后。
在一些实施方案中,本公开的阴道用抑菌组合物还进一步含有总含量在0.001-1.00%(w/w)范围内的一种或多种选自下组的植物雌激素类物质:大豆苷、黄豆苷元、黄豆黄素、葛根素、拟雌内酯、金雀异黄酮、雌马醇、芹黄素、染料木甙、染料木素、鸡豆黄素、香豆雌酚、芒柄花黄素、白藜芦醇、亚麻木酚素、以及木脂素。本公开的含植物雌激素类物质的阴道用抑菌组合 物可促进阴道黏膜上皮细胞合成糖原、促进有益的乳杆菌生长,尤其适用于绝经期或绝经后或产后。
本公开的阴道用抑菌组合物可根据不同适用需求,选择性地含有水或黄原胶或卡波姆等不同剂型基质,或选择性地进一步含有一种或多种如前所述的组分,如总含量在0.10-2.50%(w/w)范围内的苹果酸、柠檬酸、琥珀酸等二元酸和/或其盐、多元酸和/或其盐,和/或脱氢乙酸、单辛酸甘油酯等抗抑菌剂,和/或总含量在0.01-20.00%范围内的异麦芽酮糖、乳糖、麦芽糖等糖类物质,和/或总含量在0.10-6.00%(w/w)范围内的谷氨酸和/或其盐、天门冬氨酸和/或其盐等氨基酸类物质,和/或总含量在0.001-0.50%(w/w)范围内的香茅醇、芳樟醇等单萜或倍半萜类化合物,和/或总含量在0.0001-0.05%(w/w)范围内的玫瑰精油、丁香油等植物芳香油类物质,和/或总量在0.001-0.50%(w/w)范围内的维生素A、维生素C等维生素类物质,和/或甲硝唑、硝呋太尔、克霉唑等抗菌药物类物质。
本公开的阴道用抑菌组合物对阴道中的异常菌群具有抑制作用,但对阴道中的乳杆菌具有恢复和/或维护和/或促进作用,可用于恢复和/或维护阴道的正常菌群、恢复和/或维护阴道的正常微生态、恢复和/或维护阴道的正常酸度。
因而,本公开的阴道用抑菌组合物可用于清洁护理阴道和/或外阴,和/或减轻和/或消除阴道外阴瘙痒、和/或疼痛、和/或干涩、和/或刺激、和/或性交不适,和/或减轻和/或消除白带异常、和/或白带异味等,以及用于预防和/或治疗和/或辅助治疗阴道菌群失调、和/或细菌性阴道病、和/或需氧菌性阴道炎、和/或细胞溶解性阴道病、和/或阴道外阴假丝酵母菌病、和/或萎缩性阴道炎等。
本发明还提供一种抑制有害微生物的方法,包括使用抑菌组合物的步骤,其中所述抑菌组合物含有:
(1)一种或多种脂肪酸和/或其盐,所述脂肪酸选自由乙酸、羟基乙酸、 乳酸、丙酸、乙酰丙酸、丁酸、异丁酸、羟基丁酸、戊酸、己酸、庚酸、辛酸、壬酸、癸酸、十一酸、十一烯酸、以及月桂酸组成的组,优选自由丙酸、丁酸、己酸、辛酸、癸酸、以及十一酸组成的组;以脂肪酸计组分(1)的总含量在0.001-3.00%(w/w)范围内,优选在0.001-2.00%(w/w)范围内,更优选在0.001-1.50%(w/w)范围内,最优选在0.002%-1.25%(w/w)范围内;
(2)一种或多种二元酸和/或其盐,所述二元酸选自由戊二酸、己二酸、以及庚二酸组成的组,优选为己二酸;以二元酸计组分(2)的总含量在0.05-5.00%(w/w)范围内,优选在0.10-3.50%(w/w)范围内,更优选在0.50-2.50%(w/w)范围内,最优选在0.50-1.50%(w/w)范围内;
(3)一种或多种芳香醇,所述芳香醇选自由苯甲醇、2,4-二氯苯甲醇、苯乙醇、苯氧乙醇、以及肉桂醇组成的组,优选为苯乙醇、肉桂醇、或它们的混合物;组分(3)其总含量在0.03-1.00%(w/w)范围内,优选在0.03-0.70%(w/w)范围内,更优选在0.05-0.60%(w/w)范围内,最优选在0.08-0.50%(w/w)范围内;
(4)一种或多种芳香酸和/或其盐,所述芳香酸选自由苯甲酸、对羟基苯甲酸、对甲氧基苯甲酸、水杨酸、肉桂酸、龙胆酸、以及咖啡酸组成的组,优选自由苯甲酸、肉桂酸、以及对羟基苯甲酸组成的组;以芳香酸计的组分(4)的总含量在0.03-1.00%(w/w)范围内,优选在0.03-0.50%(w/w)范围内,更优选在0.05-0.25%(w/w)范围内,最优选在0.08-0.20%(w/w)范围内。
其中所述抑菌组合物采用下组的其中一种剂型:水溶液剂、水溶性凝胶剂、泡沫剂、喷雾剂、软膏剂、散剂、膜剂、胶囊剂、栓剂、以及片剂,优选水溶液剂、水溶性凝胶剂、泡沫剂、喷雾剂、以及软膏剂。
在一些实施方案中,本公开的抑制有害微生物的方法中所述的有害微生物包括但不限于下组微生物中至少一种:假丝酵母菌、金黄色葡萄球菌、大肠埃希菌、铜绿假单胞菌、阴道加德纳菌、普雷沃菌、动弯杆菌、黑曲霉菌,皮肤和/或黏膜的异常菌群,其它各种致病性或条件致病性的需氧菌、兼性需 氧菌、厌氧菌、霉菌,以及病毒HPV、HIV,等等。
因而,本公开的抑制有害微生物的方法中所述的抑菌组合物既可用于人体皮肤和/或黏膜的清洁和/或抑菌和/或消毒,如用于阴道黏膜的清洁和/或抑菌和/或消毒,也可用于各种沐浴用品、或洗发用品、或护肤品、或化妆品等个人洗护用品的防腐,或用于医疗用途的产品、药品等的防腐。
在一些实施方案中,本公开的抑制有害微生物的方法中所述的抑菌组合物为治疗性产品、或其有效组分、或其防腐剂,所述治疗性产品包括但不限于药品、消毒剂、抗菌剂、抑菌剂、黏膜表面杀微生物剂、菌群调节剂、微生态调节剂、微环境调节剂、微生物调节剂、一次性使用医疗用品等,或为医疗器械、或药物器械、或消毒器械、以及阴道用器械的组成部分。
在一些实施方案中,本公开的抑制有害微生物的方法中所述的抑菌组合物为非治疗性产品、或其有效组分、或其防腐剂,所述非治疗性产品包括但不限于保健用品、个人洗护用品、化妆品、卫生用品、一次性使用卫生用品、清洁用品、日用品、微生态护理品、除异味剂、润滑剂、湿润剂、洗剂、清洁剂、养护剂、止痒剂、清新剂等,或可作为卫生用品或清洁护理品的组成部分,如作为卫生巾、或卫生护垫、或卫生棉条的组成部分。
当本公开的抑制有害微生物的方法中所述的抑菌组合物用于防腐时,须使沐浴用品、或洗发用品、或护肤品、或化妆品、或药品、及其它医疗用途的产品等等产品中所含的本公开中所述抑菌组合物各组分的含量,亦即所述以脂肪酸计的一种或多种脂肪酸和/或其盐的总含量、以二元酸计的一种或多种二元酸和/或其盐的总含量、一种或多种芳香醇的总含量、以芳香酸计的一种或多种芳香酸和/或其盐的总含量等,均符合本公开中所述抑菌组合物中四种组分的总含量的范围。
本发明还提供一种调节阴道菌群的方法,其中调节阴道菌群包括下述中的至少一种:抑制阴道异常菌群、恢复和/或维护阴道的乳杆菌,所述方法包括使用阴道用抑菌组合物的步骤,其中所述阴道用抑菌组合物含有以脂肪酸 计的总含量在0.001-2.00%(w/w)范围内的一种或多种脂肪酸和/或其盐,所述脂肪酸选自由丁酸、戊酸、己酸、庚酸、辛酸、壬酸、癸酸、十一酸、十一烯酸、以及月桂酸组成的组,优选总含量在0.001-1.50%(w/w)范围内,更优选在0.002-1.25%(w/w)范围内的选自丁酸、己酸、辛酸、癸酸、十一酸、或它们的混合物组成的组的脂肪酸和/或其盐。
其中所述阴道用抑菌组合物采用下组的其中一种剂型:水溶液剂、水溶性凝胶剂、泡沫剂、喷雾剂、软膏剂、散剂、膜剂、胶囊剂、栓剂、以及片剂;优选水溶液剂、水溶性凝胶剂、泡沫剂、喷雾剂、以及软膏剂。
在一些实施方案中,本发明的调节阴道菌群的方法中所述的阴道用抑菌组合物还含有以二元酸计的总含量在0.50-2.50%(w/w)范围内的一种或多种二元酸和/或其盐,所述二元酸选自由戊二酸、己二酸、以及庚二酸组成的组,优选总含量在0.50-1.50%(w/w)范围内的己二酸、和/或其盐。所述己二酸等二元酸和/或其盐与本公开的丁酸等脂肪酸和/或其盐的组合,可增强所述脂肪酸和/或其盐对白假丝酵母菌的抑菌作用。
在一些实施方案中,本发明的调节阴道菌群的方法中所述的阴道用抑菌组合物还含有总含量在0.05-0.60%(w/w)范围内的一种或多种选自下组的芳香醇:苯甲醇、2,4-二氯苯甲醇、苯乙醇、苯氧乙醇、肉桂醇,优选总含量在0.08-0.50%(w/w)范围内的苯乙醇、肉桂醇、或它们的混合物。所述苯乙醇等芳香醇与本公开的丁酸等脂肪酸和/或其盐的组合,可增强所述脂肪酸和/或其盐对白假丝酵母菌、金黄色葡萄球菌、大肠埃希菌、以及阴道异常菌群等的抑菌作用。
在一些实施方案中,本发明的调节阴道菌群的方法中所述的阴道用抑菌组合物还含有以芳香酸计的总含量在0.05-0.25%(w/w)范围内的一种或多种芳香酸和/或其盐,所述芳香酸选自由苯甲酸、对羟基苯甲酸、对甲氧基苯甲酸、水杨酸、肉桂酸、龙胆酸、以及咖啡酸组成的组,优选总含量在0.08-0.20%(w/w)范围内的苯甲酸、肉桂酸、对羟基苯甲酸、或它们的混合物。 所述苯甲酸等芳香酸和/或其盐与本公开的丁酸等脂肪酸和/或其盐的组合,可增强所述脂肪酸和/或其盐对白假丝酵母菌、金黄色葡萄球菌、大肠埃希菌、以及阴道异常菌群等的抑菌作用。
在一些实施方案中,本发明的调节阴道菌群的方法中所述的阴道用抑菌组合物含有:(1)以脂肪酸计的总含量在0.001-2.00%(w/w)范围内的一种或多种脂肪酸和/或其盐,所述脂肪酸选自由丁酸、戊酸、己酸、庚酸、辛酸、壬酸、癸酸、十一酸、十一烯酸、以及月桂酸组成的组,优选总含量在0.001-1.50%(w/w)范围内,更优选在0.002-1.25%(w/w)范围内的选由自丁酸、己酸、辛酸、癸酸、十一酸、或它们的混合物组成的组的脂肪酸、和/或其盐;(2)以二元酸计的总含量在0.50-2.50%(w/w)范围内的一种或多种二元酸和/或其盐,所述二元酸选自由戊二酸、己二酸、以及庚二酸组成的组,优选总含量在0.50-1.50%(w/w)范围内的己二酸,和/或其盐;(3)总含量在0.05-0.60%(w/w)范围内的一种或多种选自下组的芳香醇:苯甲醇、2,4-二氯苯甲醇、苯乙醇、苯氧乙醇、肉桂醇,优选总含量在0.08-0.50%(w/w)范围内的苯乙醇、肉桂醇、或它们的混合物。
本公开的己二酸等二元酸和/或其盐、苯乙醇等芳香醇与丁酸等脂肪酸和/或其盐的组合,对白假丝酵母菌、金黄色葡萄球菌、大肠埃希菌等具有协同抑菌作用,以及对阴道异常菌群具有抑制作用。
在一些实施方案中,本公开的调节阴道菌群的方法中所述的阴道用抑菌组合物含有:(1)以脂肪酸计的总含量在0.001-2.00%(w/w)范围内的一种或多种脂肪酸和/或其盐,所述脂肪酸选自由丁酸、戊酸、己酸、庚酸、辛酸、壬酸、癸酸、十一酸、十一烯酸、以及月桂酸组成的组,优选总含量在0.001-1.50%(w/w)范围内,更优选在0.002-1.25%(w/w)范围内的选自由丁酸、己酸、辛酸、癸酸、十一酸、或它们的混合物组的脂肪酸、和/或其盐;(2)以二元酸计的总含量在0.50-2.50%(w/w)范围内的一种或多种二元酸和/或其盐,所述二元酸选自由戊二酸、己二酸、以及庚二酸组成的组,优选总含量 在0.50-1.50%(w/w)范围内的己二酸,和/或其盐;(3)以芳香酸计的总含量在0.05-0.25%(w/w)范围内的一种或多种芳香酸和/或其盐,所述芳香酸选自由苯甲酸、对羟基苯甲酸、对甲氧基苯甲酸、水杨酸、肉桂酸、龙胆酸、以及咖啡酸组成的组,优选总含量在0.08-0.20%(w/w)范围内的选自由苯甲酸、肉桂酸、对羟基苯甲酸、或它们的混合物组成的组的芳香酸、和/或其盐。
本公开的己二酸等二元酸和/或其盐、苯甲酸等芳香酸和/或其盐与丁酸等脂肪酸和/或其盐的组合,对白假丝酵母菌、金黄色葡萄球菌、大肠埃希菌等具有协同抑菌作用,以及对阴道异常菌群具有抑制作用。
在一些实施方案中,本公开的调节阴道菌群的方法中所述的阴道用抑菌组合物含有:(1)以脂肪酸计的总含量在0.001-2.00%(w/w)范围内的一种或多种脂肪酸和/或其盐,所述脂肪酸选自由丁酸、戊酸、己酸、庚酸、辛酸、壬酸、癸酸、十一酸、十一烯酸、以及月桂酸组成的组,优选总含量在0.001-1.50%(w/w)范围内,更优选在0.002-1.25%(w/w)范围内的选自由丁酸、己酸、辛酸、癸酸、十一酸、或它们的混合物组成的组的脂肪酸、和/或其盐;(2)总含量在0.05-0.60%(w/w)范围内的一种或多种选自下组的芳香醇:苯甲醇、2,4-二氯苯甲醇、苯乙醇、苯氧乙醇、以及肉桂醇,优选总含量在0.08-0.50%(w/w)范围内的苯乙醇、肉桂醇、或它们的混合物;(3)以芳香酸计的总含量在0.05-0.25%(w/w)范围内的一种或多种芳香酸和/或其盐,所述芳香酸选自由苯甲酸、对羟基苯甲酸、对甲氧基苯甲酸、水杨酸、肉桂酸、龙胆酸、以及咖啡酸组成的组,优选总含量在0.08-0.20%(w/w)范围内的选自由苯甲酸、肉桂酸、对羟基苯甲酸、或它们的混合物组成的组的芳香酸、和/或其盐。
本公开的苯乙醇等芳香醇、苯甲酸等芳香酸和/或其盐与丁酸等脂肪酸和/或其盐的组合,对白假丝酵母菌、金黄色葡萄球菌、大肠埃希菌等具有协同抑菌作用,以及对阴道异常菌群具有抑制作用。
在一些实施方案中,本公开的调节阴道菌群的方法中所述阴道用抑菌组 合物含有:(1)以脂肪酸计的总含量在0.001-2.00%(w/w)范围内的一种或多种脂肪酸和/或其盐,所述脂肪酸选自由丁酸、戊酸、己酸、庚酸、辛酸、壬酸、癸酸、十一酸、十一烯酸、以及月桂酸组成的组,优选总含量在0.001-1.50%(w/w)范围内,更优选在0.002-1.25%(w/w)范围内的选自由丁酸、己酸、辛酸、癸酸、十一酸、或它们的混合物组成的组的脂肪酸、和/或其盐;(2)以二元酸计的总含量在0.50-2.50%(w/w)范围内的一种或多种二元酸和/或其盐,所述二元酸选自由戊二酸、己二酸、以及庚二酸组成的组,优选总含量在0.50-1.50%(w/w)范围内的己二酸,和/或其盐;(3)总含量在0.05-0.60%(w/w)范围内的一种或多种选自下组的芳香醇:苯甲醇、2,4-二氯苯甲醇、苯乙醇、苯氧乙醇、以及肉桂醇,优选总含量在0.08-0.50%(w/w)范围内的苯乙醇、肉桂醇、或它们的混合物;(4)以芳香酸计的总含量在0.05-0.25%(w/w)范围内的一种或多种芳香酸和/或其盐,所述芳香酸选自由苯甲酸、对羟基苯甲酸、对甲氧基苯甲酸、水杨酸、肉桂酸、龙胆酸、以及咖啡酸组成的组,优选总含量在0.08-0.20%(w/w)范围内的苯甲酸、肉桂酸、对羟基苯甲酸、或它们的混合物组成的组的芳香酸和/或其盐。
本公开的己二酸等二元酸和/或其盐、苯乙醇等芳香醇、苯甲酸等芳香酸和/或其盐与丁酸等脂肪酸和/或其盐的组合,对白假丝酵母菌、金黄色葡萄球菌、大肠埃希菌等具有协同抑菌作用,以及对阴道异常菌群具有抑制作用。所述抑菌组合物用于阴道后,阴道中的异常菌群显著减少、乳杆菌显著增加,所述组合物具有抑制阴道异常菌群、恢复和/或维护和/或促进阴道中的乳杆菌的作用、以及恢复和/或维护阴道的正常酸度的作用。
在一些实施方案中,本公开的调节阴道菌群的方法中所述的阴道用抑菌组合物还进一步含有总含量在0.001-1.00%(w/w)范围内的一种或多种选自下组的雌激素类物质:己烯雌酚、己烷雌酚、雌二醇、雌酮、雌三醇、尼尔雌醇、炔雌醇、炔雌醇环戊醚、炔雌甲醚、普罗雌烯,优选雌三醇、以及普罗雌烯。雌激素类物质可促进阴道黏膜上皮细胞合成糖原,促进有益的乳杆菌 生长,本公开的含有雌激素类物质的抑菌组合物尤其适用于绝经期或绝经后或产后。
在一些实施方案中,本公开的调节阴道菌群的方法中所述的阴道用抑菌组合物还进一步含有总含量在0.001-1.00%(w/w)范围内的一种或多种选自下组的植物雌激素类物质:大豆苷、黄豆苷元、黄豆黄素、葛根素、拟雌内酯、金雀异黄酮、雌马醇、芹黄素、染料木甙、染料木素、鸡豆黄素、香豆雌酚、芒柄花黄素、白藜芦醇、亚麻木酚素、以及木脂素。植物雌激素类物质可促进阴道黏膜上皮细胞合成糖原,促进有益的乳杆菌生长,本公开的含有植物雌激素类物质的抑菌组合物尤其适用于绝经期或绝经后或产后。
在一些实施方案中,本发明的调节阴道菌群的方法,其包括将阴道用抑菌组合物用于恢复和/或维护阴道正常菌群、和/或恢复和/或维护阴道的正常微生态,和/或恢复和/或维护阴道的正常酸度、和/或清洁护理阴道和/或外阴,和/或减轻和/或消除阴道外阴瘙痒、和/或疼痛、和/或干涩、和/或刺激、和/或性交不适,和/或减轻和/或消除白带异常、和/或白带异味。
在一些实施方案中,本发明的调节阴道菌群方法,其包括将阴道用抑菌组合物用于预防和/或治疗阴道菌群失调、和/或细菌性阴道病、和/或需氧菌性阴道炎、和/或细胞溶解性阴道病、和/或阴道外阴假丝酵母菌病、和/或萎缩性阴道炎。
本发明还提供脂肪酸和/或其盐在制备用于调节阴道菌群的抑菌组合物中的用途,所述脂肪酸选自由丁酸、戊酸、己酸、庚酸、辛酸、壬酸、癸酸、十一酸、十一烯酸、以及月桂酸组成的组中的至少一种,以脂肪酸计的所述脂肪酸和/或其盐在组合物中的总含量在0.001-2.00%(w/w)范围内;优选总含量在0.001-1.50%(w/w)范围内,更优选在0.002-1.25%(w/w)范围内的选自丁酸、己酸、辛酸、癸酸、十一酸、或它们的混合组成的组的脂肪酸和/或其盐。
在一些实施方案中,根据本发明的脂肪酸和/或其盐在制备用于调节阴道 菌群的抑菌组合物中的用途,其中脂肪酸和/或其盐与本公开中调节阴道菌群的方法中使用的脂肪酸和/或其盐具有相同的浓度或性质。
在一些实施方案中,根据本发明的脂肪酸和/或其盐在制备用于调节阴道菌群的抑菌组合物中的用途,其中调节阴道菌群与本公开中调节阴道菌群的方法中调节阴道菌群的类型相同,即包括下述中的至少一种:抑制阴道异常菌群、恢复和/或维护阴道的乳杆菌。
在一些实施方案中,根据本发明的脂肪酸和/或其盐在制备用于调节阴道菌群的抑菌组合物中的用途,其中所述调节阴道菌群包括将阴道用抑菌组合物用于恢复和/或维护阴道正常菌群、和/或恢复和/或维护阴道的正常微生态,和/或恢复和/或维护阴道的正常酸度、和/或清洁护理阴道和/或外阴,和/或减轻和/或消除阴道外阴瘙痒、和/或疼痛、和/或干涩、和/或刺激、和/或性交不适,和/或减轻和/或消除白带异常、和/或白带异味。
在一些实施方案中,根据本发明的脂肪酸和/或其盐在制备用于调节阴道菌群的抑菌组合物中的用途,其中所述调节阴道菌群包括将阴道用抑菌组合物用于预防和/或治疗阴道菌群失调、和/或细菌性阴道病、和/或需氧菌性阴道炎、和/或细胞溶解性阴道病、和/或阴道外阴假丝酵母菌病、和/或萎缩性阴道炎。
本发明还提供一种抑菌组合物的制备方法,所述制备方法包括以下步骤:向赋形剂基质中加入以下组分,其中所述赋形剂基质为水溶液剂或水溶性胶体剂或泡沫剂或栓剂或片剂的赋形剂基质:
(1)以脂肪酸计的总含量在0.001-3.00%(w/w)范围内的一种或多种脂肪酸和/或其盐,所述脂肪酸选自由乙酸、羟基乙酸、乳酸、丙酸、乙酰丙酸、丁酸、异丁酸、羟基丁酸、戊酸、己酸、庚酸、辛酸、壬酸、癸酸、十一酸、十一烯酸、以及月桂酸组成的组,优选为丙酸、丁酸、己酸、辛酸、癸酸、十一酸、或它们的混合物;
(2)以二元酸计的总含量在0.05-5.00%(w/w)范围内的一种或多种选自下 组的二元酸和/或其盐:戊二酸、己二酸、庚二酸,优选己二酸;
(3)总含量在0.03-1.00%(w/w)范围内的一种或多种选自下组的芳香醇:苯甲醇、2,4-二氯苯甲醇、苯乙醇、苯氧乙醇、以及肉桂醇,优选苯乙醇、肉桂醇、或它们的混合物。
(4)以芳香酸计的总含量在0.03-1.00%(w/w)范围内的一种或多种选自下组的芳香酸和/或其盐:苯甲酸、对羟基苯甲酸、对甲氧基苯甲酸、水杨酸、肉桂酸、龙胆酸、以及咖啡酸,优选苯甲酸、肉桂酸、对羟基苯甲酸、或它们的混合物;
所述组合物采用下组的其中一种剂型:水溶液剂、水溶性凝胶剂、泡沫剂、喷雾剂、软膏剂、散剂、膜剂、胶囊剂、栓剂、以及片剂,优选水溶液剂、或水溶性凝胶剂、或泡沫剂、或喷雾剂、或软膏剂。
在一些实施方案中,其中所述制备方法中加入的所述以脂肪酸计的一种或多种脂肪酸和/或其盐的总含量优选在0.001-2.00%(w/w)范围内,更优选在0.001-1.50%(w/w)范围内,最优选在0.002%-1.25%(w/w)范围内;且/或所述加入的以二元酸计的一种或多种二元酸和/或其盐的总含量优选在0.10-3.50%(w/w)范围内,更优选在0.50-2.50%(w/w)范围内,最优选在0.50-1.50%(w/w)范围内;且/或所述加入的一种或多种芳香醇的总含量优选在0.03-0.70%(w/w)范围内,更优选在0.05-0.60%(w/w)范围内,最优选在0.08-0.50%(w/w)范围内;且/或所述加入的以芳香酸计的一种或多种芳香酸和/或其盐的总含量优选在0.03-0.50%(w/w)范围内,更优选在0.05-0.25%(w/w)范围内,最优选在0.08-0.20%(w/w)范围内。
在制备水溶性胶体剂时,需选用非流动性、粘性、水溶性胶体基质,该基质使组合物与阴道黏膜均匀接触并停留较长时间从而发挥作用。在一些实施方案中,该基质为黄原胶、和/或卡波姆、和/或聚卡波非、和/或葡聚糖、和/或葡甘聚糖、和/或黄芪胶、和/或西黄芪胶、和/或甲基纤维素(MC)、和/或羧甲基纤维素(CMC)、和/或羟乙基纤维素(HEC)、和/或羟乙基甲基纤维素 (HEMC)、和/或羟丙基甲基纤维素(HPMC),优选黄原胶、卡波姆。
在一些实施方案中,可按下述工艺流程制备组合物:按比例定量取(1)一种或多种脂肪酸和/或其盐如丙酸和/或其钠盐,(2)一种或多种二元酸和/或其盐如己二酸和/或其盐,(3)一种或多种芳香醇如苯乙醇,(4)一种或多种芳香酸和/或其盐如苯甲酸和/或其钠盐,(5)一种或多种胶体基质如黄原胶,及其它组分等,混匀,定量加蒸馏水,搅拌、混匀,各组分溶解、胶体基质溶胀呈均匀胶体;用酸和/或碱调组合物的pH值至3.1-4.8的范围、优选3.6-4.6的范围、更优选3.8-4.4的范围。在一些实施方案中,可进一步做灭菌处理,灭菌可选择如下工艺:辐射灭菌,高温灭菌(如采用115.6℃、15-20分钟;或者100℃、30分钟灭菌),或者间歇灭菌(如首先80℃、30分钟处理,然后置36℃、5-10小时,再80℃、30分钟处理,再置36℃、5-10小时,最后再80℃、30分钟处理)。可替代地,在一些实施方案中,将苯甲酸和/或其钠盐等组分单独配制成溶液后滤过除菌,再添加到经灭菌的水溶性胶状基质中。
在一些实施方案中,当制备溶液剂时,可将除黄原胶以外的上述各组分混匀,加水,溶解各组分,灭菌,分装;或溶解各组分,过滤,分装。
在一些实施方案中,当制备乳剂型软膏剂时,基质的选择和具体制备过程可参考本领域技术人员已知的方法,例如在方亮主编的《药剂学》(具体见参考文献1)中介绍的方法。
在一些实施方案中,当制备片剂时,可参考本领域技术人员已知的方法,例如在方亮主编的《药剂学》(具体见参考文献2)中介绍的方法,将定量的脂肪酸和/或其盐、二元酸和/或其盐、芳香醇、芳香酸和/或其盐、及其它组分等,与填充辅料混合均匀,直接压片,即得片剂;亦可加入辅料成分,如硬脂酸镁等润滑剂或羧甲基淀粉钠等崩解剂,混合均匀,压片。在一些实施方案中,还可将制备好的片剂分装于给药器械、或消毒器械、或医疗器械、或药物器械中。
在一些实施方案中,当制备膜剂、栓剂等时,可参考本领域技术人员已 知的方法例如在方亮主编的《药剂学》(具体见参考文献3、4)中介绍的方法。
在一些实施方案中,当制备含本公开的抑菌组合物的卫生巾、或卫生护垫、或卫生棉条时,可定量称取本公开的脂肪酸和/或其盐、二元酸和/或其盐、芳香醇、芳香酸和/或其盐等组分,例如苯甲酸钠、丙酸钠、己酸、苯乙醇、己二酸、及其它组分等,加相应辅料组分,制成散剂、或膜剂、或片剂、或胶囊剂,然后通过适当的方式或工艺内置于卫生巾、或卫生护垫、或卫生棉条等的内部;或通过适当的工艺,将本公开的脂肪酸和/或其盐、二元酸和/或其盐、芳香醇、芳香酸和/或其盐等组分,例如丙酸钠、己酸、苯乙醇、苯甲酸钠、己二酸、及其它组分等,与适当的辅料组分,附着于卫生巾或卫生护垫或卫生棉条等的内层材料上。
在一些实施方案中,当制备胶囊剂、或栓剂、或片剂等剂型时,每单位剂型含有特定含量范围的本公开的组合物的各组分。例如每单位剂型含有以脂肪酸计的总量为0.00005-0.15克的一种或多种脂肪酸和/或其盐,以二元酸和/或多元酸计的总量为0.0025-0.25克的一种或多种二元酸和/或其盐、总量为0.0015-0.050克的一种或多种芳香醇,以芳香酸计的总量为0.0015-0.05克的一种或多种芳香酸和/或其盐;优选地,每单位剂型含有以脂肪酸计的总量为0.00005-0.100克的一种或多种脂肪酸和/或其盐,以二元酸和/或多元酸计的总量为0.005-0.175克的一种或多种二元酸和/或其盐,总量为0.0015-0.035克的一种或多种芳香醇,以芳香酸计的总量为0.0015-0.025克的一种或多种芳香酸和/或其盐。
本公开的制备方法所用的各种有机酸或其盐,如脂肪酸和/或其盐、或二元酸和/或其盐、或芳香酸和/或其盐等,溶于水呈未电离的分子和电离的离子,未电离的分子和电离的离子的比例取决于溶液的pH值和该有机酸的电离常数pKa值。可见,有机酸与其盐在水中溶解后均为有机酸分子或有机酸根离子,从这个角度上看,二者没有实质性区别。
具体实施方式
现详细说明本发明的多种示例性实施方式,该详细说明不应认为是对本发明的限制,而应理解为是对本发明的某些方面、特性和实施方案的更详细的描述。应理解本发明中所述的术语仅仅是为描述特别的实施方式,并非用于限制本发明。另外,对于本发明中的数值范围,应理解为具体公开了该范围的上限和下限以及它们之间的每个中间值。在任何陈述值或陈述范围内的中间值以及任何其他陈述值或在所述范围内的中间值之间的每个较小的范围也包括在本发明内。这些较小范围的上限和下限可独立地包括或排除在范围内。
除非另有说明,否则本文使用的所有技术和科学术语具有本发明所述领域的常规技术人员通常理解的相同含义。虽然本发明仅描述了优选的方法和材料,但是在本发明的实施或测试中也可以使用与本文所述相似或等同的任何方法和材料。本说明书中提到的所有文献通过引用并入,用以公开和描述与所述文献相关的方法和/或材料。在与任何并入的文献冲突时,以本说明书的内容为准。除非另有说明,否则“%”为基于重量的百分数。
常用于皮肤和/或黏膜清洁或抑菌或消毒的抑菌剂,如聚维酮碘、氯己定等,多为广谱抑菌剂,其不但抑制大肠埃希菌、金黄色葡萄球菌、真菌等,也抑制乳杆菌等乳酸菌。护肤品、化妆品、沐浴用品等常用的防腐剂,以及医疗产品、药品常用的防腐剂,如三氯叔丁醇、苯扎氯铵等,通常对乳杆菌等乳酸菌也有抑制作用。尚缺乏对有害菌的抑制作用强、对乳杆菌等有益菌的抑制作用弱的高选择性抑菌剂或抑菌组合物。
现有技术(例如PCT/CN2017/105296,ZL201080036139、US8765819)公开了一些通过低浓度抑菌剂,例如低浓度的苯乙醇、丙酸和/或其盐、和/或苯甲酸和/或其盐等组合而成的组合物,这些含有低浓度抑菌剂的组合物可抑制大肠埃希菌、金黄色葡萄球菌,如按照中华人民共和国国家标准《一次性 使用卫生用品卫生标准》(GB15979-2002)中的试验方法和结果判断标准,对大肠埃希菌和金黄色葡萄球菌的抑菌率可达50%以上,对白假丝酵母菌的抑菌率均偏低、抑菌率<50%。
增加抑菌剂的浓度,可增强对白假丝酵母菌的抑菌作用。研究表明,适当提高“丙酸和/或其盐+苯甲酸和/或其盐+苯乙醇”的抑菌剂组合中各组分的浓度,不仅可以增强抑菌剂组合的抑菌作用,更有效地抑制大肠埃希菌、金黄色葡萄球菌等,而且对白假丝酵母菌的抑制率也大于50%。但抑菌剂浓度越高,对乳杆菌等乳酸菌的抑制作用越强。如PCT/CN2017/105296公开的实验实施例一所示,当丙酸钠浓度为0.40%(w/v)、0.50%(w/v)时,乳杆菌生长未受显著抑制;当丙酸钠浓度为0.70%(w/v)时,乳杆菌的生长则受到抑制。当苯乙醇的浓度为0.40%(w/v)时,乳杆菌生长未受显著抑制;但苯乙醇的浓度为0.50%(w/v)时,乳杆菌的生长与产酸均受抑制。
为了进一步研究开发有效抑制有害微生物但不抑制乳杆菌等有益菌的、可用于皮肤和/或黏膜清洁或抑菌或消毒的抑菌组合物,以及可作为护肤品、化妆品、沐浴用品等的防腐剂、以及作为医疗产品、药品的防腐剂的抑菌组合物,发明人持续进行深入研究。发现适当的脂肪酸和/或其盐选择性地与二元酸、芳香醇、芳香酸等组合,不仅对金黄色葡萄球菌、大肠埃希菌具有协同抑菌作用,而且对白假丝酵母菌等也具有协同抑菌作用,铜绿假单胞菌和黑曲霉菌的生长也受显著抑制。据此制备的抑菌组合物用于阴道,可使阴道的异常菌群显著减少、乳杆菌显著增加,具有调节阴道菌群和阴道酸度的作用。因而,本公开的抑菌组合物可用于皮肤和/或黏膜的清洁或抑菌或消毒;和用于沐浴用品、护肤品、化妆品的防腐,以及用于医疗产品、药品等的防腐。
为便于理解本文中提及的相关名词或词组或表述或标准的准确含义,特在此进行词义说明、界定如下:
“乳杆菌”指乳杆菌属的细菌,英文Lactobacillus,是一种革兰阳性、 杆状、无芽孢、能够发酵可代谢的糖产生大量乳酸的细菌,包含上百个种和亚种。
“乳酸菌”是能够代谢可发酵碳水化合物产生大量乳酸的细菌的统称,包含18个属、200多个种的细菌。其中,乳杆菌也是一种乳酸菌。
“阴道正常菌群”指阴道菌群Nugent评分为1-3分。阴道中的细菌以乳杆菌为主、数量多,其它种类的细菌数量少。所述“其它种类的细菌”包括革兰阳性球菌如葡萄球菌、链球菌等,革兰阴性杆菌如阴道加德纳菌、大肠埃希菌等,革兰阴性球菌如韦荣氏菌等,专性厌氧的普雷沃菌、动弯杆菌等。
“阴道异常菌群”指阴道菌群Nugent评分为5-10分。阴道中乳杆菌的数量少,其它种类的细菌数量多。所述“其它种类的细菌”包括革兰阳性球菌如葡萄球菌、链球菌等,革兰阴性杆菌如阴道加德纳菌、大肠埃希菌等,革兰阴性球菌如韦荣氏菌等,专性厌氧的普雷沃菌、动弯杆菌,等等。
“有害微生物”泛指各种致病性强的致病性微生物,或在人体免疫力降低时致病的各种条件致病性微生物,或造成食品、药品、化妆品、卫生用品等腐败变质的微生物,包括但不限于下组的微生物:假丝酵母菌、金黄色葡萄球菌、大肠埃希菌、铜绿假单胞菌、阴道加德纳菌、普雷沃菌、动弯杆菌、黑曲霉菌、皮肤和/或黏膜的异常菌群、以及病毒HPV、HIV,等等。
“组分”指组合物中的各种成分,包括抑菌剂、以及无抑菌作用的其它成分。
“抑菌剂”指具有抑菌作用的各种成分或其组合,而不限于本领域技术人员公认的常规抑菌剂或其组合。
“抑菌率”指参照GB 15979-2002《一次性使用卫生用品卫生标准》附录C的检验方法和判断标准,得出的抑菌剂对大肠埃希菌、金黄色葡萄球菌、白假丝酵母菌等的抑菌率。
“抑菌作用”指抑菌剂对细菌、真菌等的抑制作用。本文中以抑菌率的高低来判断抑菌作用的强弱,具体如下:抑菌率>50%,为“有抑菌作用”;抑 菌率>90%,为“抑菌作用强”。
“低浓度抑菌剂”指对白假丝酵母菌的抑菌率<50%、浓度较低的抑菌剂。
“高浓度抑菌剂”指对白假丝酵母菌的抑菌率>50%、浓度较高的抑菌剂。
“抑菌率无差异”或“对抑菌作用无影响”,指两个抑菌率的差异<15%。
“抑菌率有差异”或“对抑菌作用有影响”,指两个抑菌率差异为15%-30%。
“抑菌率有显著差异”或“对抑菌作用有显著影响”,指两个抑菌率差异>30%。
“协同抑菌作用”指两个或两个以上抑菌剂的组合对大肠埃希菌或金黄色葡萄球菌或白假丝酵母菌的抑菌率,较各抑菌剂单独作用的抑菌率之和高15%以上。
实施例1
本实施例为抑菌组合物的多种示例性组成。在下文中,除非另有特别说明,否则组合物中的示例性组分是指以下物质:
丙酸CAS:79-09-4、己二酸CAS:124-04-9、苯乙醇(2-苯基乙醇)CAS:60-12-8、丁酸(正丁酸)CAS:107-92-6、己酸(正己酸)CAS:142-62-1、庚二酸CAS:111-16-0、苹果酸(L-羟基丁二酸)CAS:97-67-6、肉桂酸(反式-肉桂酸)CAS:140-10-3、水杨酸(2-羟基苯甲酸)CAS:69-72-7、月桂酸:正十二酸CAS:143-07-7、戊酸(正戊酸)CAS:109-52-4、庚酸(正庚酸)CAS:111-14-8、辛酸(正辛酸)CAS:124-07-2、壬酸(正壬酸)CAS:112-05-0、癸酸(正癸酸)CAS:334-48-5、十一酸(十一烷酸)CAS:112-37-8、肉桂醇(3-苯基-2-丙烯-1-醇)CAS:104-54-1、琥珀酸(丁二酸)CAS:110-15-6、酒石酸(L-酒石酸)CAS:87-69-4、马来酸(顺丁烯二酸)CAS:110-16-7、柠檬酸CAS:77-92-9、延胡索酸(反丁烯二酸)CAS:110-17-8、十一烯酸(10-十一烯酸)CAS:112-38-9、戊二酸CAS:110-94-1。
示例1:
将己二酸1.50克、丙酸2.00克、苯乙醇0.25克、柠檬酸1.00克、麦芽糖2.50克,加入80克纯化水中,搅拌使己二酸、丙酸、苯乙醇、柠檬酸、麦芽糖溶解,再加入黄原胶2.15克,并用纯化水补足使总重为100克,搅拌溶胀呈均匀粘性胶状,用1.0mol/L的氢氧化钠溶液调pH至3.1,115.6℃、15分钟灭菌,即得本公开的水溶性胶体组合物。
示例2:
按下述配比称取原料,基本按示例1的方法制备了100克组合物:
Figure PCTCN2021075655-appb-000001
示例3:
按下述配比称取原料,基本按示例1的方法制备了100克组合物:
Figure PCTCN2021075655-appb-000002
示例4:
按下述配比称取原料,基本按示例1的方法制备了100克组合物:
Figure PCTCN2021075655-appb-000003
示例5:
按下述配比称取原料,基本按示例1的方法制备了100克组合物:
Figure PCTCN2021075655-appb-000004
示例6:
按下述配比称取原料,基本按示例1的方法制备了100克组合物:
Figure PCTCN2021075655-appb-000005
Figure PCTCN2021075655-appb-000006
示例7:
按下述配比称取原料,基本按示例1的方法制备了100克组合物:
Figure PCTCN2021075655-appb-000007
示例8:
按下述配比称取原料,基本按示例1的方法制备了100克组合物:
Figure PCTCN2021075655-appb-000008
示例9:
按下述配比称取原料,基本按示例1的方法制备了100克组合物:
Figure PCTCN2021075655-appb-000009
Figure PCTCN2021075655-appb-000010
示例10:
按下述配比称取原料,基本按示例1的方法制备了100克组合物:
Figure PCTCN2021075655-appb-000011
示例11:
按下述配比称取原料,基本按示例1的方法制备了100克组合物:
Figure PCTCN2021075655-appb-000012
示例12:
按下述配比称取原料,基本按示例1的方法制备了100克组合物:
Figure PCTCN2021075655-appb-000013
Figure PCTCN2021075655-appb-000014
示例13:
按下述配比称取原料,基本按示例1的方法制备了100克组合物:
Figure PCTCN2021075655-appb-000015
示例14:
按下述配比称取原料,基本按示例1的方法制备了100克组合物。
己二酸1.50克,苯甲酸0.20克,丙酸1.25克;
谷氨酸0.76克,谷氨酰胺0.34克,天冬氨酸0.60克,天冬酰胺0.98克,异亮氨酸0.31克,蛋氨酸0.35克,苯丙氨酸0.20克,缬氨酸0.46克,亮氨酸0.78克,脯氨酸0.89克;
黄原胶2.50克,加净化水至总重量100克,pH调至4.0
示例15:
按下述配比称取原料,基本按示例1的方法制备了100克组合物。
Figure PCTCN2021075655-appb-000016
Figure PCTCN2021075655-appb-000017
示例16
基本按照参考文献1的方法,制备每片含己二酸60毫克、苯甲酸钠5毫克、丙酸30毫克、蔗糖60毫克的片剂。
示例17
基本按照参考文献3的方法,制备每粒含己二酸60毫克、苯甲酸钠5毫克、丙酸30毫克、麦芽糖60毫克的阴道栓剂。
实施例2
本实施例用于验证组合物的效果。
体外实验一
基本按照GB15979-2002《一次性使用卫生用品卫生标准》附录C的方法,研究不同组分组合的溶液作用20分钟,对白假丝酵母菌ATCC 10231的抑菌率,其中各组分的百分比浓度均为重量百分比浓度%(w/w),pH值均为3.8,实验结果如表1所示:
表1不同溶液组合对白假丝酵母菌ATCC 10231的抑菌作用
编号 丙酸(%) 己二酸(%) 苯甲醇(%) 苯甲酸钠(%) 抑菌率(%)
1 0.50 1.50 -- 0.20 61.29
2 0.50 1.50 0.50 0.20 81.52
3 0.50 1.50 0.70 0.20 99.27
结果显示:
1、由表1第1组实验结果可见,pH值3.8时,“0.50%丙酸、1.50%己二酸、0.20%苯甲酸钠”三种组分组合的溶液,对白假丝酵母菌有抑菌作用,抑菌 率为61.29%;
2、由表1第2-3组实验结果可见,pH值3.8时,“0.50%丙酸、1.50%己二酸、0.20%苯甲酸钠”三种组分分别与2种不同浓度(0.50%、0.70%)苯甲醇组合的溶液,对白假丝酵母菌有抑菌作用或抑菌作用强,抑菌率分别为81.52%、99.27%。
综上所述,对比第2-3组与第1组实验结果可见:pH值3.8时,0.50%和0.70%苯甲醇对“0.50%丙酸、1.50%己二酸、0.20%苯甲酸钠”三种组分组合的溶液抑制白假丝酵母菌的作用有显著影响,均可增强抑菌作用。
体外实验二
基本按照GB15979-2002《一次性使用卫生用品卫生标准》附录C的方法,研究不同组分组合的溶液作用20分钟,对白假丝酵母菌ATCC 10231的抑菌率,其中各组分的百分比浓度均为重量百分比浓度%(w/w),pH值均为4.0,实验结果如表2所示:
表2不同溶液组合对白假丝酵母菌ATCC 10231的抑菌作用
编号 丙酸(%) 己二酸(%) 苯乙醇(%) 苯甲酸(%) 抑菌率(%)
1 1.50 -- 0.35 0.20 15.91
2 1.50 -- 0.35 0.25 46.09
3 1.50 1.50 0.35 0.20 67.39
4 1.50 1.50 0.35 0.25 92.17
结果显示:
1、由表2的第1组实验结果可见:pH值4.0时,1.50%丙酸、0.35%苯乙醇、0.20%苯甲酸组合的溶液,对白假丝酵母菌的抑菌率为15.91%;
2、由表2的第2组实验结果可见:pH值4.0时,1.50%丙酸、0.35%苯乙醇、0.25%苯甲酸组合的溶液,对白假丝酵母菌的抑菌率为46.09%;
3、由表2的第3组实验结果可见:pH值4.0时,1.50%丙酸、1.50%己二酸、0.35%苯乙醇、0.20%苯甲酸组合的溶液,对白假丝酵母菌有抑菌作用,抑菌率为67.39%;
4、由表2的第4组实验结果可见:pH值4.0时,1.50%丙酸、1.50%己二酸、 0.35%苯乙醇、0.25%苯甲酸组合的溶液,对白假丝酵母菌的抑菌作用强,抑菌率为92.17%。
综上所述:
1、对比第1组与第2组、第3组与第4组实验结果可见:pH值4.0时,苯甲酸浓度由0.20%升高至0.25%对含“1.50%丙酸、0.35%苯乙醇”和含“1.50%丙酸、1.50%己二酸、0.35%苯乙醇”组合的溶液抑制白假丝酵母菌的作用有影响或有显著影响,抑菌作用增强;
2、对比第1组与第3组、第2组与第4组实验结果可见:pH值4.0时,1.50%己二酸对“1.50%丙酸、0.35%苯乙醇、0.20%苯甲酸”和“1.50%丙酸、0.35%苯乙醇、0.25%苯甲酸”两种组合的溶液抑制白假丝酵母菌的作用有显著影响,抑菌作用增强。
体外实验三
基本按照GB15979-2002《一次性使用卫生用品卫生标准》附录C的方法,研究不同组分组合的溶液作用20分钟,对白假丝酵母菌ATCC 10231的抑菌率,其中各组分的百分比浓度均为重量百分比浓度%(w/w),pH值均为3.8,实验结果如表3所示:
表3不同溶液组合对白假丝酵母菌ATCC 10231的抑菌作用
编号 丙酸(%) 己二酸(%) 苯甲醇(%) 苯甲酸钠(%) 抑菌率(%)
1 -- 1.35 0.25 0.20 45.12
2 0.50 1.35 0.25 0.20 61.60
3 1.25 1.35 0.25 0.20 89.72
4 1.50 1.35 0.25 0.20 94.42
5 3.00 1.35 0.25 0.20 100.00
结果显示:
1、由表3的第1组实验结果可见:pH值3.8时,1.35%己二酸、0.25%苯甲醇、0.20%苯甲酸钠组合的溶液,对白假丝酵母菌的抑菌率为45.12%;
2、由表3的第2-5组实验结果可见:pH值3.8时,4种不同浓度的丙酸(0.50%、1.25%、1.50%、3.00%)分别与“1.35%己二酸、0.25%苯甲醇、0.20%苯甲酸 钠”组合的溶液,对白假丝酵母菌有抑菌作用或抑菌作用强,抑菌率分别为61.60%、89.72%、94.42%、100.00%。
综上所述,第2-5组和1组对比,pH值3.8时,丙酸对含“1.35%己二酸、0.25%苯甲醇、0.20%苯甲酸钠”组合的溶液抑制白假丝酵母菌的作用有影响或有显著影响,抑菌作用增强,且丙酸浓度越高,对白假丝酵母菌的抑菌作用越强。
体外实验四
基本按照GB15979-2002《一次性使用卫生用品卫生标准》附录C的方法,研究不同组分组合的溶液作用20分钟,对白假丝酵母菌ATCC 10231的抑菌率,其中各组分的百分比浓度均为重量百分比浓度%(w/w),pH值均为4.3,实验结果如表4所示:
表4不同溶液组合对白假丝酵母菌ATCC 10231的抑菌作用
编号 丙酸(%) 己二酸(%) 苯乙醇(%) 苯甲酸(%) 抑菌率(%)
1 0.54 1.50 0.30 -- 26.05
2 0.54 1.50 0.30 0.50 64.80
3 0.54 1.50 0.30 1.00 100.00
结果显示:
1、由表4的第1组实验结果可见:pH值4.3时,0.54%丙酸、1.50%己二酸、0.30%苯乙醇组合的溶液,对白假丝酵母菌的抑菌率为26.05%;
2、由表4的第2和第3组实验结果可见:pH值4.3时,“0.54%丙酸、1.50%己二酸、0.30%苯乙醇”分别与0.50%和1.00%苯甲酸组合的溶液,对白假丝酵母菌有抑菌作用或抑菌作用强,抑菌率分别为64.80%和100.00%。
综上所述,pH值4.3时,0.50%和1.00%的苯甲酸对含“0.54%丙酸、1.50%己二酸、0.30%苯乙醇”组合的溶液抑制白假丝酵母菌的作用有显著影响,抑菌作用增强,且苯甲酸浓度越高,对白假丝酵母菌的抑菌作用越强。
体外实验五
基本按照GB15979-2002《一次性使用卫生用品卫生标准》附录C的方法,研究不同组分组合的溶液作用20分钟,对白假丝酵母菌ATCC 10231的抑菌率,其中各组分的百分比浓度均为重量百分比浓度%(w/w),pH值均为4.6,实验结果如表5所示:
表5不同溶液组合对白假丝酵母菌ATCC 10231的抑菌作用
编号 丙酸(%) 己二酸(%) 苯乙醇(%) 苯甲酸钠(%) 抑菌率(%)
1 -- 1.50 0.30 1.18 84.12
2 2.00 1.50 0.30 1.18 100.00
结果显示:
1、由表5的第1组实验结果可见:pH值4.6时,1.50%己二酸、0.30%苯乙醇、1.18%苯甲酸钠组合的溶液,对白假丝酵母菌有抑菌作用,抑菌率为84.12%;
2、由表5的第2组实验结果可见:pH值4.6时,2.00%丙酸、1.50%己二酸、0.30%苯乙醇、1.18%苯甲酸钠组合的溶液,对白假丝酵母菌的抑菌作用强,抑菌率为100.00%。
综上所述,对比第1组和第2组实验结果可见:pH值4.6时,2.00%丙酸对含“1.50%己二酸、0.30%苯乙醇、1.18%苯甲酸钠”组合的溶液抑制白假丝酵母菌的作用有影响,抑菌作用增强。
体外实验六
基本按照GB15979-2002《一次性使用卫生用品卫生标准》附录C的方法,研究不同组分组合的溶液作用20分钟,对白假丝酵母菌ATCC 10231的抑菌率,其中各组分的百分比浓度均为重量百分比浓度%(w/w),pH值均为3.8。实验结果如表6所示:
表6不同溶液对白假丝酵母菌ATCC10231的抑菌作用
编号 丁酸(%) 己酸(%) 己二酸(%) 苯乙醇(%) 苯氧乙醇(%) 苯甲酸钠(%) 抑菌率(%)
1 0.88 -- -- 0.40 -- 0.20 71.52
2 -- 0.12 -- 0.40 -- 0.20 70.65
3 0.88 -- -- -- 0.40 0.20 56.75
4 -- 0.12 -- -- 0.40 0.20 35.88
5 0.88 -- 1.46 0.40 -- 0.20 100.00
6 -- 0.12 1.46 0.40 -- 0.20 100.00
7 0.88 -- 1.46 -- 0.40 0.20 100.00
8 -- 0.12 1.46 -- 0.40 0.20 100.00
结果显示:
1、由表6的第1-2组实验结果可见:pH值3.8时,“0.20%苯甲酸钠、0.40%苯乙醇”,分别与2种不同浓度的脂肪酸(0.88%丁酸、0.12%己酸)组合的溶液,对白假丝酵母菌有抑菌作用,抑菌率分别为71.52%、70.65%;
2、由表6的第3-4组实验结果可见:pH值3.8时,“0.20%苯甲酸钠、0.40%苯氧乙醇、0.88%丁酸”组合溶液,对白假丝酵母菌有抑菌作用,抑菌率为56.75%;“0.20%苯甲酸钠、0.40%苯氧乙醇、0.12%己酸”组合的溶液,对白假丝酵母菌的抑菌率为35.88%;
3、由表6的第5-6组实验结果可见:pH值3.8时,“1.46%己二酸、0.20%苯甲酸钠、0.40%苯乙醇”分别与2种不同浓度的脂肪酸(0.88%丁酸、0.12%己酸)组合的溶液,对白假丝酵母菌抑菌作用强,抑菌率均为100%;
4、由表6的第7-8组实验结果可见:pH值3.8时,“1.46%己二酸、0.20%苯甲酸钠、0.40%苯氧乙醇”分别与2种不同浓度的脂肪酸(0.88%丁酸、0.12%己酸)组合的溶液,对白假丝酵母菌抑菌作用强,抑菌率均为100%。
综上所述,
1、对比表6的第5-6组和1-2组实验结果可见:pH值3.8时,1.46%己二酸分别对“0.20%苯甲酸钠、0.40%苯乙醇、0.88%丁酸”、“0.20%苯甲酸钠、0.40%苯乙醇、0.12%己酸”组合的溶液抑制白假丝酵母菌的作用有显著影响,抑菌作用增强;
2、从表6的第7-8组和3-4组实验结果可见:pH值3.8时,1.46%己二酸分别对“0.20%苯甲酸钠、0.40%苯氧乙醇、0.88%丁酸”、“0.20%苯甲酸钠、0.40%苯氧乙醇、0.12%己酸”组合的溶液抑制白假丝酵母菌的作用有显著影响,抑菌作用增强。
体外实验七
基本按照GB15979-2002《一次性使用卫生用品卫生标准》附录C的方法,研究不同组分组合的溶液作用20分钟,对白假丝酵母菌ATCC 10231的抑菌率,其中各组分的百分比浓度均为重量百分比浓度%(w/w),pH值均为3.8。实验结果如表7所示:
表7不同溶液对白假丝酵母菌ATCC 10231的抑菌作用
编号 丙酸(%) 庚二酸(%) 苹果酸(%) 苯乙醇(%) 对羟基苯甲酸(%) 抑菌率(%)
1 2.50 -- -- 0.06 0.21 62.76
2 2.50 1.60 -- 0.06 0.21 94.84
3 2.50 -- 1.34 0.06 0.21 65.68
结果显示:
1、由表7的第1组实验结果可见:pH值3.8时,“0.21%对羟基苯甲酸、0.06%苯乙醇、2.50%丙酸”三种组分组合的溶液,对白假丝酵母菌有抑菌作用,抑菌率为62.76%;
2、由表7的第2组实验结果可见:pH值3.8时,1.60%庚二酸与“0.21%对羟基苯甲酸、0.06%苯乙醇、2.50%丙酸”组合的溶液,对白假丝酵母菌的抑菌作用强,抑菌率为94.84%;
3、由表7的第3组实验结果可见:pH值3.8时,1.34%苹果酸与“0.21%对羟基苯甲酸、0.06%苯乙醇、2.50%丙酸”组合的溶液,对白假丝酵母菌有抑菌作用,抑菌率为65.68%。
综上所述:对比第2、3组和第1组实验结果可见:pH值3.8时,1.60%庚二酸对含“0.21%对羟基苯甲酸、0.06%苯乙醇、2.50%丙酸”组合溶液抑制白假丝酵母菌的作用有显著影响,抑菌作用增强;而1.34%苹果酸对“0.21%对羟基苯甲酸、0.06%苯乙醇、2.50%丙酸”组合的溶液抑制白假丝酵母菌的作用无影响。
体外实验八
基本按照GB 15979-2002《一次性使用卫生用品卫生标准》附录C的方法, 研究含不同组分的水溶液分别作用20分钟,对白假丝酵母菌ATCC10231的抑菌作用,其中各组分的百分比浓度均为重量百分比浓度%(w/w),pH值均为3.9。实验结果如表8所示:
表8不同溶液对白假丝酵母菌ATCC10231的抑菌作用
编号 己二酸(%) 丁酸(%) 苯甲酸钠(%) 苯乙醇(%) 抑菌率(%)
1 1.46 -- -- -- 11.52
2 -- 0.60 -- -- 1.57
3 -- -- 0.14 -- 19.90
4 -- -- -- 0.40 -1.05
5 1.46 0.60 -- -- 13.61
6 -- 0.60 0.14 -- 17.80
7 -- 0.60 -- 0.40 8.90
8 1.46 0.60 0.14 -- 27.23
9 1.46 0.60 -- 0.40 25.65
10 -- 0.60 0.14 0.40 2.62
11 1.46 -- 0.14 0.40 42.41
12 1.46 0.60 0.14 0.40 89.53
结果显示:
1、由表8第1-4组实验结果可见:pH值3.9时,1.46%己二酸、0.60%丁酸、0.14%苯甲酸钠、0.40%苯乙醇分别单独作用,对白假丝酵母菌的抑菌率分别为11.52%、1.57%、19.90%、-1.05%;
2、由表8第5组实验结果可见:pH值3.9时,“1.46%己二酸、0.60%丁酸”组合的溶液,对白假丝酵母菌的抑菌率为13.61%;
3、由表8第6组实验结果可见:pH值3.9时,“0.60%丁酸、0.14%苯甲酸钠”组合的溶液,对白假丝酵母菌的抑菌率为17.80%;
4、由表8第7组实验结果可见:pH值3.9时,“0.60%丁酸、0.40%苯乙醇”组合的溶液,对白假丝酵母菌的抑菌率为8.90%;
5、由表8第8组实验结果可见:pH值3.9时,“1.46%己二酸、0.60%丁酸、0.14%苯甲酸钠”组合的溶液,对白假丝酵母菌的抑菌率为27.23%;
6、由表8第9组实验结果可见:pH值3.9时,“1.46%己二酸、0.60%丁酸、0.40%苯乙醇”组合的溶液,对白假丝酵母菌的抑菌率为25.65%;
7、由表8第10组实验结果可见:pH值3.9时,“0.60%丁酸、0.40%苯乙醇、0.14%苯甲酸钠”组合的溶液,对白假丝酵母菌的抑菌率为2.62%;
8、由表8第11组实验结果可见:pH值3.9时,“1.46%己二酸、0.14%苯甲酸钠、0.40%苯乙醇”组合的溶液,对白假丝酵母菌抑菌率为42.41%;
9、由表8第12组实验结果可见:pH值3.9时,“1.46%己二酸、0.60%丁酸、0.14%苯甲酸钠、0.40%苯乙醇”组合的溶液,对白假丝酵母菌有抑菌作用,抑菌率为89.53%。
综上所述,可见:pH值3.9时,1.46%己二酸、0.60%丁酸、0.14%苯甲酸钠、0.40%苯乙醇四种组分组合,对白假丝酵母菌的抑菌率远高于前述单独作用或两两组合或三种组分组合的抑菌率,提示此四种组分组合对白假丝酵母菌有协同抑菌作用。
体外实验九
基本按照GB 15979-2002《一次性使用卫生用品卫生标准》附录C的方法,研究不同组分组合的水溶液分别作用20分钟,对白假丝酵母菌ATCC10231的抑菌作用,其中各组分的百分比浓度均为重量百分比浓度%(w/w),溶液pH值均为4.3。实验结果如表9所示:
表9不同溶液对白假丝酵母菌ATCC10231的抑菌作用
编号 己酸(%) 己二酸(%) 苯甲酸钠(%) 苯乙醇(%) 抑菌率(%)
1 0.18 -- -- -- 2.82
2 -- 1.35 -- -- 5.81
3 -- -- 0.20 -- 6.95
4 -- -- -- 0.30 0.59
5 0.18 1.35 0.20 0.30 58.86
6 0.18 1.35 0.20 -- 25.17
7 0.18 1.35 -- 0.30 9.33
8 -- 1.35 0.20 0.30 15.37
9 0.18 -- 0.20 0.30 28.78
结果显示:
1、由表9第1-4组实验结果可见:pH值4.3时,1.35%己二酸、0.20%苯甲酸钠、0.18%己酸、0.30%苯乙醇四种组分分别单独作用,对白假丝酵母菌的抑菌率均<10%;
2、由表9第5组实验结果可见:pH值4.3时,“1.35%己二酸、0.20%苯甲酸钠、0.18%己酸、0.30%苯乙醇”四种组分组合的溶液,对白假丝酵母菌有抑菌作用,抑菌率为58.86%;
3、由表9第6-9组实验结果可见:pH值4.3时,1.35%己二酸、0.20%苯甲酸钠、0.18%己酸、0.30%苯乙醇四种组分,任意缺少一种组分组合的溶液,对白假丝酵母菌的抑菌率均低于50%。
综上所述,可见:1.35%己二酸、0.20%苯甲酸钠、0.18%己酸、0.30%苯乙醇四种组分组合的溶液对白假丝酵母菌的抑菌率显著高于其中任意三种组分组合的溶液的抑菌率,也显著高于四种组分分别单独作用的抑菌率之和,提示这四种组分对白假丝酵母菌具有协同抑菌作用。
体外实验十
基本按照GB 15979-2002《一次性使用卫生用品卫生标准》附录C的方法,研究不同组分组合的水溶液分别作用20分钟,对白假丝酵母菌ATCC10231的抑菌作用,其中各组分的百分比浓度均为重量百分比浓度%(w/w),溶液pH值均为3.8。实验结果如表10所示:
表10不同溶液白假丝酵母菌ATCC10231的抑菌作用
编号 丙酸(%) 己二酸(%) 肉桂酸(%) 苯乙醇(%) 水杨酸(%) 抑菌率(%)
1 1.50 1.50 -- 0.45 -- 30.96
2 1.50 1.50 0.03 0.45 -- 59.04
3 1.50 1.50 0.05 0.45 -- 71.19
4 1.50 1.50 0.08 0.45 -- 96.38
5 1.50 1.50 0.10 0.45 -- 100.00
6 1.50 1.50 -- 0.45 0.03 37.40
7 1.50 1.50 -- 0.45 0.05 55.58
8 1.50 1.50 -- 0.45 0.08 86.96
9 1.50 1.50 -- 0.45 0.10 94.81
结果显示:
1、由表10第1组实验结果可见:pH值3.8时,1.50%己二酸、0.45%苯乙醇、1.50%丙酸三种组分组合的溶液,对白假丝酵母菌的抑菌率为30.96%;
2、由表10第2-5组实验结果可见:pH值3.8时,四种不同浓度的肉桂酸(0.03%、0.05%、0.08%、0.10%)分别与“1.50%己二酸、0.45%苯乙醇、1.50%丙酸”组合的溶液,对白假丝酵母菌有抑菌作用或抑菌作用强,抑菌率分别为59.04%、71.19%、96.38%、100.00%;
3、由表10第6-9组实验结果可见:pH值3.8时,0.03%水杨酸与“1.50%己二酸、0.45%苯乙醇、1.50%丙酸”组合的溶液,对白假丝酵母菌的抑菌率为37.40%,三种更高浓度的水杨酸(0.05%、0.08%、0.10%)分别与“1.50%己二酸、0.45%苯乙醇、1.50%丙酸”组合的溶液,对白假丝酵母菌有抑菌作用或抑菌作用强,抑菌率分别为55.58%、86.96%、94.81%。
综上所述,可见:0.03-0.10%肉桂酸、0.05-0.10%水杨酸对含“1.50%己二酸、0.45%苯乙醇、1.50%丙酸”三种组分组合的溶液抑制白假丝酵母菌的作用有影响或有显著影响,抑菌作用随着肉桂酸或水杨酸的浓度增高而增强。
体外实验十一
基本按照GB 15979-2002《一次性使用卫生用品卫生标准》附录C的方法,研究不同组分组合的水溶液分别作用20分钟,对白假丝酵母菌ATCC10231的抑菌作用,其中各组分的百分比浓度均为重量百分比浓度%(w/w),溶液pH值均为3.8。实验结果如表11所示:
表11不同溶液对白假丝酵母菌ATCC10231的抑菌作用
Figure PCTCN2021075655-appb-000018
Figure PCTCN2021075655-appb-000019
结果显示:
1、由表11第1-6组实验结果可见:pH值3.8时,0.001-0.002%的十一酸、0.001-0.002%的十一烯酸、0.001-0.002%的月桂酸单独作用,对白假丝酵母菌的抑菌率均低于15%;
2、由表11第7组实验结果可见:pH值3.8时,“0.20%苯甲酸钠、0.25%苯乙醇、1.50%己二酸”三种组分组合的溶液,对白假丝酵母菌有抑菌作用,抑菌率为50.02%;
3、由表11第8-9组实验结果可见:pH值3.8时,“0.20%苯甲酸钠、0.25%苯乙醇、1.50%己二酸”三种组分分别与两种不同浓度的十一酸(0.001%、0.002%)组合的溶液,对白假丝酵母菌的抑菌作用强,抑菌率均高于90%;
4、由表11第10-11组实验结果可见:pH值3.8时,“0.20%苯甲酸钠、0.25%苯乙醇、1.50%己二酸”三种组分分别与两种不同浓度的十一烯酸(0.001%、0.002%)组合的溶液,对白假丝酵母菌有抑菌作用,抑菌率均高于50%;
5、由表11第12-13组实验结果可见:pH值3.8时,“0.20%苯甲酸钠、0.25%苯乙醇、1.50%己二酸”三种组分分别与两种不同浓度的月桂酸(0.001%、0.002%)组合的溶液,对白假丝酵母菌抑菌作用强,抑菌率均为100%。
综上所述,可见:0.001-0.002%的十一酸、0.002%的十一烯酸、0.001-0.002%的月桂酸分别对含“0.20%苯甲酸钠、0.25%苯乙醇、1.50%己二酸”组合的溶液抑制白假丝酵母菌的作用有显著影响,抑菌作用增强。
体外实验十二
基本按照GB 15979-2002《一次性使用卫生用品卫生标准》附录C的方法, 研究不同组分组合的水溶液分别作用20分钟,对白假丝酵母菌ATCC10231的抑菌作用,其中各组分的百分比浓度均为重量百分比浓度%(w/w)。实验结果如表12-14所示:
表12不同溶液单独作用对白假丝酵母菌ATCC 10231的抑菌作用
Figure PCTCN2021075655-appb-000020
表13不同组分两两组合的溶液对白假丝酵母菌ATCC 10231的抑菌作用
Figure PCTCN2021075655-appb-000021
表14三种不同组分组合的溶液对白假丝酵母菌ATCC 10231的抑菌作用
Figure PCTCN2021075655-appb-000022
Figure PCTCN2021075655-appb-000023
结果显示:
1、由表12的实验结果可见:pH值3.6-3.8时,10种不同浓度的脂肪酸(2.00%丙酸、2.20%丁酸、0.60%戊酸、0.20%己酸、0.07%庚酸、0.02%辛酸、0.009%壬酸、0.002%癸酸、0.001%十一酸、0.001%月桂酸)和0.25%苯甲酸钠,分别单独作用,对白假丝酵母菌的抑菌率均<20%;
2、由表13的实验结果可见:pH值3.6-3.8时,0.20-0.25%苯甲酸钠,分别与10种不同浓度的脂肪酸(2.00%丙酸、2.20%丁酸、0.60%戊酸、0.20%己酸、0.07%庚酸、0.02%辛酸、0.009%壬酸、0.002%癸酸、0.001%十一酸、0.001%月桂酸)组合的溶液,对白假丝酵母菌有抑菌作用,抑菌率均>50%,提示此两种组分组合对白假丝酵母菌具有协同抑菌作用,抑菌作用增强;
3、由表14的实验结果可见:pH值3.6-3.8时,“0.20%苯甲酸钠、0.40%苯乙醇”分别与10种不同浓度的脂肪酸(2.00%丙酸、2.20%丁酸、0.60%戊酸、0.20%己酸、0.07%庚酸、0.02%辛酸、0.009%壬酸、0.002%癸酸、0.001%十一酸、0.001%月桂酸)的组合的溶液,对白假丝酵母菌有抑菌作用或抑菌作用强,抑菌率在50%-90%之间或>90%,提示此三种组分组合对白假丝酵母菌具有协同抑菌作用,抑菌作用增强。
体外实验十三
基本按照GB 15979-2002《一次性使用卫生用品卫生标准》附录C的方法,研究不同组分组合的水溶液分别作用20分钟,对白假丝酵母菌ATCC10231的抑菌作用,其中各组分的百分比浓度均为重量百分比浓度%(w/w),pH值均为3.8。实验结果如表15所示:
表15不同溶液对白假丝酵母菌ATCC 10231的抑菌作用
Figure PCTCN2021075655-appb-000024
Figure PCTCN2021075655-appb-000025
结果显示:
1、由表15第1-10组实验结果可见:pH值3.8时,9种不同浓度的脂肪酸(2.00%丙酸、2.20%丁酸、0.60%戊酸、0.20%己酸、0.07%庚酸、0.02%辛酸、0.005%癸酸、0.003%月桂酸、0.003%十一酸)和0.30%肉桂醇分别单独作用,对白假丝酵母菌的抑菌率均小于25%;
2、由表15第11-19组实验结果可见:pH值3.8时,9种不同浓度的脂肪酸(2.00%丙酸、2.2%丁酸、0.60%戊酸、0.20%己酸、0.07%庚酸、0.02%辛酸、0.005%癸酸、0.003%月桂酸、0.003%十一酸)分别与0.30%肉桂醇组合的溶液,对白假丝酵母菌有抑菌作用或抑菌作用强,抑菌率在50-90%之间或>90%,提示此两种组分组合对白假丝酵母菌有协同抑菌作用,抑菌作用增强。
体外实验十四
基本按照GB15979-2002《一次性使用卫生用品卫生标准》附录C的方法, 研究不同组分组合的溶液作用20分钟,对白假丝酵母菌ATCC 10231的抑菌率,其中各组分的百分比浓度均为重量百分比浓度%(w/w),pH值均为3.8,实验结果如表16所示:
表16不同溶液组合对白假丝酵母菌ATCC 10231的抑菌作用
编号 丁酸(%) 庚二酸(%) 苯乙醇(%) 抑菌率(%)
1 1.00 -- -- 1.22
2 -- 1.00 -- 2.09
3 -- -- 0.60 4.98
4 1.00 -- 0.60 11.09
5 1.00 1.00 0.60 65.22
结果显示:
1、由表16第1-3组实验结果可见:pH值3.8时,1.00%丁酸、1.00%庚二酸、0.60%苯乙醇分别单独作用,对白假丝酵母菌的抑菌率均<10%;
2、由表16第4组实验结果可见:pH值3.8时,1.00%丁酸与0.60%苯乙醇组合的溶液,对白假丝酵母菌的抑菌率为11.09%;
3、由表16第5组实验结果可见:pH值3.8时,1.00%丁酸、1.00%庚二酸与0.60%苯乙醇组合的溶液,对白假丝酵母菌有抑菌作用,抑菌率为65.22%。
综上所述,可见:1.00%庚二酸与1.00%丁酸、0.60%苯乙醇三种组分组合的溶液,对白假丝酵母菌具有协同抑菌作用,抑菌作用增强。
实验实施例十五
基本按照GB 15979-2002《一次性使用卫生用品卫生标准》附录C的方法,实验研究丙酸钠与二元酸/三元酸组合的溶液作用20分钟,对白假丝酵母菌ATCC10231的抑菌作用,其中各组分的百分比浓度均为重量百分比浓度%(w/w),溶液pH值均为3.6。实验结果如表17所示:
表17不同组分组合的溶液对白假丝酵母菌ATCC10231的抑菌作用
Figure PCTCN2021075655-appb-000026
Figure PCTCN2021075655-appb-000027
结果显示:
1、由表17第1-8组实验结果可见:pH值3.6时,2.88%丙酸钠、7种不同浓度的二元酸或多元酸(4.38%己二酸、3.54%琥珀酸、4.02%苹果酸、4.50%酒石酸、3.50%马来酸、5.76%柠檬酸、3.50%延胡索酸)分别单独作用,对白假丝酵母菌的抑菌率均<25%;
2、由表17第9组实验结果可见:pH值3.6时,1.25%丙酸钠与4.38%己二酸组合的溶液,对白假丝酵母菌有抑菌作用,抑菌率为72.46%;
3、由表17第10-15组实验结果可见:pH值3.6时,1.25%丙酸钠分别与6种不同浓度的二元酸或多元酸(3.54%琥珀酸、4.02%苹果酸、4.50%酒石酸、3.50%马来酸、5.76%柠檬酸、3.50%延胡索酸)组合的溶液,对白假丝酵母菌抑菌率均<25%。
综上所述,可见:己二酸与丙酸钠组合,对白假丝酵母菌具有协同抑菌作用。
实验实施例十六
基本按照GB15979-2002《一次性使用卫生用品卫生标准》附录C的方法,研究柠檬酸、苹果酸、琥珀酸分别与“1.46%(w/w)己二酸+0.16%(w/w)苯甲酸钠+0.62%(w/w)丙酸+0.35%(w/w)苯乙醇”组合的基础抑菌液,作用20分钟, 对白假丝酵母菌ATCC10231的抑菌作用,其中各组分的百分比浓度均为重量百分比浓度%(w/w),基础抑菌液的pH值为均3.6,实验结果如表18所示。
表18柠檬酸、苹果酸、琥珀酸对抑菌作用的影响
Figure PCTCN2021075655-appb-000028
结果显示:
1、基础抑菌液对白假丝酵母菌有抑菌作用,抑菌率为53.77%;
2、基础抑菌液分别添加1.00%柠檬酸、0.70%苹果酸、0.61%琥珀酸,对白假丝酵母菌的抑菌率分别为49.25%、54.77%、53.27%。
综上所述,可见:柠檬酸、苹果酸、琥珀酸对“1.46%己二酸、0.16%苯甲酸钠、0.62%丙酸、0.35%苯乙醇”组合的基础抑菌液抑制白假丝酵母菌的作用均无影响。
体外实验十七
基本按照GB15979-2002《一次性使用卫生用品卫生标准》附录C的方法,研究不同组分组合的溶液作用20分钟,对白假丝酵母菌ATCC 10231的抑菌率,其中各组分的百分比浓度均为重量百分比浓度%(w/w),pH值均为3.8,实验结果如表19所示:
表19不同溶液组合对白假丝酵母菌ATCC 10231的抑菌作用
Figure PCTCN2021075655-appb-000029
Figure PCTCN2021075655-appb-000030
结果显示:
1、由表19的第1-9组实验结果可见:pH值3.8时,7种不同浓度的脂肪酸(1.32%丁酸、0.70%戊酸、0.20%己酸、0.12%庚酸、0.03%辛酸、0.0075%壬酸、0.005%癸酸)、2种不同浓度的二元酸(1.50%己二酸、2.00%庚二酸)分别单独作用,对白假丝酵母菌的抑菌率均<35%;
2、由表19的第10-16组实验结果可见:pH值3.8时,7种不同浓度的脂肪酸(1.32%丁酸、0.70%戊酸、0.20%己酸、0.12%庚酸、0.03%辛酸、0.0075%壬酸、0.005%癸酸)分别与1.50%己二酸组合的溶液,对白假丝酵母菌有抑菌作用或抑菌作用强,抑菌率为50%-90%之间或>90%;
3、由表19的第17-23组实验结果可见:pH值3.8时,7种不同浓度的脂肪酸(1.32%丁酸、0.70%戊酸、0.20%己酸、0.12%庚酸、0.03%辛酸、0.0075%壬酸、0.005%癸酸)分别与2.00%的庚二酸组合的溶液,对白假丝酵母菌有抑菌作用或抑菌作用强,抑菌率为50%-90%之间或>90%。
综上所述,可见:pH值3.8时,7种不同浓度的脂肪酸(1.32%丁酸、0.70%戊酸、0.20%己酸、0.12%庚酸、0.03%辛酸、0.0075%壬酸、0.005%癸酸)分别与1.50%己二酸、2.00%庚二酸组合的溶液,对白假丝酵母菌具有协同抑菌 作用,均使抑菌作用增强。
体外实验十八
基本按照GB15979-2002《一次性使用卫生用品卫生标准》附录C的方法,研究不同组分组合的溶液作用20分钟,对大肠埃希菌ATCC25922、金黄色葡萄球菌ATCC6538、白假丝酵母菌ATCC 10231的抑菌率,其中各组分的百分比浓度均为重量百分比浓度%(w/w),pH值均为3.8,实验结果如表20所示:
表20不同溶液对大肠埃希菌、金黄色葡萄球菌、白假丝酵母菌的抑菌作用
Figure PCTCN2021075655-appb-000031
由表20实验结果可见:pH值3.8时,9种不同浓度的脂肪酸(3.00%丁酸、0.45%己酸、0.30%庚酸、0.05%辛酸、0.03%壬酸、0.008%癸酸、0.006%十一酸、0.006%十一烯酸、0.006%月桂酸)、5.00%庚二酸分别单独作用,对白假丝酵母菌有抑菌作用或抑菌作用强,抑菌率为50%-90%之间或>90%;对大肠埃希菌和金黄色葡萄球菌的抑菌作用强,抑菌率均为100.00%。
体外实验十九
基本按照GB 15979-2002《一次性使用卫生用品卫生标准》附录C的方法,研究不同组分组合的水溶液分别作用20分钟,对白假丝酵母菌ATCC10231的抑菌作用,其中各组分的百分比浓度均为重量百分比浓度%(w/w),pH值均为3.8。实验结果如表21所示:
表21不同溶液对白假丝酵母菌ATCC 10231的抑菌作用
编号 丙酸(%) 庚二酸(%) 肉桂醇(%) 苯甲酸钠(%) 抑菌率(%)
1 2.00 1.50 -- 0.20 41.25
2 2.00 1.50 0.03 0.20 72.15
3 2.00 1.50 0.05 0.20 84.54
4 2.00 1.50 0.08 0.20 95.21
结果显示:
1、由表21第1组实验结果可见:pH值3.8时,1.50%庚二酸、0.20%苯甲酸钠、2.00%丙酸组合的溶液,对白假丝酵母菌的抑菌率为41.25%;
2、由表21第2-4组实验结果可见:pH值3.8时,0.03-0.08%肉桂醇与“1.50%庚二酸、0.20%苯甲酸钠、2.00%丙酸”组合的溶液,对白假丝酵母菌有抑菌作用或抑菌作用强,抑菌率为50%-90%之间或>90%。
综上所述可见,0.03-0.08%肉桂醇对“1.50%庚二酸、0.20%苯甲酸钠、2.00%丙酸”组合的溶液抑制白假丝酵母菌的作用有显著影响,抑菌作用增强。
体外实验二十
基本按照GB 15979-2002《一次性使用卫生用品卫生标准》附录C的方法,研究不同组分组合的水溶液分别作用20分钟,对白假丝酵母菌ATCC10231的抑菌作用,其中各组分的百分比浓度均为重量百分比浓度%(w/w),pH值均为4.8。实验结果如表22所示:
表22不同溶液对白假丝酵母菌ATCC 10231的抑菌作用
编号 丙酸(%) 庚二酸(%) 苯甲酸钠(%) 抑菌率(%)
1 -- 5.00 -- 15.42
2 -- -- 1.18 15.92
3 0.10 -- -- 2.90
4 0.10 5.00 1.18 61.02
结果显示:
1、由表22第1-3组实验结果可见:pH值4.8时,5.00%庚二酸、1.18%苯 甲酸钠、0.10%丙酸分别单独作用,对白假丝酵母菌的抑菌率均低于20%;
2、由表22第4组实验结果可见:pH值4.8时,“5.00%庚二酸、1.18%苯甲酸钠、0.10%丙酸”组合的溶液,对白假丝酵母菌有抑菌作用,抑菌率为61.02%。
综上所述可见,pH值4.8时,“5.00%庚二酸、1.18%苯甲酸钠、0.10%丙酸”三种组分组合的溶液,对白假丝酵母菌具有协同抑菌作用,抑菌作用增强。
体外实验二十一
基本按照GB 15979-2002《一次性使用卫生用品卫生标准》附录C的方法,研究不同组分组合的水溶液分别作用20分钟,对大肠埃希菌ATCC25922、金黄色葡萄球菌ATCC6538的抑菌作用,其中各组分的百分比浓度均为重量百分比浓度%(w/w),pH值均为4.0。实验结果如表23所示:
表23不同溶液对大肠埃希菌ATCC25922、金黄色葡萄球菌ATCC6538的抑菌作用
Figure PCTCN2021075655-appb-000032
结果显示:
1、由表23第1-4组实验结果可见:pH值4.0时,0.06%苯甲酸钠分别与0.30%苯乙醇、0.50%丙酸、0.45%丁酸、0.06%己酸组合的溶液,对大肠埃 希菌和金黄色葡萄球菌有抑菌作用,抑菌率均高于50%;
2、由表23第5-7组实验结果可见:pH值4.0时,0.30%苯乙醇分别与0.50%丙酸、0.45%丁酸、0.06%己酸组合的溶液,对大肠埃希菌和金黄色葡萄球菌有抑菌作用,抑菌率均高于50%;
3、由表23第8-10组实验结果可见:pH值4.0时,“0.045%苯甲酸钠、0.30%苯乙醇”与0.35%丙酸组合的溶液,对大肠埃希菌和金黄色葡萄球菌有抑菌作用,抑菌率均高于50%;“0.045%苯甲酸钠、0.30%苯乙醇”分别与0.30%丁酸、0.06%己酸组合的溶液,对大肠埃希菌和金黄色葡萄球菌的抑菌作用强,抑菌率均高于90%;
4、由表23第11-13组实验结果可见:pH值4.0时,“1.50%己二酸、0.045%苯甲酸钠、0.30%苯乙醇”分别与3种不同浓度脂肪酸(0.35%丙酸、0.30%丁酸、0.06%己酸)组合的溶液,对大肠埃希菌的抑菌作用强,抑菌率均高于90%,对金黄色葡萄球菌有抑菌作用,抑菌率均在50%-90%之间。
体外实验二十二
基本按照GB 15979-2002《一次性使用卫生用品卫生标准》附录C的方法,研究不同组分组合的水溶液分别作用20分钟,对白假丝酵母菌ATCC10231的抑菌作用,其中各组分的百分比浓度均为重量百分比浓度%(w/w)。实验结果如表24所示:
表24不同溶液对白假丝酵母菌ATCC 10231的抑菌作用
Figure PCTCN2021075655-appb-000033
由表24第1-3组实验结果可见:pH值分别为4.0、4.2时“0.06%柠檬酸、1.17%己二酸、0.20%丙酸、0.60%丁酸、0.20%苯甲酸钠、0.40%苯乙醇”的组合溶液在对白假丝酵母菌有抑菌作用,抑菌率分别为86.56%、66.74%,pH 值4.4时,上述组合的溶液对白假丝酵母菌的抑菌率为37.61%。
综上所述,可见:“0.06%柠檬酸、1.17%己二酸、0.20%丙酸、0.60%丁酸、0.20%苯甲酸钠、0.40%苯乙醇”组合的溶液,pH值越低,对白假丝酵母菌的抑菌作用越强。
体外实验二十三
基本按照GB 15979-2002《一次性使用卫生用品卫生标准》附录C的方法,研究不同组分组合的水溶液分别作用20分钟,对白假丝酵母菌ATCC10231的抑菌作用,其中各组分的百分比浓度均为重量百分比浓度%(w/w),溶液pH值均为3.86。实验结果如表25所示:
表25不同溶液对白假丝酵母菌ATCC 10231的抑菌作用
Figure PCTCN2021075655-appb-000034
结果显示:
1、由表25第1组实验结果可见:pH值3.86时,“1.46%己二酸、0.20%苹果酸、0.12%苯甲酸钠、0.20%丙酸、0.45%丁酸、0.30%苯乙醇、1.80%帕拉金糖”组合的溶液,对白假丝酵母菌有抑菌作用,抑菌率为75.14%;
2、由表25第2组实验结果可见:pH值3.86时,“1.46%己二酸、0.20%苹果酸、0.12%苯甲酸钠、0.20%丙酸、0.45%丁酸、0.30%苯乙醇、1.80%帕拉金糖、0.04%葛根素”组合的溶液,对白假丝酵母菌有抑菌作用,抑菌率为78.45%;
3、由表25第3组实验结果可见:pH值3.86时,“1.46%己二酸、0.20%苹果酸、0.12%苯甲酸钠、0.20%丙酸、0.45%丁酸、0.30%苯乙醇、1.80%帕拉金糖、0.06%葛根素”组合的溶液,对白假丝酵母菌有抑菌作用,抑菌率为76.24%。
综上所述可见,溶液pH值3.86时,其组分中分别包含的0.04%、0.06%的葛根素,对白假丝酵母菌的抑制作用无影响,抑菌作用未减弱。。
可以理解地,其他雌激素类物质,例如己烯雌酚、己烷雌酚、雌二醇、雌酮、雌三醇、尼尔雌醇、炔雌醇、炔雌醇环戊醚、炔雌甲醚、普罗雌烯,以及其他植物雌激素类物质,例如大豆苷、黄豆苷元、黄豆黄素、葛根素、拟雌内酯、金雀异黄酮、雌马醇、芹黄素、染料木甙、染料木素、鸡豆黄素、香豆雌酚、芒柄花黄素、白藜芦醇、亚麻木酚素、木脂素,与葛根素的性质和作用原理类似,因此,也可推及前述的雌激素类物质和植物雌激素类物质不会明显减弱组合物对白假丝酵母菌的抑制作用。
体外实验二十四
基本按照GB 15979-2002《一次性使用卫生用品卫生标准》附录C的方法,研究不同组分组合的水溶液分别作用20分钟,对白假丝酵母菌ATCC10231的抑菌作用,其中各组分的百分比浓度均为重量百分比浓度%(w/w),pH值均为4.0。实验结果如表26所述:
表26不同溶液对白假丝酵母菌ATCC 10231的抑菌作用
Figure PCTCN2021075655-appb-000035
结果显示:
对比表26中的第1组和第2组的实验结果可见:pH值4.0时,0.55%谷氨酸对“0.14%苹果酸、1.46%己二酸、0.20%苯甲酸钠、1.67%丙酸、0.40%苯乙醇”组合的溶液抑制白假丝酵母菌的作用无影响。
可以理解地,其他适当的氨基酸类物质,例如谷氨酰胺、L-天冬氨酸、天冬氨酰胺、亮氨酸、异亮氨酸、苯丙氨酸、缬氨酸、脯氨酸、苏氨酸,与谷氨酸的性质和作用原理类似,因此,也可推及前述的氨基酸类物质也不会影响组合物对白假丝酵母菌的抑制作用。
体外实验二十五
基本按照GB 15979-2002《一次性使用卫生用品卫生标准》附录C的方法,研究不同组分组合的水溶液分别作用20分钟,对大肠埃希菌ATCC25922、金黄色葡萄球菌ATCC6538的抑菌作用,其中各组分的百分比浓度均为重量百分比浓度%(w/w),pH值均为3.8。实验结果如表27所示:
表27不同溶液对大肠埃希菌ATCC25922、金黄色葡萄球菌ATCC6538的抑菌作用
Figure PCTCN2021075655-appb-000036
结果显示:
1、由表27第1-4组实验结果可见:pH值3.8时,1.75%己二酸分别与1.50%丙酸、1.30%丁酸、0.50%戊酸、0.20%己酸组合的溶液,对大肠埃希菌抑菌作用强,抑菌率均为100.00%,对金黄色葡萄球菌有抑菌作用或抑菌作用强,抑菌率为50%-90%之间或>90%;
2、由表27第5-8组实验结果可见:pH值3.8时,0.03%肉桂醇、1.75%己二酸分别与1.50%丙酸、1.30%丁酸、0.50%戊酸、0.20%己酸组合的溶液,对大肠埃希菌和金黄色葡萄球菌抑菌作用强,抑菌率均为100.00%;
3、由表27第9-12组实验结果可见:pH值3.8时,0.03%肉桂酸、1.75%己二酸分别与1.50%丙酸、1.30%丁酸、0.50%戊酸、0.20%己酸组合的溶液, 对大肠埃希菌和金黄色葡萄球菌抑菌作用强,抑菌率均为100.00%。
体外实验二十六
基本参照2020版《中华人民共和国药典》四部1121抑菌效力检查法的方法和结果判定标准,研究组合物中各抑菌剂的对金黄色葡萄球菌、铜绿假单胞菌、大肠埃希菌、白色念珠菌、黑曲霉的抑菌作用,实验结果如表28所示。
表28组合物 1抑菌效力实验
Figure PCTCN2021075655-appb-000037
注:
1.组合物含:1.50%(w/w)己二酸、0.14%(w/w)苯甲酸钠、0.32%(w/w)苯乙醇、0.54%(w/w)丙酸、0.20%(w/w)己酸、0.20%(w/w)帕拉金糖、0.60%(w/w)麦芽糖、0.0005%(w/w)玫瑰精油、2.15%(w/w)黄原胶
2.指各间隔时间测定的菌数量的lg值与1ml(g)供试品中接种的菌数lg值的相差值
3.未增加,是指对前一个测定时间,实验菌增加的数量不超过0.5lg
由表28实验结果可见:pH4.2时,各实验菌14天相对于0天添加的菌浓度减少的lg值均为5,28天相对于14天减少的lg值未增加,符合要求;可见,本实验pH4.2的组合物具有防腐作用。
值得说明的是,即使实验的条件、方法等都完全一样,但是由于实验误差的存在,在重复实验时,体外抑菌实验的结果例如抑菌率仍会有所差异,然而此差异是合理的,属于本领域技术人员可以理解的。因而,本公开文件的体外实验数据与在先申请文件中的数据如果存在不一致的,以本公开的数据为准。
体内实验一
含不同组分的3组凝胶每天1次、每次0.5毫升,连续5天食蟹猴阴道内给药,取阴道拭子测pH值和涂片染色镜检,观察凝胶对食蟹猴阴道分泌物pH值和阴道菌群的影响,实验结果如表29所示:
表29含不同组分的抑菌凝胶对食蟹猴阴道酸度和菌群的影响
Figure PCTCN2021075655-appb-000038
注:
1:B组凝胶含2.50%(w/w)麦芽糖、0.20%(w/w)异麦芽酮糖、0.16%(w/w)苯甲酸钠、0.60%(w/w)丙酸钠、0.35%(w/w)苯乙醇、1.00%(w/w)柠檬酸、1.168%(w/w)己二酸、2.15%(w/w)黄原胶,调pH至3.6
2:C组凝胶含2.50%(w/w)麦芽糖、0.20%(w/w)异麦芽酮糖、0.16%(w/w)苯甲酸钠、0.60%(w/w)丙酸钠、0.35%(w/w)苯乙醇、0.61%(w/w)琥珀酸、1.168%(w/w)己二酸、2.15%(w/w)黄原胶,调pH至3.6
3:第2组凝胶含1.15%(w/w)丙酸钠、0.45%(w/w)苯乙醇、0.20%(w/w)苯甲酸钠、1.50%(w/w)麦芽糖、1.00%(w/w)柠檬酸、2.15%(w/w)黄原胶,调pH至3.6
4:Nugent评分为阴道分泌物涂片、革兰染色后显微镜镜检,根据细菌的染色、形态、数量进行评分,具体如下:
≥7分,阴道细菌以革兰阴性杆菌、和/或阴性球菌及阳性球菌为主,粗大阳性杆菌无或极少;
4-6分,阴道细菌以革兰阴性杆菌、和/或阴性球菌、和/或阳性球菌为主,粗大革兰阳性杆菌少;
0-3分,阴道菌群正常,细菌以粗大革兰阳性杆菌为主。
结果显示:
1、从表29第B组实验结果可见:pH值3.6、含“2.50%(w/w)麦芽糖、0.20%(w/w)异麦芽酮糖、0.16%(w/w)苯甲酸钠、0.60%(w/w)丙酸钠、0.35%(w/w)苯乙醇、1.00%(w/w)柠檬酸、1.168%(w/w)己二酸、2.15%(w/w)黄原胶”的凝胶,用药5次,3只食蟹猴阴道分泌物pH值均降至3.8,阴道菌群Nugent评分均降至0-3分;
2、从表29第C组实验结果可见:pH值3.6、含“2.50%(w/w)麦芽糖、0.20(w/w)异麦芽酮糖、0.16%(w/w)苯甲酸钠、0.60%(w/w)丙酸钠、0.35%(w/w)苯乙醇、0.61%(w/w)琥珀酸、1.168%(w/w)己二酸、2.15%(w/w)黄原胶”的凝胶,用药5次,3只食蟹猴阴道分泌物pH值均降至3.8,阴道菌群Nugent评分3只中1只降至0-3分,2只降至4-6分;
3、从表29第2组实验结果可见:pH值3.6,含“1.15%(w/w)丙酸钠、0.45%(w/w)苯乙醇、0.20%(w/w)苯甲酸钠、1.50%(w/w)麦芽糖、柠檬酸1.00%(w/w)、2.15%(w/w)黄原胶”的凝胶,用药5次,5只食蟹猴中阴道分泌物pH值3只均降至3.8,1只降至4.4,1只因月经脱落;阴道菌群Nugent评分3只均降至0-3分,1只仍>7分,1只因月经脱落。
综上所述可见,本实验的pH值3.6的3组凝胶均具有抑制阴道异常菌群、恢复阴道酸度、恢复阴道乳杆菌的作用,含己二酸及分别含柠檬酸、琥珀酸的2组凝胶(B、C组)中B组效果优于C组和不含己二酸的第2组凝胶,不含己二酸的第2组凝胶抑制阴道异常菌群、恢复阴道酸度、恢复阴道乳杆菌的作用在三组凝胶中最弱。
体内实验二
含不同组分的3组凝胶每天1次、每次0.5毫升,连续5天恒河猴阴道内给药,取阴道分泌物测pH值和涂片染色镜检,观察凝胶对恒河猴阴道分泌物pH值和阴道菌群的影响,实验结果如表30所示:
表30含不同组分的抑菌凝胶对恒河猴阴道酸度和菌群的影响
Figure PCTCN2021075655-appb-000039
Figure PCTCN2021075655-appb-000040
注:
1:A组凝胶含2.00%(w/w)异麦芽酮糖、0.12%(w/w)苯甲酸钠、0.60%(w/w)丁酸、1.31%(w/w)己二酸、0.30%(w/w)苯乙醇、0.35%(w/w)苹果酸、2.15%(w/w)黄原胶,调pH至4.1
2:B组凝胶含2.00%(w/w)异麦芽酮糖、0.12%(w/w)苯甲酸钠、0.60%(w/w)丁酸、0.0010%(w/w)癸酸、1.31%(w/w)己二酸、0.30%(w/w)苯乙醇、0.35%(w/w)苹果酸、2.15%(w/w)黄原胶,调pH至4.1
3:C组凝胶含2.00%(w/w)异麦芽酮糖、0.12%(w/w)苯甲酸钠、0.60%(w/w)丁酸、0.0015%(w/w)癸酸、1.31%(w/w)己二酸、0.30%(w/w)苯乙醇、0.35%(w/w)苹果酸、2.15%(w/w)黄原胶,调pH至4.1
4:同体内实验一的注4
结果显示:
1、从A组实验结果可见:pH值4.1、含“1.31%(w/w)己二酸、0.35%(w/w)苹果酸、0.30%(w/w)苯乙醇、0.12%(w/w)苯甲酸钠、0.60%(w/w)丁酸”、以及2.00%(w/w)异麦芽酮糖、2.15%(w/w)黄原胶的凝胶,用药5次,4只恒河猴中的3只其阴道分泌物pH值均降至3.8,阴道菌群Nugent评分均降至0-3分;1只恒河猴的阴道分泌物pH值仍为5.4,阴道菌群Nugent评分降至4-6分。
2、从B组实验结果可见:pH值4.1、含“1.31%(w/w)己二酸、0.35%(w/w)苹果酸、0.30%(w/w)苯乙醇、0.12%(w/w)苯甲酸钠、0.60%(w/w)丁酸、0.0010%(w/w)癸酸”、以及2.00%(w/w)异麦芽酮糖、2.15%(w/w)黄原胶的凝胶,使用5次,5只恒河猴中的3只其阴道分泌物pH值降至3.8,阴道菌群Nugent评分降至0-3分;1只的阴道分泌物pH值降至4.1,阴道菌群Nugent评分降至4-6分;1只的阴道分泌物pH值仍为5.4,阴道菌群Nugent评分降至4-6分。
3、从C组实验结果可见:pH值4.1、含“1.31%(w/w)己二酸、0.35%(w/w)苹果酸、0.30%(w/w)苯乙醇、0.12%(w/w)苯甲酸钠、0.60%(w/w)丁酸、0.0015%(w/w)癸酸”、以及2.0%(w/w)异麦芽酮糖、2.15%(w/w)黄原胶的凝胶,使用5次,2只恒河猴中1只的阴道分泌物pH值降至3.8,阴道菌群Nugent评分降至0-3分;另1只的阴道分泌物pH值降至4.1,阴道菌群Nugent评分降至4-6分。
综上所述可见,本实验的组分中分别包含0.60%(w/w)丁酸、0.00125%(w/w)癸酸、0.0015%(w/w)癸酸的三组凝胶,具有抑制阴道异常菌群、调节阴道菌群、恢复阴道乳杆菌、恢复阴道酸度正常的作用。
体内实验三
含不同组分的5组凝胶每天1次、每次0.5毫升,连续5天食蟹猴阴道内给药,取阴道拭子测pH值和涂片染色镜检,观察凝胶对食蟹猴阴道分泌物pH值和阴道菌群的影响,实验结果如表31所示:
表31含不同组分的抑菌凝胶对食蟹猴阴道酸度和菌群的影响
Figure PCTCN2021075655-appb-000041
注:
1:第1组凝胶含0.14%(w/w)苯甲酸钠、0.54%(w/w)丙酸、1.46%(w/w)己二酸、0.30%(w/w)苯乙醇、0.35%(w/w)苹果酸、2.15%(w/w)黄原胶,调pH至3.8
2:第2组凝胶含2.00%(w/w)麦芽糖、0.14%(w/w)苯甲酸钠、0.54%(w/w)丙酸、1.46%(w/w)己二酸、0.30%(w/w)苯乙醇、0.35%(w/w)苹果酸、2.15%(w/w)黄原胶,调pH至3.8
3:第3组凝胶含2.0%(w/w)异麦芽酮糖、0.14%(w/w)苯甲酸钠、0.54%(w/w)丙酸、1.46%(w/w)己二酸、0.30%(w/w)苯乙醇、0.35%(w/w)苹果酸、2.15%(w/w)黄原胶,调pH至3.8
4:第4组凝胶含2.00%(w/w)异麦芽酮糖、0.12%(w/w)苯甲酸钠、0.38%(w/w)丙酸、1.31%(w/w)己二酸、0.0015%(w/w)癸酸、0.30%(w/w)苯乙醇、0.35%(w/w)苹果酸、2.15%(w/w)黄原胶,调pH至3.9
5:第5组凝胶含2.00%(w/w)异麦芽酮糖、0.12%(w/w)苯甲酸钠、0.38%(w/w)丙酸、1.31%(w/w)己二酸、0.01%(w/w)辛酸、0.30%(w/w)苯乙醇、0.35%(w/w)苹果酸、2.15%(w/w)黄原胶,调pH至3.9
6:同体内实验一的注4
结果显示:
1、从表31第1组至第3组实验结果可见:不含糖的第1组凝胶、含2.00%(w/w)麦芽糖的第2组凝胶、含2.00%(w/w)异麦芽酮糖的第3组凝胶,除糖组分之外,3组凝胶的其它组分完全相同,pH值均为3.8,均含“0.14%(w/w)苯甲酸钠、0.54%(w/w)丙酸、1.46%(w/w)己二酸、0.30%(w/w)苯乙醇、0.35%(w/w)苹果酸、2.15%(w/w)黄原胶”。
用药3次,阴道分泌物pH值3个组均降至4.1或以下;阴道菌群Nugent评分,不含糖的第1组的4只食蟹猴两只降至4-6分,两只降至0-3分;含麦芽糖的第2组的2只食蟹猴均降至0-3分;含异麦芽酮糖的第3组的3只食蟹猴中的2只降至0-3分,1只降至4-6分。
2、从表31第4组实验结果可见:pH值3.9、含“2.00%(w/w)异麦芽酮糖、0.12%(w/w)苯甲酸钠、0.38%(w/w)丙酸、1.31%(w/w)己二酸、0.30%(w/w)苯乙醇、0.35%(w/w)苹果酸、0.0015%(w/w)癸酸、2.15%(w/w)黄原胶”的凝胶,用药5次,2只食蟹猴的阴道分泌物pH值均降至3.8,阴道菌群Nugent评分1只降至0-3分,另1只降至4-6分。
3、从表31第5组实验结果可见:pH值3.9、含“2.00%(w/w)异麦芽酮糖、0.12%(w/w)苯甲酸钠、0.38%(w/w)丙酸、1.31%(w/w)己二酸、0.30%(w/w)苯乙醇、0.35%(w/w)苹果酸、0.01%(w/w)辛酸、2.15%(w/w)黄原胶”的凝胶,用药3次,2只食蟹猴的阴道分泌物pH值均降至3.8,阴道菌群Nugent评分均降至0-3分。
综上所述可见:
1、本实验pH值3.8、含“1.46%(w/w)己二酸、0.35%(w/w)苹果酸、0.54%(w/w)丙酸、0.30%(w/w)苯乙醇、0.14%(w/w)苯甲酸钠”的组合、但不含糖的凝胶,具有抑制阴道异常菌群、恢复阴道酸度、恢复阴道乳杆菌的作用,如第1组实验结果所示。但进一步还含有麦芽糖或异麦芽酮糖的第2组、第3组的凝胶,比不含糖的第1组的凝胶,其恢复阴道乳杆菌的作用更快、更 强,如第2组实验、第3组实验结果所示。
2、本实验pH值3.9、含“1.31%(w/w)己二酸、0.35%(w/w)苹果酸、0.38%(w/w)丙酸、0.30%(w/w)苯乙醇、0.12%(w/w)苯甲酸钠、2.0%(w/w)异麦芽酮糖”,以及分别含0.0015%(w/w)癸酸、0.01%(w/w)辛酸的凝胶,具有抑制阴道异常菌群、恢复阴道酸度的作用,和恢复阴道乳杆菌的作用,如第4组实验、第5组实验结果所示。
体内实验四
含不同组分的3组凝胶每天1次、每次0.5毫升,连续5天食蟹猴阴道内给药,取阴道拭子测pH值和涂片染色镜检,观察凝胶对食蟹猴阴道分泌物pH值和阴道菌群的影响,实验结果如表32所示:
表32含不同组分的抑菌凝胶对食蟹猴阴道酸度和菌群的影响
Figure PCTCN2021075655-appb-000042
注:
1:第1组凝胶含2.00%(w/w)异麦芽酮糖、0.12%(w/w)苯甲酸钠、0.38%(w/w)丙酸、1.31%(w/w)己二酸、0.04%(w/w)庚酸、0.30%(w/w)苯乙醇、0.35%(w/w)苹果酸、2.15%(w/w)黄原胶,调pH至3.9
注2:第2组凝胶含2.00%(w/w)异麦芽酮糖、0.12%(w/w)苯甲酸钠、0.38%(w/w)丙酸、1.31%(w/w)己二酸、0.10%(w/w)己酸、0.30%(w/w)苯乙醇、0.35%(w/w)苹果酸、2.15%(w/w)黄原胶,调pH至3.9
注3:第3组凝胶含2.00%(w/w)异麦芽酮糖、0.12%(w/w)苯甲酸钠、0.38%(w/w)丙酸、1.31%(w/w)己二酸、0.20%(w/w)戊酸、0.30%(w/w)苯乙醇、0.35%(w/w)苹果酸、2.15%(w/w)黄原胶,调pH至3.9
注4:同体内实验一的注4
结果显示:
1、从表32第1组实验结果可见:pH值3.9、含“2.00%(w/w)异麦芽酮糖、0.12%(w/w)苯甲酸钠、0.38%(w/w)丙酸、1.31%(w/w)己二酸、0.30%(w/w)苯乙醇、0.35%(w/w)苹果酸、0.04%(w/w)庚酸、2.15%(w/w)黄原胶”的凝胶,用药5次,食蟹猴的阴道分泌物pH值降至3.8,阴道菌群Nugent评分降至0-3 分。
2、从表32第2组实验结果可见:pH值3.9、含“2.00%(w/w)异麦芽酮糖、0.12%(w/w)苯甲酸钠、0.38%(w/w)丙酸、1.31%(w/w)己二酸、0.30%(w/w)苯乙醇、0.35%(w/w)苹果酸、0.10%(w/w)己酸、2.15%(w/w)黄原胶”的凝胶,用药5次,2只食蟹猴的阴道分泌物pH值均降至4.1或以下,阴道菌群Nugent评分均降至0-3分。
3、从表32第3组实验结果可见:pH值3.9、含“2.00%(w/w)异麦芽酮糖、0.12%(w/w)苯甲酸钠、0.38%(w/w)丙酸、1.31%(w/w)己二酸、0.30%(w/w)苯乙醇、0.35%(w/w)苹果酸、0.20%(w/w)戊酸、2.15%(w/w)黄原胶”的凝胶,用药5次,2只食蟹猴的阴道分泌物pH值仍为5.4,阴道菌群Nugent评分1只食蟹猴降至0-3分,另1只降至4-6分。
综上所述可见,本实验pH值3.9、含“2.00%(w/w)异麦芽酮糖、0.12%(w/w)苯甲酸钠、0.38%(w/w)丙酸、1.31%(w/w)己二酸、0.30%(w/w)苯乙醇、0.35%(w/w)苹果酸”以及分别含0.04%(w/w)庚酸、0.10%(w/w)己酸、0.20%(w/w)戊酸、2.15%(w/w)黄原胶的3组凝胶,具有抑制阴道异常菌群、恢复阴道乳杆菌的作用。分别含0.04%(w/w)庚酸、0.10%(w/w)己酸的2组凝胶,还具有恢复阴道酸度的作用。
体内实验五
含不同组分的6组凝胶每天1次、每次0.5毫升,连续5天食蟹猴阴道内给药,取阴道拭子测pH值和涂片染色镜检,观察凝胶对食蟹猴阴道分泌物pH值和阴道菌群的影响,实验结果如表33所示:
表33含不同组分抑菌剂凝胶对食蟹猴阴道酸度和菌群的影响
Figure PCTCN2021075655-appb-000043
Figure PCTCN2021075655-appb-000044
注:
1:第1组凝胶含0.10%(w/w)己酸、1.50%(w/w)己二酸、2.00%(w/w)麦芽糖、2.15%(w/w)黄原胶,调pH至3.1
2:第2组凝胶含2.00%(w/w)丙酸、0.30%(w/w)肉桂醇、0.60%(w/w)琥珀酸、2.00%(w/w)麦芽糖、2.15%(w/w)黄原胶,调pH至3.8
3:第3组凝胶含0.02%(w/w)辛酸、0.25%(w/w)苯甲酸、1.00%(w/w)柠檬酸、2.00%(w/w)麦芽糖、2.15%(w/w)黄原胶,调pH至3.8
4:第4组凝胶含0.20%(w/w)苯甲酸、0.25%(w/w)苯甲醇、0.001%(w/w)十一酸、1.00%(w/w)苹果酸、2.00%(w/w)麦芽糖、2.15%(w/w)黄原胶,调pH至3.80
5:第5组凝胶含0.20%(w/w)苯甲酸、0.50%(w/w)丙酸、1.50%(w/w)己二酸、2.00%(w/w)麦芽糖、2.15%(w/w)黄原胶,调pH至3.8
6:第6组凝胶含1.00%(w/w)庚二酸、0.60%(w/w)苯乙醇、1.25%(w/w)丁酸、2.00%(w/w)麦芽糖、2.15%(w/w)黄原胶,调pH至3.8
7:同体内实验一的注4
结果显示:
1、从表33第1组实验结果可见:pH值3.1、含“0.10%(w/w)己酸、1.50%(w/w)己二酸、2.00%(w/w)麦芽糖、2.15%(w/w)黄原胶”的凝胶,用药5次,3只食蟹猴中1只因月经终止实验,其余2只的阴道分泌物pH值一只仍为5.4,另一只降至3.8,阴道菌群Nugent评分1只降至4-6分,另一只降至0-3分;
2、从表33第2组实验结果可见:pH值3.8、含“2.00%(w/w)丙酸、0.30%(w/w)肉桂醇、0.60%(w/w)琥珀酸、2.00%(w/w)麦芽糖、2.15%(w/w)黄原胶”的凝胶,用药5次,2只食蟹猴中1只阴道分泌物pH值降至4.1,1只仍为5.4,阴道菌群Nugent评分1只降至4-6分,1只降至0-3分;
3、从表33第3组实验结果可见:pH值3.8、含“0.02%(w/w)辛酸、0.25%(w/w)苯甲酸、1.00%(w/w)柠檬酸、2.00%(w/w)麦芽糖、2.15%(w/w)黄原胶”,用药5次,2只食蟹猴阴道分泌物pH值1只降至3.8,1只降至4.1;阴道菌群Nugent 评分两只均降至0-3分;
4、从表33第4组实验结果可见:pH值3.8、含“0.20%(w/w)苯甲酸、0.25%(w/w)苯甲醇、0.001%(w/w)十一酸、1.00%(w/w)苹果酸、2.00%(w/w)麦芽糖、2.15%(w/w)黄原胶”用药5次,2只食蟹猴中阴道分泌物pH值1只降至4.6、1只降至3.8;阴道菌群Nugent评分1只降至4-6分,1只降至0-3分;
5、从表33第5组实验结果可见:pH值3.8、含“0.20%(w/w)苯甲酸、0.50%(w/w)丙酸、1.50%(w/w)己二酸、2.00%(w/w)麦芽糖、2.15%(w/w)黄原胶”,用药5次,2只食蟹猴中阴道分泌物pH值1只降至4.6、1只降至3.8;阴道菌群Nugent评分1只降至4-6分,1只降至0-3分;
6、从表33第6组实验结果可见:pH值3.8、含“1.00%(w/w)庚二酸、0.60%(w/w)苯乙醇、1.25%(w/w)丁酸、2.00%(w/w)麦芽糖、2.15%(w/w)黄原胶”,用药5次,2只食蟹猴中阴道分泌物pH值1只降至3.8、1只降至4.1;阴道菌群Nugent评分1只降至0-3分,1只降到4-6分。
综上所述,可见:以上6种组合物凝胶,具有抑制阴道异常菌群、恢复阴道酸度的作用,和恢复阴道乳杆菌的作用。
体内实验六
组分中包含己二酸、延胡索酸的凝胶每天1次、每次0.5毫升,连续5天食蟹猴阴道内给药,取阴道拭子测pH值和涂片染色镜检,观察凝胶对食蟹猴阴道分泌物pH值和阴道菌群的影响,实验结果如表34所示:
表34含己二酸、延胡索酸的凝胶对食蟹猴阴道酸度和菌群的影响
Figure PCTCN2021075655-appb-000045
注:
1:第1组凝胶含1.50%(w/w)延胡索酸、1.00%(w/w)丙酸、0.08%(w/w)肉桂酸、0.25%(w/w)苯乙醇、1.40%(w/w)麦芽糖、2.15%(w/w)黄原胶,调pH至3.8
2:第2组凝胶含1.50%(w/w)己二酸、1.00%(w/w)丙酸、0.08%(w/w)肉桂酸、0.25%(w/w)苯乙醇、1.40%(w/w)麦芽糖、2.15%(w/w)黄原胶,调pH至3.8
3:同体内实验一的注4
结果显示:
1、从表34第1组实验结果可见:pH值3.8、含“1.50%(w/w)延胡索酸、1.00%(w/w)丙酸、0.08%(w/w)肉桂酸、0.25%(w/w)苯乙醇、1.40%(w/w)麦芽糖、2.15%(w/w)黄原胶”的凝胶,用药5次,2只食蟹猴的阴道分泌物pH值仍为5.4,阴道菌群Nugent评分其中1只仍>7分、另1只降至4-6分
2、从表34第2组实验结果可见:pH值3.8、含“1.50%(w/w)己二酸、1.00%(w/w)丙酸、0.08%(w/w)肉桂酸、0.25%(w/w)苯乙醇、1.40%(w/w)麦芽糖、2.15%(w/w)黄原胶”的凝胶,用药5次,2只食蟹猴的阴道分泌物pH值,2只均降至4.1,阴道菌群Nugent评分均降至0-3分。
综上所述可见,本实验的含1.50%(w/w)己二酸的凝胶,具有抑制阴道异常菌群、恢复阴道的乳杆菌、恢复阴道酸度的作用。
临床观察一
细菌性阴道病(BV)患者10例、健康志愿者5例,凝胶A每天1次、每次4.5g,连续5天阴道内给药,用药第3天(V1)和停药3天后(V2),取阴道拭子测pH值和涂片染色镜检,观察凝胶对阴道分泌物pH值和阴道菌群的影响,实验结果如表35所示:
表35凝胶A对BV患者与健康志愿者阴道酸度和菌群的影响
Figure PCTCN2021075655-appb-000046
Figure PCTCN2021075655-appb-000047
注1:凝胶A含1.46%(w/w)己二酸、0.70%(w/w)丙酸钠、0.14%(w/w)苯甲酸钠、0.32%(w/w)苯乙醇、1.00%(w/w)柠檬酸、1.60%(w/w)麦芽糖、0.20%(w/w)帕拉金糖、0.0005%(w/w)玫瑰精油、2.15%(w/w)黄原胶,调pH至3.70
注2:pH值采用pH标准范围比色卡进行测定,比色卡分两个范围,3.8-4.1表示正常,4.6-5.4表示异常
注3:同体内实验一的注7
结果显示:
1、从表35的BV患者实验结果可见:pH值3.70、含“1.46%(w/w)己二酸、0.70%(w/w)丙酸钠、0.14%(w/w)苯甲酸钠、0.32%(w/w)苯乙醇、1.00%(w/w)柠檬酸、1.60%(w/w)麦芽糖、0.20%(w/w)帕拉金糖、0.0005%(w/w)玫瑰精油、2.15%(w/w)黄原胶”的凝胶,用药3次,10例BV患者中7例其pH值降至3.8-4.1,阴道菌群Nugent评分3例降至3分及以下,4例降至4-6分。
用药5次后停药3天进行观察,10例BV患者中9例其pH值降至3.8-4.1,阴道菌群Nugent评分降至3分以下,1例pH值仍为4.6-5.4,阴道菌群Nugent评分降至6分。
2、从表35的健康志愿者的实验结果可见:pH值3.70,含“1.46%(w/w)己二酸、0.70%(w/w)丙酸钠、0.14%(w/w)苯甲酸钠、0.32%(w/w)苯乙醇、1.00%(w/w)柠檬酸、1.60%(w/w)麦芽糖、0.20%(w/w)帕拉金糖、0.0005%(w/w)玫瑰精油、2.15%(w/w)黄原胶”的凝胶,用药3次,对健康志愿者的阴道分泌物pH值和阴道菌群均无影响。
用药5次后停药3天进行观察,对健康志愿者阴道分泌物pH值和菌群均无影响。
综上所述可见:本实验pH值3.70、含“1.46%(w/w)己二酸、0.70%(w/w)丙酸钠、0.14%(w/w)苯甲酸钠、0.32%(w/w)苯乙醇、1.00%(w/w)柠檬酸、1.60%(w/w)麦芽糖、0.20%(w/w)帕拉金糖、0.0005%(w/w)玫瑰精油、 2.15%(w/w)黄原胶”的凝胶可使BV患者阴道中异常菌群显著减少,乳杆菌显著增加,pH值下降,但对健康志愿者的正常的阴道分泌物pH值和正常菌群均无影响,提示该凝胶具有抑制阴道异常菌群、恢复和/或维护阴道乳杆菌、恢复和/或维护阴道正常酸度的作用。
参考文献:
1.方亮主编:《药剂学》,人民卫生出版社,2016年第8版,第243-252页;
2.方亮主编:《药剂学》,人民卫生出版社,2016年第8版,第211-228页;
3.方亮主编:《药剂学》,人民卫生出版社,2016年第8版,第234-237页;
4.方亮主编:《药剂学》,人民卫生出版社,2016年第8版,第280-284页。
尽管本发明已经参考示例性实施方案进行了描述,但应理解本发明不限于公开的示例性实施方案。在不背离本发明的范围或精神的情况下,可对本发明说明书的示例性实施方案做多种调整或变化。权利要求的范围应基于最宽的解释以涵盖所有修改和等同结构与功能。

Claims (24)

  1. 一种抑菌组合物,其特征在于,包含以下组分:
    (1)一种或多种脂肪酸和/或其盐,所述脂肪酸选自由乙酸、羟基乙酸、乳酸、丙酸、乙酰丙酸、丁酸、异丁酸、羟基丁酸、戊酸、己酸、庚酸、辛酸、壬酸、癸酸、十一酸、十一烯酸、以及月桂酸组成的组,以脂肪酸计组分(1)的总含量在0.001-3.00%(w/w)范围内;
    (2)一种或多种二元酸和/或其盐,所述二元酸选自由戊二酸、己二酸、以及庚二酸组成的组,以二元酸计组分(2)的总含量在0.05-5.00%(w/w)范围内;
    (3)一种或多种芳香醇,所述芳香醇选自由苯甲醇、2,4-二氯苯甲醇、苯乙醇、苯氧乙醇、以及肉桂醇组成的组,组分(3)的总含量在0.03-1.00%(w/w)范围内;
    (4)一种或多种芳香酸和/或其盐,所述芳香酸选自由苯甲酸、对羟基苯甲酸、对甲氧基苯甲酸、水杨酸、肉桂酸、龙胆酸、以及咖啡酸组成的组,以芳香酸计组分(4)的总含量在0.03-1.00%(w/w)范围内;
    所述抑菌组合物的剂型选自由水溶液剂、水溶性凝胶剂、泡沫剂、喷雾剂、软膏剂、散剂、膜剂、胶囊剂、栓剂、以及片剂组成的组的一种。
  2. 根据权利要求1所述的抑菌组合物,其特征在于,所述抑菌组合物中组分(1)的总含量在0.001-2.00%(w/w)范围内;且/或
    组分(2)的总含量在0.10-3.50%(w/w)范围内;且/或
    组分(3)的总含量在0.03-0.70%(w/w)范围内;且/或
    组分(4)的总含量在0.03-0.50%(w/w)范围内。
  3. 根据权利要求1所述的抑菌组合物,其特征在于,所述抑菌组合物中进一步包含组分(5):选自由苹果酸、柠檬酸、琥珀酸、酒石酸、马来酸、以及异柠檬酸组成的组的一种或多种二元酸和/或多元酸,和/或其盐,其总 含量在0.10-2.50%(w/w)范围内。
  4. 根据权利要求1所述的抑菌组合物,其特征在于,所述抑菌组合物中进一步包含一种或多种糖,所述糖选自由葡萄糖、果糖、甘露糖、半乳糖、麦芽糖、异麦芽糖、蔗糖、异麦芽酮糖、乳糖、乳果糖、海藻糖、纤维二糖、蜜二糖、龙胆二糖、蔗果三糖、蔗果四糖、蔗果五糖、异麦芽三糖、异麦芽四糖、异麦芽五糖、低聚龙胆糖、棉子糖、潘糖、麦芽寡糖、低聚异麦芽酮糖、低聚果糖、葡甘聚糖、低聚半乳糖、糊精、淀粉、以及糖原组成的组,其总含量在0.01-20.00%(w/w)范围内,优选总含量在0.10-2.00%(w/w)范围内。
  5. 根据权利要求1所述的抑菌组合物,其特征在于,所述抑菌组合物进一步包含一种或多种氨基酸和/或其盐,所述氨基酸选自由L-谷氨酸、谷氨酰胺、L-天冬氨酸、天冬氨酰胺、亮氨酸、异亮氨酸、苯丙氨酸、缬氨酸、脯氨酸、以及苏氨酸组成的组,其总含量在0.10-6.00%(w/w)范围内,优选总含量在0.50-3.00%(w/w)范围内。
  6. 根据权利要求1所述的抑菌组合物,其特征在于,所述抑菌组合物进一步包含一种或多种单萜或倍半萜类化合物,所述单萜或倍半萜类化合物选自由香茅醇、芳樟醇、香叶醇、橙花醇、桉叶醇、松油醇、香芹醇、薄荷醇、以及薰衣草醇组成的组。
  7. 根据权利要求1所述的抑菌组合物,其特征在于,所述抑菌组合物进一步包含一种或多种植物芳香油类物质,所述植物芳香油类物质选自由玫瑰精油、丁香油、麝香草油、薰衣草油、薄荷油、艾叶油、桉叶油、黄樟油、山苍子精油、肉桂精油、月桂叶油、以及百里香油组成的组。
  8. 根据权利要求1所述的抑菌组合物,其特征在于,所述抑菌组合物进一步包含一种或多种维生素,所述维生素选自由维生素A、维生素C、维生素D、以及维生素E组成的组。
  9. 根据权利要求1所述的抑菌组合物,其特征在于,所述抑菌组合物进一步包含一种或多种选自下组的物质:脱氢乙酸、脱氢乙酸钠、山梨酸、山梨酸钾、山梨酸钠、纳他霉素、岩白菜素、环庚三烯酚酮、肉桂醛、土槿乙酸、绿原酸、1,2-戊二醇、1,2-己二醇、1,6-己二醇、1,2-辛二醇、1,2-癸二醇、对羟基苯乙酮、2,4-二羟基苯乙酮、对羟基苯甲酸甲酯、对羟基苯甲酸乙酯、对羟基苯甲酸丙酯、溶菌酶、单辛酸甘油酯、单癸酸甘油酯、以及单月桂酸甘油酯。
  10. 根据权利要求1所述的抑菌组合物,其特征在于,所述抑菌组合物进一步包含一种或多种抗菌药物,所述抗菌药物选自由硝基咪唑类药物,如甲硝唑、替硝唑、奥硝唑;氨基糖甙类药物,如庆大霉素、妥布霉素、阿米卡星、西索米星、奈替米星;喹诺酮类药物,如环丙沙星、氧氟沙星、左氧氟沙星;呋喃类药物,如硝呋太尔、硝呋醛肟、呋喃西林、呋喃唑酮、呋喃妥因;磺胺类药物,如磺胺嘧啶银、磺胺醋酰钠;吡咯类药物,如克霉唑、氟康唑、咪康唑、酮康唑;丙烯胺类药物,如萘替芬、特比萘芬;多烯类抗生素,如两性霉素B、制霉菌素、制酵母菌素、以及纳他霉素组成的组。
  11. 根据权利要求1所述的抑菌组合物,其特征在于,所述抑菌组合物为pH值在3.1-4.8范围内,优选3.6-4.6范围内,更优选3.8-4.4范围内的水溶液剂、水溶性凝胶剂、泡沫剂、喷雾剂、以及软膏剂。
  12. 根据权利要求1所述的抑菌组合物,其特征在于,所述抑菌组合物 为治疗性产品、或其有效组分、或其防腐剂,其中所述治疗性产品以下组中的一种形式存在:药品、消毒剂、抗菌剂、抑菌剂、皮肤黏膜表面杀微生物剂、菌群调节剂、微生态调节剂、微环境调节剂、微生物调节剂、一次性使用医疗用品,或者以医疗器械、药物器械、消毒器械、以及阴道用器械的组成部分的形式存在。
  13. 根据权利要求1所述的抑菌组合物,其特征在于,所述抑菌组合物为非治疗性产品、或其有效组分、或其防腐剂,其中所述非治疗性产品以下组中的其中一种形式存在:保健用品、卫生用品、个人洗护用品、化妆品、一次性使用卫生用品、清洁用品、日用品、微生态护理品、除异味剂、润滑剂、湿润剂、洗剂、清洁剂、养护剂、止痒剂、清新剂,或者以卫生巾、卫生护垫、以及卫生棉条的组成部分的形式存在。
  14. 根据权利要求1所述的抑菌组合物,其特征在于,其中所述抑菌组合物为阴道用抑菌组合物,所述阴道用抑菌组合物包括以下组分:
    (1)一种或多种脂肪酸和/或其盐,所述脂肪酸选自由乙酸、羟基乙酸、乳酸、丙酸、乙酰丙酸、丁酸、戊酸、己酸、庚酸、辛酸、壬酸、癸酸、十一酸、十一烯酸、以及月桂酸组成的组,以脂肪酸计的组分(1)的总含量在0.001-2.00%(w/w)范围内;
    (2)一种或多种二元酸和/或其盐,所述二元酸选自由戊二酸、己二酸、以及庚二酸组成的组,以二元酸计的组分(2)的总含量在0.50-2.50%(w/w)范围内;
    (3)一种或多种芳香醇,所述芳香醇选自由苯甲醇、2,4-二氯苯甲醇、苯乙醇、苯氧乙醇、以及肉桂醇组成的组,组分(3)其总含量在0.05-0.60%(w/w)范围内;
    (4)一种或多种芳香酸和/或其盐,所述芳香酸选自由苯甲酸、对羟基 苯甲酸、对甲氧基苯甲酸、水杨酸、肉桂酸、龙胆酸、以及咖啡酸组成的组,以芳香酸计的组分(4)的总含量在0.05-0.25%(w/w)范围内。
    所述阴道用抑菌组合物的剂型选自由水溶液剂、水溶性凝胶剂、泡沫剂、喷雾剂、软膏剂、散剂、膜剂、胶囊剂、栓剂、以及片剂组成的组。
  15. 一种抑制有害微生物的方法,其特征在于,包括使用根据权利要求1-14任一项所述的抑菌组合物的步骤。
  16. 根据权利要求15的方法,其特征在于,所述有害微生物包括:假丝酵母菌、金黄色葡萄球菌、大肠埃希菌、铜绿假单胞菌、阴道加德纳菌、普雷沃菌、动弯杆菌、黑曲霉菌、以及人体皮肤和/或黏膜部位的异常菌群。
  17. 一种调节阴道菌群的方法,其特征在于,包括使用阴道用抑菌组合物的步骤,其中,所述阴道用抑菌组合物含有一种或多种脂肪酸和/或其盐,所述脂肪酸选自由丁酸、戊酸、己酸、庚酸、辛酸、壬酸、癸酸、十一酸、十一烯酸、以及月桂酸组成的组,以脂肪酸计的所述脂肪酸和/或其盐的总含量在0.001-2.00%(w/w)范围内;
    其中,所述阴道用抑菌组合物的剂型选自由水溶液剂、水溶性凝胶剂、泡沫剂、喷雾剂、软膏剂、散剂、膜剂、胶囊剂、栓剂、以及片剂组成的组;
    所述调节阴道菌群包括下述中的至少一种:抑制阴道异常菌群、恢复和/或维护阴道的乳杆菌。
  18. 根据权利要求17所述的方法,其特征在于,所述阴道用抑菌组合物进一步包含一种或多种二元酸和/或其盐,所述二元酸选自由戊二酸、己二酸、以及庚二酸组成的组,以二元酸计的所述二元酸和/或其盐的总含量在0.50-2.50%(w/w)范围内。
  19. 根据权利要求17所述的方法,其特征在于,所述阴道用抑菌组合物进一步包含一种或多种芳香醇,所述芳香醇选自由苯甲醇、2,4-二氯苯甲醇、苯乙醇、苯氧乙醇、以及肉桂醇组成的组,其总含量在0.05-0.60%(w/w)范围内。
  20. 根据权利要求17所述的方法,其特征在于,所述阴道用抑菌组合物进一步包含一种或多种芳香酸和/或其盐,所述芳香酸选自由苯甲酸、对羟基苯甲酸、对甲氧基苯甲酸、水杨酸、肉桂酸、龙胆酸、以及咖啡酸组成的组,以芳香酸计的所述芳香酸和/或其盐的总含量在0.05-0.25%(w/w)范围内。
  21. 根据权利要求17所述的方法,其特征在于,所述阴道用抑菌组合物进一步包含一种或多种雌激素或植物雌激素类物质,所述雌激素或植物雌激素类物质选自由己烯雌酚、己烷雌酚、雌二醇、雌酮、雌三醇、尼尔雌醇、炔雌醇、炔雌醇环戊醚、炔雌甲醚、普罗雌烯、大豆苷、黄豆苷元、黄豆黄素、葛根素、拟雌内酯、金雀异黄酮、雌马醇、芹黄素、染料木甙、染料木素、鸡豆黄素、香豆雌酚、芒柄花黄素、白藜芦醇、亚麻木酚素、以及木脂素组成的组,其总含量在0.001-1.00%(w/w)范围内。
  22. 根据权利要求17所述的方法,其特征在于,所述阴道用抑菌组合物用于包括恢复和/或维护阴道正常菌群、和/或恢复和/或维护阴道的正常微生态、和/或恢复和/或维护阴道的正常酸度、和/或清洁护理阴道和/或外阴,和/或减轻和/或消除阴道外阴瘙痒、和/或疼痛、和/或干涩、和/或刺激、和/或性交不适,和/或减轻和/或消除白带异常、和/或白带异味。
  23. 根据权利要求17所述的方法,其特征在于,所述阴道用抑菌组合物 用于预防和/或治疗阴道菌群失调、和/或细菌性阴道病、和/或需氧菌性阴道炎、和/或细胞溶解性阴道病、和/或阴道外阴假丝酵母菌病、和/或萎缩性阴道炎。
  24. 脂肪酸和/或其盐在制备用于调节阴道菌群的抑菌组合物中的用途,其特征在于,所述脂肪酸选自由丁酸、戊酸、己酸、庚酸、辛酸、壬酸、癸酸、十一酸、十一烯酸、以及月桂酸组成的组中的至少一种,以脂肪酸计的所述脂肪酸和/或其盐在抑菌组合物中的总含量在0.001-2.00%(w/w)范围内,所述调节阴道菌群包括下述中的至少一种:抑制阴道异常菌群、恢复和/或维护阴道的乳杆菌。
PCT/CN2021/075655 2020-02-12 2021-02-05 抑菌组合物及其制备方法和用途 WO2021160049A1 (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN202180014214.2A CN115515556A (zh) 2020-02-12 2021-02-05 抑菌组合物及其制备方法和用途
EP21753951.9A EP4101437A4 (en) 2020-02-12 2021-02-05 BACTERIOSTATIC COMPOSITION, METHOD FOR PREPARATION AND USE
CA3167761A CA3167761A1 (en) 2020-02-12 2021-02-05 Bacteriostatic composition, preparation method therefor and use thereof
US17/886,476 US20220395481A1 (en) 2020-02-12 2022-08-12 Bacteriostatic composition, preparation method therefor, and use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202010101402.6 2020-02-12
CN202010101402 2020-02-12
CN202011324292 2020-11-15
CN202011324292.6 2020-11-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/886,476 Continuation US20220395481A1 (en) 2020-02-12 2022-08-12 Bacteriostatic composition, preparation method therefor, and use thereof

Publications (1)

Publication Number Publication Date
WO2021160049A1 true WO2021160049A1 (zh) 2021-08-19

Family

ID=77291383

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/075655 WO2021160049A1 (zh) 2020-02-12 2021-02-05 抑菌组合物及其制备方法和用途

Country Status (4)

Country Link
US (1) US20220395481A1 (zh)
EP (1) EP4101437A4 (zh)
CA (1) CA3167761A1 (zh)
WO (1) WO2021160049A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113605090A (zh) * 2021-09-06 2021-11-05 安徽高梵电子商务有限公司 一种羽绒服除味清新喷雾及其制备方法
CN113718530A (zh) * 2021-09-06 2021-11-30 安徽高梵电子商务有限公司 一种含有海洋生物成分的羽绒服除味剂
CN113756103A (zh) * 2021-09-06 2021-12-07 安徽高梵电子商务有限公司 羽绒服腥味快速去除喷雾及其制备方法
CN114903918A (zh) * 2022-05-27 2022-08-16 北京恩吉赛生物科技有限公司 女性微生态抑菌修复凝胶及制备方法和应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116210697B (zh) * 2023-03-02 2024-05-14 西北农林科技大学 反式肉桂酸在提高苹果树腐烂病抗性中的应用
CN117338636B (zh) * 2023-12-04 2024-02-23 江西中医药大学 一种用于精油缓释的材料及其应用
CN117717612A (zh) * 2023-12-19 2024-03-19 中山自然说生物科技有限公司 一种私密护理组合物及其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002322090A (ja) * 2001-04-27 2002-11-08 Kao Corp 抗菌性組成物
WO2011041938A1 (zh) * 2009-10-08 2011-04-14 富莱生物技术投资有限公司 一种以苯甲酸和有机酸防腐剂相联合作为有效成分的组合物及其用途
CN103648482A (zh) * 2011-07-15 2014-03-19 根特大学 阴道内递送系统
WO2015135470A1 (zh) * 2014-03-13 2015-09-17 曾忠铭 一种阴道用组合物与该组合物的用途
WO2019147875A1 (en) * 2018-01-26 2019-08-01 The Procter & Gamble Company Methods and compositions for reducing the feeling of vaginal dryness
CN110368324A (zh) * 2019-08-28 2019-10-25 海南厢珠物联科技股份有限公司 一种抑制大肠杆菌,白色念珠菌,金黄色葡萄球菌的制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670160A (en) * 1990-08-24 1997-09-23 Schulke & Mayr Gmbh Preservatives and their use
US20060051384A1 (en) * 2004-09-07 2006-03-09 3M Innovative Properties Company Antiseptic compositions and methods of use
ITMI20131971A1 (it) * 2013-11-26 2015-05-27 Fidia Farmaceutici Composizioni farmaceutiche ad attività idratante e lubrificante
JP6780123B2 (ja) * 2016-10-09 2020-11-04 深▲せん▼優麗康生物技術有限公司Shenzhen Eulikan Biotechnology Co., Ltd. 静菌剤配合の膣用組成物の調製への用途及び膣用組成物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002322090A (ja) * 2001-04-27 2002-11-08 Kao Corp 抗菌性組成物
WO2011041938A1 (zh) * 2009-10-08 2011-04-14 富莱生物技术投资有限公司 一种以苯甲酸和有机酸防腐剂相联合作为有效成分的组合物及其用途
US8765819B2 (en) 2009-10-08 2014-07-01 Zhongming Zeng Composition comprising benzoic acid in combination with organic acid preservatives as active ingredients and the use thereof
CN103648482A (zh) * 2011-07-15 2014-03-19 根特大学 阴道内递送系统
WO2015135470A1 (zh) * 2014-03-13 2015-09-17 曾忠铭 一种阴道用组合物与该组合物的用途
WO2019147875A1 (en) * 2018-01-26 2019-08-01 The Procter & Gamble Company Methods and compositions for reducing the feeling of vaginal dryness
CN110368324A (zh) * 2019-08-28 2019-10-25 海南厢珠物联科技股份有限公司 一种抑制大肠杆菌,白色念珠菌,金黄色葡萄球菌的制剂

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Pharmacopoeia of the People's Republic of China", vol. IV, 2020, article "Bacteriostatic Effectiveness Testing"
BORGES SANDRA, SILVA JOANA, TEIXEIRA PAULA: "The role of lactobacilli and probiotics in maintaining vaginal health", ARCHIVES OF GYNECOLOGY AND OBSTETRICS, vol. 289, no. 3, 1 March 2014 (2014-03-01), DE, pages 479 - 489, XP055835465, ISSN: 0932-0067, DOI: 10.1007/s00404-013-3064-9 *
FANG LIANG: "Pharmaceutics", 2016, PEOPLE'S MEDICAL PUBLISHING HOUSE, pages: 280 - 284
See also references of EP4101437A4

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113605090A (zh) * 2021-09-06 2021-11-05 安徽高梵电子商务有限公司 一种羽绒服除味清新喷雾及其制备方法
CN113718530A (zh) * 2021-09-06 2021-11-30 安徽高梵电子商务有限公司 一种含有海洋生物成分的羽绒服除味剂
CN113756103A (zh) * 2021-09-06 2021-12-07 安徽高梵电子商务有限公司 羽绒服腥味快速去除喷雾及其制备方法
CN113605090B (zh) * 2021-09-06 2023-01-31 安徽高梵电子商务有限公司 一种羽绒服除味清新喷雾及其制备方法
CN113756103B (zh) * 2021-09-06 2023-01-31 安徽高梵电子商务有限公司 羽绒服腥味快速去除喷雾及其制备方法
CN113718530B (zh) * 2021-09-06 2023-01-31 安徽高梵电子商务有限公司 一种含有海洋生物成分的羽绒服除味剂
CN114903918A (zh) * 2022-05-27 2022-08-16 北京恩吉赛生物科技有限公司 女性微生态抑菌修复凝胶及制备方法和应用
CN114903918B (zh) * 2022-05-27 2024-04-16 北京恩吉赛生物科技有限公司 女性微生态抑菌修复凝胶及制备方法和应用

Also Published As

Publication number Publication date
EP4101437A4 (en) 2023-05-10
CA3167761A1 (en) 2021-08-19
US20220395481A1 (en) 2022-12-15
EP4101437A1 (en) 2022-12-14

Similar Documents

Publication Publication Date Title
WO2021160049A1 (zh) 抑菌组合物及其制备方法和用途
CA3039556C (en) Use of 2-phenylethanol in combination with other antimicrobial agents for vagina
EP1072269B1 (en) Use of dextrin, starch or glycogen for the treatment of bacterial vaginosis
US11951116B2 (en) Vaginal composition and use thereof
EP1911454B1 (en) A composition and method of regulating and maintaining the vaginal bacterial flora and the normal acidity in the vagina
US8765819B2 (en) Composition comprising benzoic acid in combination with organic acid preservatives as active ingredients and the use thereof
ES2532863T3 (es) Uso de nifuratel para tratar infecciones provocadas por especies de Atopobium
US6964949B2 (en) Pharmaceutical compositions for promoting the growth of gram-positive bacilli and increasing the acidity in the vagina and the use thereof
EP2643003B1 (en) Vaginal composition based on alkyl polyglucosides
EP1646378B1 (en) Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superfinfections and fungal recurrences
CN115515556A (zh) 抑菌组合物及其制备方法和用途
CN112773780A (zh) 一种阴道外阴用组合物及其用途
US8309103B2 (en) Association of fluconazole-tinidazole for the treatment of vaginal infections, its composition, preparation process and usage

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21753951

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 3167761

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021753951

Country of ref document: EP

Effective date: 20220912